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Ras proteins are crucial for the regulation of cellular proliferation, differentiation, and 
survival. These small GTPases act as a binary on/off switch, which reversibly binds to GTP 
or GDP, respectively. In humans, there are four Ras isoforms: KRAS4A, KRAS4B, HRAS 
and NRAS. They share almost complete sequence homology (~85%), however differ in the 
last 25 amino acids, termed the hypervariable region. This region is responsible for the 
specific localisation of the different Ras isoforms at the plasma membrane, where they 
occupy distinct non-overlapping nucleotide-dependent nanoclusters. These transient Ras 
nanoclusters are essential signalling platforms that recruit various effectors for Ras 
activation. Although, Ras activity is crucial for the normal functions of a living cell, it can 
also be detrimental, for example, in cancer. Mutations of the Ras gene renders them 
constitutively active and are highly prevalent in cancers (~17%). This has led to many efforts 
into the development of a Ras inhibitor as a cancer treatment. However, it has shown to be 
challenging, therefore, complementary research into understanding the regulation of Ras 
function and localisation has also been of importance as a possible indirect therapeutic.   
Since the discovery of Ras, only a handful of Ras nanocluster regulators have been found. 
Therefore, the main aim of this project is to be able to identify a novel interactor of Ras with 
a particular interest in the organisation of Ras nanoclusters. Here, APEX2 was used to 
perform an unbiased screen of the proximal protein microenvironment in different Ras 
isoforms (KRAS4B, HRAS and NRAS). Nearby proteins were labelled with biotin 
generated by the APEX2-Ras and later enriched for mass spectrometry analysis. Nearly 
3000 proteins were identified, with a group of phospholipid-binding proteins called annexins 
being amongst the top hits. Investigations into the relationship between Ras and annexins 
revealed that both HRAS WT and G12V interact with annexin 6.  The spatial patterning of 
Ras proteins on the plasma membrane in the presence of annexin 6 demonstrated that this 
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1.1. THE RAS SUPERFAMILY OF SMALL GTPASES 
1.1.1. Small GTPases 
In humans, the Ras superfamily consists of over 160 small guanosine triphosphatases 
(GTPases), which all share a fundamental role of GTP binding and hydrolysis (Qu et al., 
2019). These proteins are further subdivided based on their sequence homology and function 
into the following groups: Ras, Rho, Ran, Rab and ADP-ribosylation factor (Arf) (Qu et al., 
2019). For example, the Ras subfamily regulates cellular proliferation, Rho and Ran 
members are involved in actin dynamics and nuclear transport, respectively (Bishop and 
Hall, 2000; Macara, 2001). Whereas Rab and Arf subfamilies are fundamental for vesicular 
movement (Segev, 2001; D’Souza-Schorey and Chavrier, 2006).  
All of these monomeric proteins together with their associated regulators and effectors play 
a central role for a plethora of signal transduction pathways, ranging from the regulation of 
gene expression to vesicular transport. They have a high affinity for guanosine triphosphate 
(GTP) and guanosine diphosphate (GDP) at their conserved ~20kDa G-domain located at 
the N-terminus. This domain contains two important regions: switch I and switch II, which 
undergo conformational changes when GTP-bound (Milburn et al., 1990). Rendering the 
GTPase active and allowing for tight binding of effectors, which propagates its subsequent 
signalling pathway (Scolnick, Papageorge and Shih, 1979).  
Regulatory proteins such as guanine-nucleotide exchange factors (GEFs) and GTPase-
activating proteins (GAPs) promote the exchange of GDP/GTP in most GTPases (Cherfils 
and Zeghouf, 2013). During this cycle, GEFs regulate the conversion of GDP to GTP, 
whereas GAPs stimulate GTP hydrolysis. Although, small GTPases have intrinsic 
hydrolysis activity, the rate is relatively low in some members such as the Ras subfamily 
and therefore require additional aid from GAPs (Bourne, Sanders and McCormick, 1990). 
However, there are certain atypical GTPases that do not undergo the GDP/GTP cycle, 
instead they are regulated on a transcriptional level (Haga and Ridley, 2016).  
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1.1.2. Discovery of Ras 
The founding members of the Ras superfamily emerged through the isolation of 
transforming retroviruses in rodent models, whereby oncogenic viruses induced sarcomas 
in infected rodents. Ras research first dates back to 1964, where murine leukaemia virus 
extracted from leukaemic rats were found to trigger the production of sarcomas in new-born 
rodents (Harvey, 1964). Another murine sarcoma retrovirus was discovered in the later years 
following a serial passage of a mouse leukaemic virus in Wister-Furth rats (Kirsten and 
Mayer, 1967). The highly expressed gene product responsible for the cellular transformation 
in these virally infected cells was a 21kDa protein (p21), which differed in gene sequence 
between the Harvey and Kirsten sarcoma viruses. An alternative form of this p21 protein 
was later shown to be constitutively expressed at a low level in normal healthy cells (Ellis 
et al., 1981).       
Human homologs of these genes responsible for inducing rat sarcomas (Ras) were later 
discovered and were named KRAS and HRAS, respectively after its initial discovery in 
Kirsten- and Harvey- rat sarcoma viruses. The link between the human and viral form of 
RAS was made by the hybridisation of specific probes for viral RAS genes to DNA isolated 
from NIH-3T3 cells transformed with DNA from bladder and lung carcinoma cells. This 
revealed restriction fragments that were homologous to the transforming genes  present in 
the sarcoma viruses (Der, Krontiris and Cooper, 1982). This was later supported by the 
detection of HRAS and KRAS in human tumour cell lines of bladder and lung carcinomas, 
respectively (Hall et al., 1983; Shimizu, Goldfarb, Suard, et al., 1983).  
By 1983, the third Ras member was identified. Transforming sequences were found in DNA 
isolated from fibrosarcoma and rhabdomyosarcoma cell lines, which resulted in  the 
morphological transformation of NIH-3T3 cells (Marshall, Hall and Weiss, 1982). 
Similarly, DNA from a human neuroblastoma cell line, SK-N-SH also showed to transform 
NIH-3T3 cells (Shimizu, Goldfarb, Perucho, et al., 1983). The DNA isolated from these 
different studies were shown to be identical and related to the other RAS genes. This third 
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Ras gene was later named neuroblastoma rat sarcoma (NRAS) (Marshall, Hall and Weiss, 
1982; Hall et al., 1983; Shimizu, Goldfarb, Perucho, et al., 1983). 
The transforming property of Ras was found to be due to a single point mutation. In T24 
human bladder carcinoma cells, Ras was activated by the substitution of guanosine instead 
of thymidine, which altered the twelfth amino acid from a glycine to a valine (G12V) (Reddy 
et al., 1982). The first clinical case reporting of mutated KRAS in a lung cancer biopsy was 
the beginning to the discovery of the wide prevalence of mutated Ras in numerous human 
cancers (Santos et al., 1984).    
1.2. THE RAS SUBFAMILY 
1.2.1. Ras members 
The Ras subfamily consists of 36 members that all affect similar cellular processes such as 
proliferation, growth, and gene expression. Aside from the initial founding members: 
KRAS, HRAS and NRAS, other members include MRAS, RRAS, RAP, RAL and RIT (Qu 
et al., 2019).  
The genes: KRAS, HRAS and NRAS encode for four different Ras proteins: KRAS4A, 
KRAS4B, HRAS and NRAS, of which are all ubiquitously expressed; however, expression 
levels vary dependent on the tissue type. The two isoforms of KRAS are the product of 
alternate splicing, which results in different fourth exons of the KRAS gene (hereafter 
KRAS4B will be referred to KRAS, unless otherwise stated) (Newlaczyl, Coulson and Prior, 
2017). 
1.2.2. Structure 
Each of the three Ras genes differ in DNA length: 35kb (KRAS), 3kb (HRAS) and 7kb 
(NRAS) and are also located on different chromosomes: 12p12.1, 11p15.5 and 1p13.2, 
respectively (Popescu et al., 1985; Zabel et al., 1985). Despite the differences in DNA 
length, these genes all encode for four coding exons each, which result in very similar sized 
proteins of 188-9 amino acids (21kDa) that share high sequence homology (~90%) in the 
5 
 
first 166 amino acids but vastly differ in the remaining sequence. These represent the G-
domain and membrane targeting regions, respectively (Lowy and Willumsen, 1993).  
1.2.2.1. G-domain 
Binding of GDP/GTP, Ras effectors and regulators occurs within the first half of the 
catalytic G-domain. This is called the effector lobe (aa 1-86) and shares the identical DNA 
sequence amongst all the Ras isoforms. Whereas the allosteric lobe (aa 87-166) differs 
between the Ras isoforms and only share an approximate 82% sequence match. The 
allosteric lobe has shown to play a role in communicating with the effector lobe in order to 
modulate Ras-membrane interactions (Parker and Mattos, 2015).  
Crystal structures of Ras have revealed that the catalytic domain consists of six-stranded β-
sheets, which forms the hydrophobic core (Fig. 1.1). Surrounding the core are five α-helices, 
which are interconnected by ten hydrophilic loops. Amongst this polypeptide chain are five 
conserved GDP/GTP (G) binding motifs: G1, G2, G3, G4 and G5. These regions are 
fundamental for GDP/GTP exchange, GTP hydrolysis and GTP-induced conformational 
changes (Gorfe, Grant and McCammon, 2008). 
 
Figure 1.1| Schematic of the G catalytic domain - The composition of the catalytic domain is made 
up of β-strands (blue arrows), α-helices (red helices) and interconnecting loops (lines). Each G-
binding motif is highlighted. 
The first motif, G1 (aa 10-17) represents the P-loop (GXXXXGKS/T), which connects the 
β1 strand to the α1 helix. The P-loop also binds GDP or GTP by forming bonds with the α- 
and β-phosphates on the nucleotides via its NH2 groups on the main chain and lysine side 
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chain (Milburn et al., 1990; Schlichting et al., 1990). The second motif, G2 also more 
commonly known as switch I (aa 30-38), contains the N-terminus of the β2 strand and its 
preluding neighbour loop, L2 (Milburn et al., 1990; Bourne, Sanders and McCormick, 
1991). Conformational changes to L2 occur when bound to GTP (Tong et al., 1989; Milburn 
et al., 1990). Here, the invariant threonine residue (Thr-35) on the loop interacts with the γ-
phosphate of GTP (Pai et al., 1989). As a result, the orientation of Thr-35 is altered, allowing 
it to bind tightly to a crucial magnesium (Mg2+) co-factor via its hydroxyl side chain (John 
et al., 1993). The third motif, G3 represents switch II (aa 59-76) and consists of the L4 loop 
and α2 helix. The NH2 backbone of residues 60 and 61 form hydrogen bonds with the γ-
phosphate, which induces conformational changes to the L4 loop and alters the orientation 
of α2 (Milburn et al., 1990; Stouten et al., 1993)  
The P-loop, switch I and switch II regions are all components of the effector lobe (Pai et al., 
1989).  Whereas the allosteric lobe is composed of the remaining G motifs: G4 (aa 112-119) 
and G5 (143-147). Together these motifs along with G1 aid the tight binding of the 
nucleotide via their interactions with the guanine base and β-phosphate, respectively (Parker 
and Mattos, 2015). The fourth motif, G4 is composed of the β5 strand and L8 loop. Its 
N/TKXD motif mediates guanine specificity via its Asp side chain and stabilises the 
guanine-binding site through bonds between its Asn and Lys side chains with residues 13 
and 14 in G1. Lastly, the fifth motif, G5 is found in the loop, between the β6 strand and α5 
helix. It predominantly stabilises nucleotide binding via its SAK motif but can also bind 
directly to guanine via its Ala group (Bourne, Sanders and McCormick, 1991). Altogether, 
the allosteric lobe plays a crucial role in the intercommunication between the effector lobe, 
membrane targeting domain and the plasma membrane.   
In more recent times, a switch III region was discovered using HRAS. It consists of the β2-
β3 loop and the α5 helix, which together with α4 and the hypervariable region (HVR) 
reorients the G-domain accordingly to the plasma membrane during Ras activation 
(Abankwa et al., 2008).  
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1.2.2.2. Membrane targeting domain 
Unlike the G-domain, the membrane targeting domain (aa 166-188/189)/HVR is specific 
for each Ras isoform (Hancock, Paterson and Marshall, 1990). This region is divided into a 
linker domain and a targeting domain (Fig.1.2). The linker domain has shown to stabilise 
Ras localisation at the plasma membrane and other subcellular regions  (Prior and Hancock, 
2001). Whereas the targeting domain is a site for post-translational modifications (PTMs) 
that are required for membrane trafficking and localisation (Laude and Prior, 2008). At the 
C-terminal of the targeting domain is a CAAX motif, whereby C is cysteine, A is usually an 
aliphatic amino acid like isoleucine, leucine or valine and X is serine or methionine. This 
motif plays an important role for membrane localisation of which will be discussed in 
section 1.4 (Reiss et al., 1990).  Collectively, both the linker and targeting domains 
contribute to the precise localisation of Ras to the inner plasma membrane as well as other 
intracellular compartments (S. J. Plowman and Hancock, 2005; Wright and Philips, 2006; 
Laude and Prior, 2008; Henis, Hancock and Prior, 2009; Prior and Hancock, 2012).  
 
Figure 1.2| Ras sequence – Sequence homology between the different Ras isoforms for the two 
main components: G-domain and HVR are displayed. Important residues from the HVR that form 
the three signals required for membrane targeting are highlighted for each Ras isoform.    
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1.3. RAS SIGNALLING 
1.3.1. Receptor tyrosine kinase pathway 
Cell surface receptors transmit external signals to a multitude of signalling pathways to elicit 
a relevant biological response (Lemmon and Schlessinger, 2010). Receptor tyrosine kinases 
(RTKs) are fundamental receptors for Ras activation. These receptors can be triggered by 
growth factors such as epidermal growth factor (EGF), insulin-like growth factor (IGF) and 
fibroblast growth factor (FGF) (Fantl, Johnson and Williams, 1993). Ligand binding at the 
extracellular region of RTKs induces receptor oligomerisation, which releases the cis-
autoinhibition and triggers trans-autophosphorylation of the cytoplasmic tyrosine kinase 
domains (Lemmon and Schlessinger, 2010). These phosphotyrosine residues become the 
docking sites for proteins that contain a Src homology-2 (SH2) or a phosphotyrosine-binding 
(PTB) domain (Wagner et al., 2013). In the context of Ras activation, the SH2/SH3 domain-
containing adaptor protein: Grb2 binds to the autosphosphorylated RTK and recruits a Ras-
GEF called Son-of Sevenless (Sos) via its SH3 domain (Rozakis-Adcock et al., 1993). This 
activates Sos, which in turn promotes the exchange of GDP for GTP on Ras (Buday and 
Downward, 1993).  
1.3.2. Ras activation 
1.3.2.1. GEFs 
The off-rate for GDP (t1/2 = 6 min, koff = 2x10-3s-1) in Ras is relatively slow, therefore GEFs 
are required to accelerate this GDP/GTP exchange rate (Hunter et al., 2015). Aside from 
Sos, other types of Ras GEFs include RAPGEF, RASGRP and RASGRF (Bos, Rehmann 
and Wittinghofer, 2007). These GEFs catalyses the dissociation of GDP from Ras by 
reducing its nucleotide affinity via modifications to the nucleotide-binding site. However, 
GEFs do not favour whether GDP or GTP binds, instead the cellular concentration of GDP 
versus GTP determines whether Ras is GDP or GTP-bound, respectively (Boriack-Sjodin et 
al., 1998).  
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1.3.2.2. Conformational switch 
As mentioned previously, the switch I (aa 30-38) and II (aa 59-76) regions are located within 
the G-domain and play an important role in the binding of GDP/GTP (Pai et al., 1989; 
Milburn et al., 1990). When GEF is bound, it interacts with these switch regions to perturb 
the binding of GDP and the Mg2+ ion. Typically, GEF binds the switch I region and pulls 
this switch region away, resulting in the opening of the nucleotide binding site. In the context 
of Sos, it displaces this region with a helical hairpin. Then, uses the hydrophobic Ala-59 
residue on the switch II domain to repel the Mg2+ ion from the Mg2+ binding site 
(Wittinghofer et al., 1991; John et al., 1993).  
Conformational changes amongst the P-loop, switch I and switch II regions result in GDP 
being displaced (Boriack-Sjodin et al., 1998). Ras becomes GTP-bound, i.e., active, when 
the cellular concentration of GTP exceeds GDP by approximately tenfold in the cytoplasm. 
Once GTP-bound, GEF is displaced. Here, switch I and II regions are held in an active 
conformation due to the hydrogen bonds between the γ-phosphate oxygens and the main 
chain NH groups of the two residues: Thr35 and Gly60 (Pai et al., 1989; Wittinghofer et al., 
1991).  
There are two different conformations of Ras in its GTP-bound state: state 1 (‘open’) and 
state 2 (‘closed’). The open conformation favours nucleotide exchange and is less capable 
of effector interactions, whereas the closed conformation encourages effector binding and 
GTP hydrolysis (Shima et al., 2010). Different Ras isoforms are thought to favour a 
particular state, for example, KRAS is predominantly found in an open state, whereas HRAS 
and NRAS is preferential to the closed state (Gorfe, Grant and McCammon, 2008; Parker et 
al., 2018).  
1.3.2.3. GTP hydrolysis 
Additional GTPase activity is required from Ras GAPs, such as p120GAP and RASA1, to 
accelerate GTP hydrolysis of Ras due to its relatively low intrinsic GTPase rate (t1/2 = 16 
mins, koff =6x10-4s-1) (Hunter et al., 2015).  In HRAS, GAP stabilises the interaction between 
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the Gly61 residue (from the switch II region) and H2O molecule (Frech et al., 1994). In 
addition, it inserts a catalytic arginine finger near the β- and γ-phosphates, which contains a 
main chain carbonyl group that aids the extraction of a hydrogen atom from the water 
molecule (Kötting et al., 2008). The resulting hydroxyl ion is involved in the nucleophilic 
attack on the γ-phosphate of GTP, which cleaves the phosphomonoester bond,  thus 
releasing the phosphate and returning the switch regions back to its flexible GDP-bound 
conformation (Scheffzek et al., 1997).  
1.3.3. Ras effector pathway  
1.3.3.1. Effector binding 
 
Figure 1.3| Schematic of Ras effector pathways – Exchange of GDP to GTP via GEF leads to 
activation of Ras. As a result, conformational change occurs, allowing GTP-bound Ras to bind to an 
effector and activate its downstream pathway. 
In its active conformation i.e., bound to GTP, the core effector domain within the switch I 
region forms a loop on the surface, providing a platform for high affinity Ras effector 
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binding. This effector binding region is identical amongst all four Ras isoforms (Spoerner 
et al., 2001). To date, over 10 different classes of Ras effectors have been discovered, where 
several classes consist of different isoforms. Examples include Raf, phosphoinositide 3-
kinase (PI3K), Ral guanine nucleotide dissociation stimulator (RalGDS), T cell lymphoma 
invasion and metastasis-inducing protein 1 (Tiam1), Afadin 6 (AF6), RIN (Ras and Rab 
interactor), Ras association domain family (RASSF), phospholipase C ε (PLCε) and GAP 
(Sjölander et al., 1991; Dickson et al., 1992; Kuriyama et al., 1996; Rajalingam et al., 2007).  
These Ras effectors are defined as proteins that preferentially bind to GTP-bound Ras, 
whereby mutations within the core effector domain would lead to impairment of this 
interaction. They are further characterised by the presence of a Ras binding domain (RBD) 
or Ras association domains (RA), which differs in sequence between the Ras effectors. 
However, common to all is their topology of a ubiquitin fold consisting of a ββαββαβ tertiary 
structure (Nassar et al., 1995).      
1.3.3.2. Raf/MAPK pathway 
The Raf/MAPK pathway and PI3K/Akt pathway are key downstream signalling pathways 
of Ras. The Raf family of serine/threonine kinases consist of three members: a-Raf, b-Raf 
and c-Raf.  These proteins are involved in the Raf-MEK (mitogen-activated protein kinase 
kinase)-ERK (extracellular signal-regulated kinases) cascade, which ultimately regulates 
processes such as proliferation, differentiation, cell survival and cell motility (Leevers, 
Paterson and Marshall, 1994).  
Ras activation leads to the recruitment of cytosolic Raf to the plasma membrane (Vojtek, 
Hollenberg and Cooper, 1993). Dimerization of Raf is a fundamental step for Raf activation. 
However, the prerequisites of this process are unclear and of debate whether monomeric or 
dimeric active Ras mediates the formation of Raf dimers or alternatively, Raf dimers induce 
Ras dimerization (Inouye et al., 2000; Rushworth et al., 2006; Rajakulendran et al., 2009; 
Ritt et al., 2010; Nan et al., 2015; Ambrogio et al., 2018; Travers et al., 2018). All three Raf 
members can dimerise with each other, but for Ras signalling, there is a preference for b-
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Raf-c-Raf heterodimers (Weber et al., 2001; Garnett et al., 2005; Rushworth et al., 2006; 
Ritt et al., 2010). In addition to dimerization, the Raf cysteine-rich domain (CRD) also needs 
to engage with Ras via its farnesyl group as well as membrane phospholipids in order to 
release the autoinhibition, thus allowing for full Raf activation to occur (Ghosh et al., 1996; 
Luo et al., 1997; Cutler et al., 1998; Hekman et al., 2002; Terrell and Morrison, 2019).  
When Raf dimerizes, the Raf kinase domains come in contact, which leads to 
transactivation. This induces its catalytic activity, allowing it to phosphorylate MEK 
proteins: MEK1 (MAP2K1) and MEK2 (MAP2K2). These in turn phosphorylates ERK1 
and 2 (also known as MAPK3 and MAPK1) (Howe et al., 1992; Leevers and Marshall, 
1992). The activated ERK proteins dimerizes and activates a variety of nuclear transcription 
factors (TFs) such as ETS1/2, Myc, JUN, FOS, NF-κB and AP-1, as well as other kinases 
like JNK (Chang et al., 2003). As a result, cells enter S-phase and the expression of negative 
regulators such as Sprouty and MAPK phosphatases (dual specificity phosphatases 1-6) are 
induced (Ozaki et al., 2001; Kidger et al., 2017).   
1.3.3.3. PI3K/Akt pathway 
Another well-characterised Ras effector pathway involves PI3K proteins, which are 
important for cell survival and proliferation (Sjölander et al., 1991; Rodriguez-Viciana et 
al., 1994). These heterodimeric proteins are lipid kinases that consist of a p85 regulatory 
subunit and a p110α catalytic subunit (Gupta et al., 2007). They bind to GTP-Ras via their 
RBD and consequently become activated. The activated PI3K catalyses the conversion of a 
phospholipid component of the plasma membrane, phosphatidylinositol (4,5)-biphosphate 
(PIP2) into phosphatidylinositol (3,4,5)-triphosphate (PIP3). The latter recruits inactive 
cytosolic Akt to the plasma membrane via the engagement of the PH domain of Akt (Ebner 
et al., 2017). In addition to Akt, PIP3 also recruits PDK1 to the plasma membrane. PDK1 
along with TORC2 phosphorylate the threonine and serine residues of Akt (Hemmings and 
Restuccia, 2012). This results in the activation of Akt, which dissociates from the plasma 
membrane to activate a series of cytosolic and nuclear proteins that promote cell survival 
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via the inhibition of proapoptotic pathways (Rameh and Cantley, 1999). Examples include 
preventing apoptosis via phosphorylation of Mdm2, negatively regulating proapoptotic Bcl-
2 members: BAD and BAX as well as inhibiting NF-κB (nuclear factor kappa B) via the 
phosphorylation of IκB (inhibitor of NFκB) (Brunet, Datta and Greenberg, 2001; Ogawara 
et al., 2002).  
1.4. LOCALISATION 
1.4.1. Post-translational modifications 
Ras proteins are first synthesised on cytosolic free polysomes (Prior and Hancock, 2012). 
Then trafficked to the plasma membrane following a series of PTMs, which generate 
isoform-specific membrane anchors that allow for precise localisation amongst the inner 
leaflet of the plasma membrane (Hancock, Paterson and Marshall, 1990; Casey and Seabra, 
1996; Boyartchuk, Ashby and Rine, 1997; Dai et al., 1998).  
1.4.1.1. First signal: farnesylation, proteolysis and methylation 
All Ras isoforms undergo CAAX processing, which consists of three obligate steps: 
farnesylation, proteolysis and carboxyl methylation (Fig. 1.2) (Casey and Seabra, 1996; 
Boyartchuk, Ashby and Rine, 1997; Dai et al., 1998). The first PTM occurs when the 
globular hydrophilic Ras protein encounters farnesyltransferase (FTase) in the cytosol 
(Casey and Seabra, 1996). Here, FTase catalyses the addition of a 15-carbon farnesyl 
isoprenoid lipid to the cysteine residue of the CAAX motif via a stable thioester linkage. As 
a result, the farnesylated Ras is able to traffic and bind to the cytosolic face of the 
endoplasmic reticulum (ER) membrane (Choy et al., 1999), where an integral membrane 
endoprotease: Ras-converting enzyme 1 (RCE1) is located (Boyartchuk, Ashby and Rine, 
1997). This enzyme cleaves the C-terminal AAX tripeptide. The resulting terminal 
farnesylated cysteine residue is next methylated by an ER resident enzyme, 
isoprenylcysteine carboxylmethyltransferase (ICMT) to produce a hydrophobic tail that can 
interact with the phospholipid bilayer (Dai et al., 1998). These three PTMs generates the 
first signal required for membrane targeting.    
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1.4.1.2. Second signal: polylysine residues or palmitoyl groups 
A second signal is necessary for membrane targeting as it stabilises the weak interaction 
generated by the initial PTMs. Subsequent steps following CAAX processing are dependent 
on the Ras isoform (Choy et al., 1999). For KRAS4B, the farnesyl group is sufficient for 
direct trafficking from the ER to the inner plasma membrane due to the presence of polybasic 
hexa-lysine residues (aa 175-180). These positively charged residues facilitate membrane 
localisation as they interact electrostatically with the negatively charged phospholipids 
present within the membrane (Hancock, Paterson and Marshall, 1990).  
Contrastingly, additional PTMs are required for HRAS, NRAS and KRAS4A. These Ras 
isoforms undergo an exocytic pathway to the plasma membrane via the Golgi, where they 
are either mono- or di-palmitoylated (Hancock, Paterson and Marshall, 1990; Choy et al., 
1999; Apolloni et al., 2000). This process occurs on the cytosolic face of the Golgi 
membrane via a palmitoyl acyltransferase (PAT) called DHHC domain-containing 9-Golgi 
complex-associated protein of 16kDa (DHHC9-GCP16) (Swarthout et al., 2005). This 
heterodimeric protein complex adds a 16C palmitic acid on to one (NRAS - C181, KRAS4A 
– C180) or two (HRAS – C181 and C184) cysteine residues via a thioester bond. As a result 
of this protein modification, the C-terminal becomes more hydrophobic (Hancock et al., 
1989).   
1.4.1.3. Third signal: basic and acidic residues 
For HRAS, the combination of the farnesyl group and two palmitoyl groups are sufficient 
for stable membrane interactions. Whilst the monopalmitoylated NRAS and KRAS4A 
require a third signal to increase its membrane stability. A study revealed that palmitoylated 
Ras isoforms have a stretch of six basic residues at the linker domain of the HVR, which 
contributes to membrane localisation via electrostatic interactions. In addition, a pair of 
acidic residues that are also present in the linker domain of NRAS and KRAS4A have been 
shown to stabilise palmitoylation. Moreover, KRAS4A has an additional basic patch that 
provides further membrane affinity (Laude and Prior, 2008).     
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1.4.2. Endomembrane trafficking  
The addition of these lipid groups renders Ras more lipophilic and thus aiding its association 
with membranes (Fig.1.4). Studies have shown evidence of Ras localisation and signalling 
on subcellular membranes of various organelles such as ER, Golgi, endosomes and 
mitochondria (Choy et al., 1999; Rebollo, Pérez-Sala and Martínez-A, 1999; Chiu et al., 
2002; Lu et al., 2009). The ability of the different Ras isoforms to associate with 
endomembranes vary between isoforms (NRAS>HRAS>KRAS) (Choy et al., 1999). But 
overall, majority of Ras localisation and signalling occurs in the plasma membrane, despite 
a larger abundance of endomembranes within the cell. This non-equilibrium localisation is 
maintained by the combination of changes in membrane affinities, unidirectional vesicular 
trafficking, and chaperone proteins. Together, these regulate trafficking of Ras proteins 
leaked from the plasma membrane and prevent rapid diffusion of Ras proteins to 
intracellular membranes (Schmick, Kraemer and Bastiaens, 2015).  
 
Figure 1.4| Ras localisation – Trafficking of Ras isoforms from the ER to the plasma membrane 
through different mechanisms. At the plasma membrane, Ras isoforms occupy distinct nucleotide -
dependent non-overlapping nanoclusters.   
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1.4.2.1. Modulation of Ras trafficking 
Ras proteins can become detached from the plasma membrane via different processes. For 
KRAS, dissociation from the plasma membrane can occur either spontaneously, indirectly 
via the constitutive internalisation of the plasma membrane or by processes regulated by 
calmodulin (CaM) or protein kinase C (PKC) (Bivona et al., 2006; Schmick, Kraemer and 
Bastiaens, 2015; Agamasu et al., 2019). In a calcium-dependent manner, CaM binds to the 
farnesyl side chain of KRAS via its hydrophobic binding pocket, independent of whether 
KRAS is GDP- or GTP-bound (Agamasu et al., 2019; Grant et al., 2020). As a result, CaM 
extracts KRAS from the plasma membrane due to its higher affinity for KRAS. However, 
the underlying molecular mechanism is still unclear due to inconsistencies in the literature 
(Sperlich et al., 2016; Agamasu et al., 2019; Grant et al., 2020).  Alternatively, KRAS is 
able to interact with other intracellular membranes, as a result of phosphorylation by PKC. 
This enzyme phosphorylates the S181 residue of the polybasic region, allowing KRAS to 
rapidly dissociate from the plasma membrane (Bivona et al., 2006).  
Whereas, for the palmitoylated Ras isoforms, HRAS and NRAS, removal of their palmitoyl 
groups i.e., depalmitoylation is sufficient to reduce their affinity to the plasma membrane. 
Dissimilar to farnesylation, palmitoylation is reversible. This process can only occur at the 
Golgi, whereas the reverse process, depalmitoylation, is ubiquitous (Rocks et al., 2010). 
However, typically, depalmitoylation occurs at the plasma membrane via an enzyme called 
acyl protein thioesterase 1 (APT1) (Duncan and Gilman, 1998; Rocks et al., 2005). This 
cytosolic enzyme is first localised to the plasma membrane via self-palmitoylation before it 
cleaves the thioester bond between Ras and the palmitoyl group/s (Kong et al., 2013). As a 
result, the Ras protein loses its avidity for the plasma membrane and undergoes retrograde 
trafficking to other membranes (Rocks et al., 2005). Although, non-vesicular trafficking of 
depalmitoylated proteins can also occur (Goodwin et al., 2005). These depalmitoylated Ras 
proteins can re-enter the Golgi, where repalmitoylation occurs and cycles these proteins 
back to the plasma membrane via vesicular trafficking (Choy et al., 1999; Apolloni et al., 
2000; Goodwin et al., 2005; Rocks et al., 2005).  
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The constant cycling between palmitoylation and depalmitoylation allows for dynamic 
trafficking between the Golgi, plasma membrane and other subcellular membranes. The spill 
over of palmitoylated Ras can be redistributed to other subcellular membranes, however 
depalmitoylation occurs ubiquitously at a rapid rate (Rocks et al., 2010). The kinetics of the 
palmitoylation/depalmitoylation cycle varies between the different isoforms due to the 
differences in the number of palmitoyl groups present. HRAS (<20 min) has a longer half-
life than NRAS (< 5 min), since the additional palmitate group increases the duration of the 
membrane interaction (Rocks et al., 2005). These differences could account in part for the 
isoform-specific activity (Rocks et al., 2005) 
In the cytosol, Ras isoforms can diffuse freely until they encounter a membrane by binding 
to chaperone proteins called phosphodiesterase-δ (PDEδ). This cytosolic GDI-like 
solubilising factor binds to farnesylated Ras and shields their hydrophobic farneyl tail from 
the aqueous environment, thus enhancing its diffusion around the cytoplasm (Chandra et al., 
2012; Schmick et al., 2014). Only depalmitoylated HRAS and NRAS can bind PDEδ, since 
palmitoyl groups interfere with this interaction. Once bound, these Ras proteins can explore 
the cell interior at a faster rate, thereby increasing the encounter frequency with the Golgi, 
where it can become repalmitoylated and shuttled back to the plasma membrane (Chandra 
et al., 2012). Trapping of KRAS at the perinuclear membranes can occur when the KRAS-
PDEδ complex encounters GTP-bound Arf-like protein 2 (Arl2) (Ismail et al., 2011). This 
G-protein binds to PDEδ via its allosteric site, inducing a conformational change that 
releases Ras from PDEδ at the perinuclear membranes, where it is shuttled off into recycling 
endosomes that re-localise Ras to the plasma membrane (Chandra et al., 2012; Schmick et 
al., 2014). This process aids the enrichment of KRAS at the plasma membrane, thus 
opposing leakage to other endomembranes (Schmick, Kraemer and Bastiaens, 2015). 
1.4.2.2. Endoplasmic reticulum and Golgi 
Both HRAS and NRAS have shown to signal from the ER and Golgi, as illustrated by the 
engagement of c-Raf to their oncogenic variants at these subcellular locations (Chiu et al., 
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2002). In addition, endogenous palmitoylation-deficient HRAS responded to mitogens 
independently of endocytosis in both the ER and Golgi. Therefore,  this type of activation 
does not depend on activated epidermal growth factor receptors (EGFRs) (Chiu et al., 2002). 
The observed Ras activation in the Golgi was later suggested to be the result of 
depalmitoylated Ras-GTP, which had trafficked back to the Golgi from the plasma 
membrane either via a non-vesicular or vesicular route (Goodwin et al., 2005; Rocks et al., 
2005). However, others have also suggested an alternative model, whereby in situ activation 
of HRAS and NRAS occur in the Golgi (Bivona et al., 2003; Mor et al., 2007).   For 
example, T cell receptor (TCR) engagement alone resulted in the accumulation of 
palmitoylated Ras-GTP at the Golgi but not on the plasma membrane. However, 
redistribution of palmitoylated Ras-GTP to both the Golgi and plasma membrane occurs 
during co-stimulation of TCR and co-receptor, lymphocyte function-associated antigen 1 
(LFA-1) (Mor et al., 2007). 
1.4.2.3. Mitochondria 
All three Ras isoforms have shown to localise to the mitochondria. It appears that interaction 
with Bcl-2 directs their trafficking to the mitochondria. (Rebollo, Pérez-Sala and Martínez-
A, 1999). A later study suggested that both KRAS and NRAS contributes to the normal 
morphology of mitochondria. Whereby, KRAS localised to the outer mitochondria 
membrane (OMM), whereas NRAS was able to localise to both the OMM and inner 
mitochondria membrane (IMM) independent of PTMs (Wolfman et al., 2006). At the OMM, 
KRAS can interact with Bcl-XL, which eventually leads to apoptosis (Bivona et al., 2006).  
1.4.2.4. Endosomes 
Studies have demonstrated that all Ras isoforms can localise on endosomes. In the clathrin-
dependent route, KRAS is internalised from the plasma membrane via clathrin-coated pits 
and transported along an endosomal pathway, in which KRAS can become activated in late 
endosomes before being eventually targeted to lysosomes (Lu et al., 2009). Similarly, 
receptor-mediated Ras activation at the plasma membrane can activate RIN1, which in turn 
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stimulates Rab5A-mediated internalisation of Ras and thus attenuates cell surface receptor 
signalling (Tall et al., 2001).  
Palmitoylated isoforms have shown to traffic via recycling endosomes along the exocytic 
pathway from the Golgi to the plasma membrane. (Misaki et al., 2010). Whereby, the 
interaction with the endosomal membrane is stabilised by ubiquitination (Jura et al., 2006). 
The detection of c-Raf interaction with HRAS at the endosomal membrane also indicates 
that in addition to Ras localisation, signalling can also occur on endosomes (Roy, Wyse and 
Hancock, 2002).  
1.4.2.5. Nucleus 
At current, there is a lack of substantial evidence for Ras localisation at the nucleus. One 
study detected HRAS in the nuclear extracts from mouse fibroblast cells. Its appearance in 
the nuclei fluctuated with the cell cycle, whereby peak HRAS detection occurred during S 
phase (Contente, Yeh and Friedman, 2011). In another study, confocal microscopy and 
subcellular fractionation of normal human dermal fibroblasts (NHDF) and HEK293 cells 
were used to demonstrate localisation of KRAS4B to the nucleolus, of which appeared to 
be dependent on its interaction with the  nucleolar protein, nucleolin (Birchenall-Roberts et 
al., 2006).    
1.4.2.6. Subcellular signalling 
Ras signalling has shown to differ between the subcellular locations, which also often results 
in different outcomes. An example being the involvement of Ras in thymic selection. Here, 
Ras signalling occurs at the plasma membrane during negative selection, but in the Golgi 
for positive selection where the kinetics are much slower (Daniels et al., 2006). This also 
correlates with another study which reported that more transient and dynamic (mins) 
signalling occurs at the plasma membrane compared to endomembranes, where activity was 
longer (>1hr) and more sustained (Chiu et al., 2002).  
Interestingly, a proteomic study using green fluorescent protein (GFP)-tagged KRAS and 
NRAS chimeras that consisted of different organelle-specific targeting motifs at the C-
20 
 
terminus revealed that Golgi-Ras and mitochondrial-Ras displayed similar signalling 
outputs in terms of phosphoproteome responses as plasma membrane-Ras, particularly in 
KRAS. Whereas, responses in ER/Golgi-Ras and endo-Ras were relatively low (Hernandez-
Valladares and Prior, 2015).   
More recently, HRAS signalling in different subcellular regions was investigated using 
multiple biochemical networks: the interactome, phosphoproteome and transcriptome. 
Results revealed a vast difference in these networks amongst the various locations: plasma 
membrane, ER and Golgi. Their main findings showed that the majority of phosphorylation 
events as a result of HRAS activation were detected at the plasma membrane, whereas on a 
transcriptional basis, most genes were regulated when Ras signalled from the ER (Santra et 
al., 2019).  
Studies exploring Ras subcellular localisation have often exhibit discrepancies, which could 
be due to the uses of different cell models and methodology. Many of these were conducted 
using subcellular fractionation, which could result in false positives (Choy et al., 1999; 
Rebollo, Pérez-Sala and Martínez-A, 1999). In addition, many of the earlier studies lacked 
in vivo models. However, overall, it is evident that Ras localises to different subcellular 
locations, but the extent of their signalling is most likely context dependent.      
1.5. RAS NANOCLUSTERS 
1.5.1. Plasma membrane  
The plasma membrane is a complex and dynamic platform. Whereby, the fluid mosaic 
model depicts a non-equilibrium mixture of lipids and proteins organised to form the 
phospholipid bilayer (Singer and Nicolson, 1972).  
1.5.1.1. Composition  
The four major phospholipids that constitute more than half of the lipid composition of the 
plasma membrane include: sphingomyelin (SPH), phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and phosphatidylserine (PS) (Spector and Yorek, 1985). 
SPH and PC make up the majority of the outer membrane, whereas the inner membrane is 
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predominantly composed of PE, PS and phosphatidylinositol (PI) (Connor et al., 1992). 
Additionally, glycolipids and cholesterol are also present in the plasma membrane, where 
they contribute to 5-10% and 30-40% of the membrane lipid composition, respectively 
(Spector and Yorek, 1985; Warnock et al., 1993). 
1.5.1.2. Microdomains 
Among the plasma membrane, these lipid species are non-uniformly distributed and can 
laterally segregate into functional microdomains. This is due to the interaction between the 
saturated lipids and sterols, which can either be in a liquid ordered (Lo) or disordered (Ld) 
phase (Kusumi and Sako, 1996; Silvius, Del Giudice and Lafleur, 1996; Filippov, Orädd 
and Lindblom, 2004). Both phases are fluid and therefore allow for motion, however Lo 
phase is dependent on cholesterol and enriched in saturated lipids whereas Ld phase is low 
in cholesterol (Filippov, Orädd and Lindblom, 2004). This results in the generation of an 
array of lipid microenvironments, which act like signalling platforms that differ in dynamics. 
These are crucial for biological processes as they facilitate signal transduction (Prior et al., 
2001).  
The presence of the two phases allow for lipid rafts to be assembled. These have often been 
defined as non-ionic detergent resistant glycosphingolipid- and cholesterol-rich membrane 
compartments (Simons and Sampaio, 2011). However, this model has often been 
controversial due to the lack of technology with the spatial and temporal capacity to directly 
investigate these dynamic nanoscale structures (Munro, 2003). In addition to lipid rafts, 
other membrane microdomains exists such as caveolae, clathrin-coated pits and focal 
adhesions (Hooper, 1999).  
1.5.2. Properties of Ras nanoclusters 
Ras proteins predominantly localise on the inner plasma membrane. Here, they undergo 
constant diffusion with similar rates as free lipids and can assemble into transient distinct 
nanoscale domains (Murakoshi et al., 2004; Tian et al., 2007). The specific localisation of 
Ras nanoclusters on the plasma membrane is determined by the isoform as well as to their 
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nucleotide state, i.e. GDP- or GTP-bound (Fig.1.5) (Prior et al., 2003). The combination of 
their unique membrane anchors and G-domain allow for the formation of these spatially 
distinct nanoclusters. Although, the minimal membrane anchor is also sufficient for 
nanoclustering albeit slightly different to full-length Ras (Zhou et al., 2017). These Ras 
nanoclusters are fundamental platforms for effector binding and downstream activation. 
They function as switches that convert ligand input into high-fidelity Ras signal transduction 
via an analogue-digital-analogue circuit (Tian et al., 2007).  
At the plasma membrane, around 44% of the Ras proteins assemble into nanoclusters. These 
immobile nanodomains are highly dynamic with a turnover of 0.1-1 second, dependent on 
its nucleotide state. The diameter of a nanocluster can span from 12 to 20nm and can contain 
around 6-7 Ras proteins, which could exist as dimers, trimers and other high ordered 
oligomer (Murakoshi et al., 2004; S.J. Plowman and Hancock, 2005). There have been 
suggestions that dimers exist as the intermediate structure on the plasma membrane, where 
it forms the foundation for further oligomerisation and thus nanocluster formation (Tian et 
al., 2010; Sarkar-Banerjee et al., 2017). The remaining 56% of Ras proteins diffuse freely 
as mobile monomers (S.J. Plowman and Hancock, 2005).  
Earlier studies on Ras nanoclusters used relatively crude techniques. One methodology 
facilitated the use of non-ionic detergents at low temperatures to isolate the detergent-
resistant membrane fraction, which supposedly contains lipid rafts that are rich in SPH, 
cholesterol and glycolipids. This essentially solubilised the majority of the plasma 
membrane with the exception of these tightly packed membrane components. However, this 
process could introduce artefacts by ultimately generating artificial domains, therefore this 
membrane model was not ideal for reflecting the in vivo state (Heerklotz, 2002). Similarly, 
the use of sucrose density-gradient ultracentrifugation also carried the risk of perturbing 
membrane structures (Song et al., 1996). The evolution of high-resolution microscopy has 
been instrumental in providing more of an insight to the properties of Ras nanoclusters. For 
example, immunogold electron microscopy (EM) has been commonly used to visualise 2D 
23 
 
sheets of plasma membrane labelled with gold against Ras in order to analyse their spatial 
distribution (Parton and Hancock, 2004).  
1.5.3. Regulators of Ras nanoclustering 
The assembly of Ras nanoclusters depend on other factors. The three main components that 
are of importance include the actin cytoskeleton, lipid microenvironment as well as various 
regulatory proteins (Elad-Sfadia et al., 2004; Plowman et al., 2005; Belanis et al., 2008; 
Zhou et al., 2014). The proteome and lipidome microenvironments of Ras nanoclusters are 
generally not well-understood with only a few numbers of Ras nanocluster regulators having 
been identified to date. These include nucleolin, nucleophosmin (NPM), caveolin (CAV-1), 
galectin 1 (Gal-1), galectin 3 (Gal-3) and apoptosis-stimulating of p53 protein 2 (ASPP2).    
1.5.3.1. Nucleolin and NPM 
Both nucleolin and NPM are nucleolar proteins that can traffic to the cytoplasm. They are 
both involved in ribosome biogenesis and chromatin remodelling, however one study 
revealed that these nucleolar proteins were able to localise to the plasma membrane where 
they might be involved in the regulation of Ras nanoclustering (Inder et al., 2009a; 
Abdelmohsen and Gorospe, 2012; Box et al., 2016).  
Using affinity chromatography, NPM and nucleolin were found to bind to the HVR of 
KRAS (Inder et al., 2009a). Specifically, the N-terminal of NPM was responsible for 
binding the C-terminal polybasic domain of KRAS. This interaction was further enhanced 
when the farnesyl group was blocked, which coincided with later results whereby interaction 
between NPM/nucleolin and KRAS was seen at the plasma membrane, where the farnesyl 
group is hidden in the lipid bilayer. Lastly, EM immunogold labelling revealed that both 
NPM and nucleolin increased KRAS WT and KG12V expression at the plasma membrane, 
which corresponded to an increase in ERK activation. However, only NPM was able to 
increase KRAS nanoclustering (Inder et al., 2009a). Although, the exact mechanism is 
unclear, the authors suggested that nucleolin might act like a chaperone protein and aid the 
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localisation of KRAS to the plasma membrane, whereas NPM interacts with KRAS at the 
plasma membrane in order to regulate their clustering (Inder, Hill and Hancock, 2010).     
1.5.3.2. CAV-1 
As mentioned previously, caveolae are a type of plasma membrane microdomain. These 
small invaginations enriched with cholesterol and glycosphingolipids span between 50-
80nm (Örtegren et al., 2004). One of the major components of caveolae is CAV1 (Rothberg 
et al., 1992). Depletion of CAV1 affects the membrane lipid profile and organisation, in 
particular the glycosphingolipid and sphingolipid biosynthesis pathway become 
desregulated. Clustering of PS was also observed in CAV1-KD cells, suggesting that CAV1 
modulates the organisation of PS at the plasma membrane. Similarly, CAV1 appears to play 
a role in the organisation of Ras nanoclusters. Whereby the effect of CAV1 depletion 
differed between the different isoforms, KRAS nanoclustering was enhanced whereas 
HRAS nanoclustering was reduced. Overall, it appears that CAV1 can alter Ras 
nanoclustering via its role in modulating the lipid composition of the plasma membrane 
(Ariotti et al., 2014).      
1.5.3.3. Gal-1 and Gal-3 
Galectins are defined by their conserved β-galactoside binding sites located in their 
carbohydrate recognition domains. Similar to Ras, they are synthesised in the cytosol, where 
they can reside or alternatively traffic to the nucleus. Some galectins can also undergo a 
non-classical secretory pathway (Johannes, Jacob and Leffler, 2018).  Two members of the 
galectin family, Gal-1 and Gal-3 have found to play important roles in the regulation of 
specific Ras nanoclusters (Belanis et al., 2008; Shalom-Feuerstein et al., 2008).      
An initial study showed that Gal-1 was recruited to the plasma membrane as a result of 
HRAS activation (Paz et al., 2001). Results revealed that Gal-1 was important for active 
HRAS nanoclustering, since decreased HG12V clustering was seen with reduced Gal-1 
expression (Prior et al., 2003). Using a combination of high-resolution microscopy 
techniques such as EM, fluorescence lifetime imaging-fluorescence resonance energy 
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transfer (FLIM-FRET) and biomolecular fluorescence complementation (BiFC) 
microscopy, it was demonstrated that Gal-1 is an important component of active HRAS 
nanoclusters. Interestingly, it appeared that Gal-1 aided the stabilisation of these structures 
and as a result, prolonged Raf activation. In addition, Gal-1 can also function as a chaperone 
protein that aids the transport of depalmitoylated HRAS to the Golgi (Belanis et al., 2008). 
Previously, computational modelling showed that Gal-1 bound directly to the C-terminal 
farnesyl group of active HRAS via its hydrophobic prenyl-binding pocket (Rotblat et al., 
2004). However, this model has since been revised by another group, which showed that the 
interaction occurs indirectly via its association with the RBD of Ras effectors. This newer 
theory proposes that Gal-1 is recruited to Ras effectors like Raf as a result of Ras activation. 
It is suggested that the ability of Gal-1 to dimerise and therefore generate Gal-1 dimers could 
in turn stabilise the Raf dimers (Blaževitš et al., 2016). Altogether, Gal-1 appears to be a 
HRAS-GTP specific nanocluster regulator.   
Another important regulator of Ras nanoclustering is Gal-3 (Shalom-Feuerstein et al., 2008). 
Active KRAS appears to recruit Gal-3 to the plasma membrane, whereby the hydrophobic 
pocket of the carbohydrate recognition domain of Gal-3 is responsible for binding the 
farnesyl group of KRAS. Here, Gal-3 acts as a scaffold for the formation of KRAS-GTP 
nanoclusters. Its fundamental role in KRAS biology was demonstrated by the reduction in 
downstream Ras signalling and transformative potential in the presence of impaired Gal-3 
that harbour mutated prenyl binding pockets (Shalom-Feuerstein et al., 2008).    
1.5.3.4. ASPP2 
Unlike other Ras nanocluster regulators mentioned, ASPP2 is the only regulator to date that 
has shown to enhance clustering of all Ras isoforms (Posada et al., 2016). In oncogenic 
G12V mutants of KRAS, HRAS and NRAS, ASPP2 increased Ras effector signalling but 
with an outcome of promoting senescence and reducing mammosphere formation. 
Interestingly, ASPP2 was found to block Gal-1 regulated nanoclustering, thus diverting the 
cellular fate from pro-tumourigenic to anti-tumourigenic. Although it is unclear how ASPP2 
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interacts with Ras, it has been previously shown that ASPP2 can induce Raf dimerization 
and therefore the authors suggested that ASPP2 might act in a similar manner to Gal-1 in 
inducing the observed nanoclustering effects (Z. Wang et al., 2013; Posada et al., 2016).       
1.5.4. Ras isoform-dependent nanoclusters 
The microenvironment of isoform-specific nanoclusters differ and exhibit dissimilarities in 
their dependence for actin, lipid species and types of proteins for their assembly and 
localisation (Elad-Sfadia et al., 2004; Plowman et al., 2005; Belanis et al., 2008; Zhou et 
al., 2014).  
1.5.4.1. KRAS 
The KRAS membrane anchor comprises of basics residues that allow for electrostatic 
interactions with the anionic lipids amongst the plasma membrane. This is further 
complicated by the G-domain, which adopts different orientations with respect to the plasma 
membrane depending on whether its GDP or GTP-bound (Abankwa et al., 2010). However, 
one study has shown that the membrane anchor does not simply engage the plasma 
membrane as a result of electrostatics. Instead, the membrane anchor encodes a complex 
lipid sorting code. The combination of the prenyl group along with the code determines the 
dynamic conformation of the membrane anchor and thus the residues involved in membrane 
binding, which ultimately defines the lipid preferences (Zhou et al., 2017).     
As a result of this lipid-sorting code, KRAS nanoclusters localise in PS enriched non-raft, 
i.e. cholesterol-independent, regions of the membrane (Prior et al., 2003; Zhou et al., 2014). 
These clusters are also dependent on another lipid species, phosphatidic acid (PA) and actin 
(Plowman et al., 2005; Zhou et al., 2014). In its GTP-bound form, KRAS also interacts with 
a regulatory protein, Gal-3, which promotes the activation of both Raf and PI3K (Elad-
Sfadia et al., 2004). 
1.5.4.2. HRAS and NRAS 
GDP-bound HRAS nanoclusters are cholesterol- and actin-dependent; in contrast to GTP-
bound nanoclusters (Prior et al., 2003; Zhou et al., 2014). Regulatory protein, Gal-1 binds 
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to and stabilises GTP-bound HRAS nanoclusters. Additionally, Gal-1 diverts the activation 
towards the Raf pathway as opposed to the PI3K pathway (Belanis et al., 2008).  
 
Figure 1.5| Schematic of isoform- and nucleotide-dependent Ras nanoclusters – Nanoclusters 
(represented by the Ras molecule) occupy either Ld non-lipid rafts or Lo lipid rafts, which vary in 
lipid composition, dependence on actin and regulatory proteins. 
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Phosphatidylinositol 4-phosphate (PI4P) is present in both active and non-active HRAS 
nanoclusters, however PIP2 and phosphatidylinositol 3-phosphate (PI3P) are preferentially 
associated with the latter (Zhou et al., 2014). For both KRAS and HRAS, the cluster 
lifetimes for inactive Ras (<0.1s) is significantly shorter than active Ras (0.5-1s) (Murakoshi 
et al., 2004). However, this is unknown for NRAS, which has only been shown to be 
dependent on cholesterol when active (Roy et al., 2005). 
Altogether, it appears that KRAS nanoclusters localise within non-raft membranes 
irrespective of nucleotide state, whereas HRAS and NRAS nanoclusters laterally segregate 
between raft and non-raft regions depending on whether GDP- or GTP-bound (Prior et al., 
2003; Roy et al., 2005). However, it is likely that this is an oversimplification of the 
nanocluster microenvironments. Nonetheless, further studies and higher resolution 
techniques will help unravel and provide a better insight into these complex nano-
organisations.   
1.6. ROLE IN CANCER 
1.6.1. Oncogenic Ras 
Normal cells require stimulatory signals to transition from a quiescent state to an activated 
proliferative state. However, in the presence of an oncogene, i.e. a gene with transformative 
potential, a cell can become self-sufficient and propagate its own cellular growth and 
proliferation (Hanahan and Weinberg, 2011). The Ras proto-oncogene can become 
oncogenic when an activating mutation occurs within its gene, leading to aberrant 
constitutive cellular signalling (Marshall, Hall and Weiss, 1982). These  mutations are 
common and are responsible for the high number of Ras-related cancer cases (Mo, Coulson 
and Prior, 2018).    
In cancer, majority of these Ras mutations occur at codons 12, 13 and 61, which are located 
within the P-loop and switch II region, respectively (Mo, Coulson and Prior, 2018). 
Normally, the amino acid at codons 12 and 13 is glycine, however mutations at these 
positions often result in a single base substitution. As a result, glycine can convert into 
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different amino acids (with the exception of proline) such as alanine (A), arginine (R) 
aspartate (D), cysteine (C), serine (S) or  valine (V) (Muñoz-Maldonado, Zimmer and 
Medová, 2019). As a result of the mutation, GTP hydrolysis is hindered as it prevents the 
entry of the arginine finger of GAP into the GTPase site (Scheffzek et al., 1997).  
Similarly, mutations at glutamine-61 impairs both the GAP-mediated and intrinsic GTPase 
activity (Frech et al., 1994). Other less common mutations such as A146 have shown to 
affect nucleotide binding by increasing GDP dissociation (Edkins et al., 2006). These 
activating mutations result in Ras becoming resistant to GAPs and thus remaining GTP-
bound. Therefore, cells harbouring the Ras mutation are no longer in a state of equilibrium 
and instead undergo uncontrolled cellular growth and proliferation, which often leads to 
transformation of the cell. However, not all of these activating mutations result in equal 
transformation (Der, Finkel and Cooper, 1986; Miller and Miller, 2012; Winters et al., 
2017).   
1.6.2. Incidence of Ras mutations 
 
Figure 1.6| Ras mutations – Most common Ras mutations occur in the effector lobe at codons 12, 
13 and 61. Percentage of each Ras mutation contributing to the total number of Ras -related cancer 
cases are shown for each Ras isoform (adapted from Mo, Coulson and Prior, 2018).  
Ras mutations are present in around 17% of human cancer cases. Majority of these cases are 
linked to KRAS mutations (69%), which are predominantly associated with lung, pancreatic 
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and colorectal carcinomas. The next commonly mutated Ras isoform is NRAS (22%), with 
over half of these cases being associated to melanomas. The least frequently mutated Ras, 
HRAS is only present in around 9% of these cases and occur mainly in bladder cancers and 
head and neck cancers (Mo, Coulson and Prior, 2018).  
Another complexity added to the incidences of Ras-associated cancers are the different types 
of Ras mutations (Fig. 1.6). Most of the KRAS mutations (81%) occur at G12, whereas in 
NRAS cases, a large proportion (62%) are linked to Q61. Differently, HRAS mutations 
display only a slight bias towards Q61 (38%) compared to G12 (26%), G13 (23%) and other 
mutations (13%) (Mo, Coulson and Prior, 2018).  
1.7. RAS THERAPEUTICS  
The high prevalence of Ras mutations in cancers makes it a desirable drug target for cancer 
therapy. Since its discovery, there have been many attempts at both direct and indirect 
inhibition, however, an FDA-approved anti-Ras therapy has yet to be discovered 
(Friedlaender et al., 2020).   
1.7.1. Direct inhibitors 
At current, therapeutics for direct inhibition have focused on either targeting their activation 
state, effector binding or dimerization (Lacal and Aaronson, 1986; Spencer-Smith et al., 
2017; Friedlaender et al., 2020).  
1.7.1.1. KRAS G12C inhibitors 
One of the more successful drug targets recognises a pocket in the switch II region of GDP-
bound Ras and prevents Sos-GEF activity, as well as effector binding by disrupting both the 
switch I and II regions. This novel drug specifically binds to the mutant cysteine in KRAS 
G12C (accounts for 11% of KRAS-mutated cancers) and prevents it from being GTP-bound 
(Ostrem et al., 2013). Currently, three KRAS G12C small molecule inhibitors are being 
tested in clinical trials: AMG-510, ARS-3248 and MRTX849, mainly in patients with non-
small cell lung carcinoma (NSCLC) where this mutation is most commonly found (Canon 
et al., 2019; Fell et al., 2020; Friedlaender et al., 2020). The promising findings from the 
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first clinical trial of AMG-510 revealed that the treatment either partially shrank the tumour 
or prevented progression of tumour growth in the 13 NSCLC participants (Friedlaender et 
al., 2020). 
Aside from blocking nucleotide exchange, other inhibitors have been used to target effector 
binding sites. One of the first Ras inhibitors to be discovered was Y13-259, a neutralising 
monoclonal antibody which blocked effector binding. However, this treatment failed to 
penetrate cells and therefore was not successful (Lacal and Aaronson, 1986). More 
promising drugs are being discovered using computational analyses of Ras structures, as 
these reveal potential ligand binding pockets that could block Ras-effector interactions 
(Tanaka, Williams and Rabbitts, 2007).  
1.7.1.2. Inhibition of Ras dimerization  
A more recent approach is to inhibit Ras dimerization, which is considered to be a 
prerequisite for nanocluster formation and subsequent Ras signalling. A monobody, NS1 
has been used to target the α4-α5 region, the proposed dimerization site. Preliminary data 
reveals that the monobody was able to inhibit Ras dimerization and its consequential 
signalling. Transformation mediated by oncogenic Ras was abrogated both in vitro and in 
vivo (Spencer-Smith et al., 2017).  
1.7.2. Indirect inhibitors 
The lack of deep binding pockets for small inhibitory molecules observed in structural 
studies revealed a possible caveat in using direct inhibition as a pharmacological treatment. 
Therefore, efforts have also been made towards indirect methods, which focus on targeting 
other factors such as membrane localisation; a fundamental process required for oncogenic 
Ras activity (Whyte et al., 1997; Zhou et al., 2012; Cho, Park and Hancock, 2013; van der 
Hoeven et al., 2013).   
1.7.2.1. Farnesyltransferase inhibitors 
Some of the first attempts at preventing Ras association with the membrane centred on 
targeting enzymes required for PTMs of the Ras CAAX domain, in particular the inhibition 
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of FTases (FTIs). However, results soon revealed that KRAS and NRAS were unaffected 
by FTIs, due to an alternative lipidation process via geranylgeranyltransferases (Whyte et 
al., 1997). On the other hand, HRAS appears to be dependent on FTases and therefore, FTIs 
could be beneficial in HRAS-associated cancers. However, its specificity for other 
substrates may also cause potential toxicity (Cohen-Jonathan et al., 2009).    
1.7.2.2. PDEδ inhibitor 
Another inhibitor tested was Deltarasin. This drug targets PDEδ, which binds the 
farnesylated tail of KRAS and is required for efficient membrane localisation (Chandra et 
al., 2012; Zimmermann et al., 2013). Disruption of this interaction led to KRAS mis-
localisation and a reduction in activity (Zimmermann et al., 2013). However, its specificity 
for KRAS has been questioned as it appears to regulate other Ras isoforms as well as other 
farnesylated proteins (Chandra et al., 2012).   
1.7.2.3. Pharmacological agents against Ras nanoclustering 
Other attempts are based on perturbing Ras nanoclustering. An L-type calcium channel 
blocker called Fendiline has shown to specifically reduce KRAS nanoclustering by 
redistributing KRAS to other cellular components. However, its actual mechanism is 
unknown but does not appears to be related to its known role of calcium channel inhibition 
(van der Hoeven et al., 2013).  
Staurosporines and nonsteroidal anti-inflammatory drugs (NSAIDs) have shown to alter the 
concentration of PS and cholesterol within the plasma membrane, respectively (Zhou et al., 
2012; Cho, Park and Hancock, 2013). It appears that staurosporines inhibit KRAS 
nanoclustering specifically by redistributing PS from the plasma membrane to 
endomembranes, but the underlying mechanism is not linked to its the role in terms of PKC 
inhibition (Cho, Park and Hancock, 2013). Whereas NSAIDs like indomethacin perturb 
lateral segregation between cholesterol-dependent and independent regions in HRAS and 




1.8.1. Isoform-specific differences 
It has become increasingly evident that Ras isoforms are not functionally redundant, 
differing in aspects ranging from localisation to human disease (Prior et al., 2003; Tidyman 
and Rauen, 2016; Mo, Coulson and Prior, 2018). Ras isoforms are similar in sequence 
amongst the G-domain region, however main differences occur at the C-terminal which is 
responsible for membrane localisation. As mentioned previously, these Ras isoforms 
assemble into spatially distinct nanoscale domains at the plasma membrane, where 
downstream signalling occur. The occupancy of different locations within the plasma 
membrane exposes each Ras isoform to a unique combination of lipids and proteins, where 
the available pool of effectors could differ for each Ras isoform (Zhou and Hancock, 2015).  
Previously reported, different Ras isoforms exhibit differences in Ras signalling, whereby 
KRAS and HRAS are coupled to more potent activation of Raf and PI3K, respectively (Yan 
et al., 1998). Whereby, this isoform-specific signalling could be due to the orientation of the 
effector-binding domain (Abankwa et al., 2010). However, more recently, a large-scale 
short interfering RNA (siRNA) screen highlighted that effector dependence differed 
according to the cell line investigated (Yuan et al., 2018). It has also been suggested that the 
use of ectopic overexpression could also distort the signalling outcomes, since the signalling 
pattern of endogenously expressed Ras differed from those overexpressed (Hood et al., 
2019). Although, Ras effector signalling appears to be context-dependent, the variation in 
signalling between the Ras isoforms cannot be disputed due to the observed functional 
differences. For example, in mice colonic epithelium, mutant HRAS hindered growth of 
endodermal progenitors, whereas mutant KRAS stimulated their proliferation (Quinlan et 
al., 2008). 
Another important line of evidence for isoform differences come from clinical studies. Each 
Ras isoform is biased towards certain cancer types as well as different RASopathies, a group 
of developmental syndromes caused by germline mutations of Ras or Ras related proteins. 
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Each RASopathy present unique features in addition to a set of morphological and 
behavioural traits shared amongst these rare genetic disorders (Tidyman and Rauen, 2016). 
Both KRAS and NRAS mutations have been found in Noonan syndrome (Schubbert et al., 
2006; Cirstea et al., 2010), whereas only HRAS and KRAS mutations are present in Costello 
(CS) and cardiofaciocutaneous (CFC) syndromes, respectively (Aoki et al., 2005; Niihori et 
al., 2006). Aside from the common dysmorphic craniofacial features and learning 
difficulties, CS patients also present with a likelihood of developing malignancies like 
rhabdomyosarcomas and neuroblastomas (Gripp et al., 2002). Differently, CFC individuals 
are characterised by the presence of distinct pigmented nevi (Siegel et al., 2011).  The 
manifestation of these different clinical features in association with each Ras isoform 
presents a clear indication of their fundamental differences.  
1.8.2. Project Aims 
Ras mutations are responsible for millions of new cancer cases each year (Mo, Coulson and 
Prior, 2018). The search for a therapeutic drug to target Ras has been longsome and puzzling, 
which highlights the importance of delving into Ras biology in order to identify new 
approaches for Ras inhibition. One of the fundamental bases for Ras function stems from its 
localisation; nanoclustering is required for optimal Ras signalling.  
The proteome microenvironment of Ras nanoclusters is not well understood, therefore, 
identification of novel proteins within Ras nanoclusters that could be vital for its regulation 
and/or assembly could be of therapeutic interest (Fig.1.7). More importantly, distinguishing 
the differences between the Ras isoform nanoclusters may identify isoform-specific 
proteins, that could be candidate targets for cancers associated with a certain Ras isoform.  
Thus, the project aims are as follows: 
1. To investigate the protein microenvironment of all three Ras isoforms in both their 
inactive and active (GTP-bound and G12V mutant) state.  
2. To produce a shortlist of proteins that might play a role in Ras nanoclustering. 
35 
 
3. To explore its relationship with Ras and whether it has an effect on Ras 
nanoclustering.  
 
Figure 1.7| Identification of novel Ras nanocluster regulators – Comparison of the protein 
microenvironments of inactive and active KRAS, HRAS and NRAS isoforms in order to identify 






Material and Methods 
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2.1. CELL BIOLOGY  
All reagents were purchased from Thermo Fisher Scientific unless stated otherwise.  
2.1.1. Cell culture 
For this project, human cervix carcinoma cell lines, HeLa S3 (ATCC) were used due to their 
high transfection efficiency. Cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) with GlutaMAX (31966021) supplemented with 10% fetal bovine serum (FBS 
(10270) in a humidified incubator maintained at 37°C and 5% CO2. Every 48-72 hours, cells 
were washed with phosphate buffered saline (PBS (14200067)) followed by incubation with 
0.5% Trypsin-EDTA (15400054) before being passaged at a 1:3 – 1:7 ratio.  
2.1.2. DNA transfection 
GeneJuice Transfection Reagent (Merck, 70967) was used for transient expression of Ras 
and annexins in HeLa S3 cells. Seeding density varied for experiment type. For western 
blots, 3x105 cells/well were seeded into a 6-well plate. Whereas 1.1x107 cells were seeded 
equally between two 15cm2 plate for mass spectrometry. Following overnight incubation, 
culture medium was replaced with fresh media. Preparation of transfection reagent consisted 
of adding 6/45µl GeneJuice into 0.1/1ml Opti-MEM (51985026) and incubated for 5 
minutes at room temperature. Then 1/15 µg of DNA was mixed into the Opti-MEM solution 
and left at room temperature for a further 20 minutes. The resulting solution was gently 
added to the cells and incubated at 37°C for 24 hours before being harvested.   
2.1.3. siRNA knockdown 
For siRNA knockdown experiments of annexin 2 and 6, ON-TARGETplus Human 
SMARTpool (5 nmol) of ANXA2 (Dharmacon, L-010741-00- 0005), ANXA6 (Dharmacon, 
L-011210-00- 0005) and non-targeting control (NT1, Dharmacon, D-001810-10-05) siRNA 
were used. These were resuspended with 1x siRNA buffer to a stock concentration of 20µM 
and stored at -20°C before use. The previous day, 1.5x105 cells/well were seeded into a 6-
well plate. Then two solutions were prepared for the knockdown, which were initially 
incubated separately at room temperature for 5 minutes. The first solution consisted of 2µl 
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siRNA and 83µl Opti-MEM and the second solution was made up of 2µl RNAiMax and 
83µl Opti-MEM. After the incubation, the solutions were combined and stored at room 
temperature for 20 minutes. Media was aspirated from the cells and replaced with 830µl 
fresh media for each well (6-well plate) before the addition of the siRNA reaction. After 6 
hours, media was exchanged for fresh media. Cells were lysed after 48-72 hours.  
2.1.4. Cell treatment 
Stimulated and serum-starved samples were washed twice with PBS and replaced with 
serum-free DMEM media post-transfection (24 hours). Cells were starved for 5 hours. For 
stimulated samples, following serum-starvation, media was exchanged for fresh media 
supplemented with 20% FBS for 5 minutes before cell lysis.      
2.2. MOLECULAR BIOLOGY 
All reagents unless otherwise stated were purchased from New England Biolabs.  
2.2.1. Primers  
Primers (Eurofins Genomics) were designed to amplify the FLAG-tagged APEX2 inserts 
from the template: APEX2-Actin in pEGFP. In addition to the insert, a restriction 
endonuclease (RE) site, NheI was introduced to the N-terminus as well as a linker region 
and another RE site, BglII to the C-terminus.  
Table 2.1| Summary of primers used for APEX2 cloning. 
Name Sequence (5’ – 3’) Length Tm GC content  
N_APX2_SM TCCGCTAGCGCTACCGGTCGCCACCAT
GGACTACAAGGAT 












65 >75°C 67.7% 
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2.2.2. Plasmids  
Plasmids Company Catalog no. 
EGFP-KRAS WT As previously described (Prior et al., 2001) 
EGFP-KRAS G12V As previously described (Prior et al., 2001) 
EGFP-HRAS WT As previously described (Prior et al., 2001) 
EGFP-HRAS G12V As previously described (Prior et al., 2001) 
EGFP-NRAS WT As previously described (Aran and Prior, 2013) 
EGFP-NRAS G12V As previously described (Aran and Prior, 2013) 
GFP-tK As previously described (Prior et al., 2001) 
GFP-tH As previously described (Prior et al., 2001) 
FLAG-APEX2-KRAS WT Made in house  
FLAG-APEX2-HRAS WT Made in house 
FLAG-APEX2-NRAS WT Made in house 
FLAG-APEX2-KG12V Made in house 
FLAG-APEX2-HG12V Made in house 
FLAG-APEX2-NG12V Made in house 
FLAG-APEX2-tK Made in house 
FLAG-APEX2-tH Made in house 
FLAG-APEX2 Made in house 
mCherry- KRAS WT Gift from Dr Luke Chamberlain (Uni. Of Strathclyde)  
mCherry- KG12V Gift from Dr Luke Chamberlain (Uni. Of Strathclyde)  
mCherry- HRAS WT Gift from Dr Luke Chamberlain (Uni. Of Strathclyde)  
mCherry- HG12V Gift from Dr Luke Chamberlain (Uni. Of Strathclyde)  
mCherry- NRAS WT Gift from Dr Luke Chamberlain (Uni. Of Strathclyde)  
mCherry- NG12V Gift from Dr Luke Chamberlain (Uni. Of Strathclyde)  
APEX2-Actin in pEGFP Addgene 66172 
pcDNA3.1(+)-N-eGFP-annexin 2 GenScript Ohu13706C  
pcDNA3.1(+)-N-eGFP-annexin 6 GenScript Ohu00168C  
pcDNA3.1(+)-N-eGFP-annexin A7 GenScript Ohu02797C  
pEGFP-C1 Clontech (Discontinued)  
pEGFP-C2 Clontech 6083-1 
pEGFP-C3 Clontech 6082-1 
Table 2.2| List of plasmids.  
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2.2.3. Polymerase Chain Reaction   
The primers as listed in Table 2.1 were reconstituted with water to a stock concentration of 
100pmol/µl. This was further diluted to 20mM using water for use in the polymerase chain 
reaction (PCR). Each PCR sample consisted of the following 41.5µl water, 5µl dNTPs 
(25mM), 1µl Pfu Ultra II hot start polymerase, 0.5µl forward primer (20mM), 0.5µl reverse 
primer and 1µl DNA template (50ng/µl). 
For the amplification of FLAG-tagged APEX2 that were capable of insertion into the three 
pEGFP vectors: C1, C2 and C3, three different inserts were required. Therefore, three 
different PCRs were set up using the N-APX2_SM as the forward primer and either 
C1_APX1_SM, C2_APX2_SM or C3_APX2_SM as the reverse primer. Actin-APEX2 in 
pEGFP was used as the template DNA for the amplification of APEX2 and water was used 
as a control template. The reactions were placed in a thermal cycler where the samples were 
heated to 95°C for 2 minutes before undergoing 35 sequential cycles of 30 seconds at 95°C, 
30 seconds at 55°C and 30 seconds at 72°C. Followed by 5 minutes at 72°C. The resulting 
PCR products were visualised using gel electrophoresis and the correct sized gel bands were 
excised for DNA extraction.  
2.2.4. Agarose gel electrophoresis 
0.8-1.2% agarose gels were prepared by heating together UltraPure™ Agarose (Invitrogen, 
15510-019) and 1X TAE (diluted from 50X TAE (National Diagnostics, EC-872)). Once 
dissolved, ethidium bromide was added to the solution at a final concentration of 0.5µg/ml, 
then poured into gel tanks to set at room temperature. Samples were prepared using 6X gel 
loading dye (B7021S) and ran alongside Quick-Load 1kb plus DNA Ladder (N0550) and/or 
100bp DNA ladder (B7025). Typically, the gels were ran in 1X TBE running buffer (diluted 
from 10X TBE (National Diagnostic, EC-860)) for 50-80 minutes at 120V.     
2.2.5. Ligation 
DNA was eluted from gel pieces containing either vector or insert DNA using the QIAquick 
Gel Extraction Kit (Qiagen, 28115). Resulting DNA was mixed in a 3:1 ratio of insert to 
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vector and adjusted to 9µl with nuclease-free H2O, then incubated with 10µl Quick Ligase 
Reaction buffer and 1µl Quick Ligase from the Quick Ligation Kit (M2220) for 5 minutes 
at room temperature. Then stored on ice before being transformed into competent cells.    
2.2.6. TOPO PCR cloning 
To generate subcloning vector intermediates containing the APEX2 inserts, the Zero 
Blunt™ TOPO PCR kit (ThermoFisher Scientific, K283020) was used. Firstly, PCR 
amplification products were resolved using gel electrophoresis and visualised under UV 
light for excision. DNA was extracted from the excised gel pieces using the QIAquick Gel 
Extraction Kit. Resulting blunt-end PCR products were directly inserted into TOPO vector 
via incubation of both these components with a salt solution for 30 minutes at room 
temperature. Transformation of these cloning vectors into TOPO10 cells were performed as 
described in the next subsection.   
2.2.7. Bacterial transformation 
Ligation products were transformed into either TOPO10 or DH5α cells by a succession of 
incubations at different temperatures: 20 minutes on ice followed by heat shock at 42°C for 
30 seconds and another 2 minutes on ice. The resulting cells were incubated with SOC 
medium for 1 hour at 37°C in a shaker of 225rpm to encourage bacterial growth. This was 
spread on LB agar plates containing the relevant antibiotic (100µg/ml ampicillin or 50µg/ml 
kanamycin) and incubated overnight at 37°C. Colonies were selected and amplified in LB 
media supplemented with appropriate antibiotic at 37°C with gentle shaking (225rpm) 
overnight. The bacterial culture was spun down at 15,000g for 10 minutes and plasmid DNA 
was extracted using the QIAprep Spin Miniprep kit (Qiagen, 27104) following 
manufacturer’s instructions. The resulting plasmid DNA was validated via RE test digests 
and sent for sequencing (MRC PPU DNA Sequencing and Services, Dundee, Scotland). 
Amplification of plasmid DNA was performed using the QIAGEN Plasmid Maxi Kit 
(Qiagen, 12163) following confirmation of the DNA sequence. In addition, glycerol stocks 
were made by pelleting 5ml overnight bacterial culture and resuspending in 2ml of 40% 
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glycerol in LB broth. This was stored at -80°C.  
2.2.8. Restriction endonuclease digest 
NheI-HF (R3131) and BglII (R1044) enzymes were used to do a test digest of the TOPO10-
APEX2 plasmids to check for the FLAG tagged-APEX2 insert. Once confirmed, the same 
enzymes were used to digest TOPO10-APEX2-C1/C2/C3 and the following vectors: 
pEGFP-C1, -C2. -C3, -truncated minimal membrane anchors of KRAS (tK) and HRAS (tH). 
Each RE digest reaction consisted of 2µg DNA, 1µl NheI-HF, 1µl BglII, 4µl NEBuffer™ 
2.1 (B7202S) and made up to a total volume of 50µl with dH2O. The reaction was incubated 
for 15 hours at 37°C, then in 80°C for 2 minutes. Test digests were scaled to 10µl volume 
reactions. Resulting products were validated using gel electrophoresis. Gel bands for the 
APEX2 inserts and EGFP-absent vectors were excised, then DNA was extracted from these 
gel pieces. The resulting APEX2 inserts was ligated to each vector accordingly to generate 
APEX2-C1, APEX2-C2, APEX2-C3, APEX2-tK and APEX2-tH.     
For the generation of APEX2-KRAS WT, -KG12V, -HRAS WT and -HG12V, SacI-HF and 
KpnI were used to digest APEX2-C1/C2/C3 and EGFP-KRAS WT/KG12V/HRAS 
WT/HG12V in NEBuffer™ 2.1 (B7202S) for 4 hours at 37°C, followed by 65°C for 20 
minutes. Similarly, APEX2-NRAS WT and -NG12V were cloned using BamHI-HF and 
SacI-HF. These REs were incubated with either APEX2-C3 or EGFP-NRAS WT/NG12V 
for 4 hours at 37°C in CutSmart® Buffer (B7204S), then at 65°C for a further 20 minutes. 
Digested products were ran on an agarose gel and DNA was extracted from the 
corresponding gel band.  The final products were formed via ligation of the APEX2 insert 
with the respective Ras vector. Lastly, these constructs were verified by DNA sequencing.  
2.3. PROTEIN BIOCHEMISTRY 
2.3.1. Reagents 
Reagent Company Catalog No. 
Biotin Sigma-Aldrich B4501 
Biotin phenol  Iris-Biotech 41994-02-9 
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Bovine Serum Albumin  First Link 41-10-410 
Bromophenol blue Sigma-Aldrich B0126 
DTT Melford biolaboratories  20291 
Glycerol Sigma-Aldrich G6279 
Glycine Melford biolaboratories G0709 
Hydrochloric acid Sigma-Aldrich 320331 
Hydrogen Peroxide, 30%  Sigma-Aldrich H1009 
Methanol Thermo Fisher Scientific M/4000/PC17 
Nonidet P-40 substitute Fluka 74385 
PMSF G-Biosciences 786-055 
Potassium chloride Sigma-Aldrich P5405 
Protease inhibitor cocktail  Sigma-Aldrich P8340 
Sodium Ascorbate Sigma-Aldrich A-7631 
Sodium Azide Sigma-Aldrich 13412 
Sodium Carbonate Sigma-Aldrich S2127 
Sodium Chloride Thermo Fisher Scientific S/3160/60 
Sodium deoxycholate Sigma-Aldrich 30970 
Sodium dodecyl sulfate Sigma-Aldrich L4509 
Tris Base Thermo Fisher Scientific BP152-1 
Trolox Sigma-Aldrich 238813-25G 
Tween GeneFlow EC-607 
Urea Sigma-Aldrich U1363 
Table 2.3| List of reagents used for protein biochemistry experiments. 
2.3.2. Cell lysis  
For non-APEX2 experiments, cells were placed on ice and washed twice in ice cold PBS to 
remove any traces of media. Then NP40 lysis buffer (0.5% Nonidet P-40 substitute (w/v), 
25mM Tris (pH 7.5), 100mM NaCl, 50mM NaF, milliQ water) was added directly to the 
cells and incubated for 15 minutes with gentle rocking. Lysates were collected and 
impurities were pelleted by centrifugation (15,000g, 10 minutes, 4°C). Supernatant was 
collected and protein concentration was measured using the Pierce™ BCA Protein Assay 
Kit (Thermo Fisher Scientific, 23225). 
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2.3.3. Proximity labelling 
Preliminary experiments using RIPA lysis buffer (50mM Tris, 150mM NaCl, 1% Triton X-
100, 0.1% SDS, 0.5% sodium deoxycholate in d H2O adjusted to pH 7.5) appeared to result 
in the contamination of genomic DNA on western blots, therefore NP40 lysis buffer was 
used instead. The NP40 lysis buffer was modified for the APEX2 experiments by 
supplementation with 1:250 mammalian protease inhibitor (MPI), 1mM PMSF, 10mM 
sodium ascorbate, 10mM sodium azide and 5mM trolox. 
Previous to cell lysis, cell media was replaced with prewarmed DMEM supplemented with 
biotin phenol (BP, final concentration: 500μM) for 30 minutes (37°C, 5% CO2) at 24 hours 
post-transfection. Then hydrogen peroxide (H2O2) was added to each well (final 
concentration – 1mM) for 15-240 seconds. For control samples, no H2O2 was added. Media 
from each well was immediately aspirated after specified incubation period of H2O2 and 
washed three times with quencher solution (10mM sodium ascorbate, 10mM sodium azide, 
5mM trolox in PBS). Then NP40 lysis buffer containing MPI and quenchers were added to 
the cells for 15 minutes with gentle rocking at room temperature (due to the precipitation of 
trolox if performed on ice). Cell lysates were collected and centrifuged at 15,000g for 10 
minutes at 4°C.  Supernatant was quantified using the Pierce™ 660nm protein assay then 
stored at -20°C before use.  
For the enrichment of biotinylated proteins, an initial small-scale experiment was performed 
using 360µg lysate to 20/30/40µl streptavidin beads. This was later scaled up for mass 
spectrometry experiments, where 2.5mg lysate was incubated with prewashed streptavidin 
beads (total volume – 2.2ml) for 1 hour on a rotator at room temperature. Here, the sample 
was divided into two Lo-bind tubes, i.e., 1.25mg lysate with 104.2μl streptavidin beads. 
Samples were pelleted on a magnetic rack and flowthrough was removed. The remaining 
beads were washed with a series of buffers in the following order: twice with RIPA buffer 
(10mM Tris-HCl (pH 7.5), 150mM NaCl, 1% Triton X100, 0.1% SDS (ThermoFisher 
Scientific), 1% Sodium deoxycholate, milliQ water), once with 1M KCL, 0.1M Na2CO3, 
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5M urea in 10mM Tris-HCl and twice again with RIPA buffer. At each wash step, the beads 
were vortexed, placed on the rotator for 5 minutes, then pelleted on a magnetic rack.  
Proteins were eluted from the beads by boiling the beads with 3X sample buffer (diluted 
from 6X sample buffer, 276mM Tris-HCl (pH 6.8), 7.9% SDS, 7.3% DTT, 28.4% glycerol, 
0.009% bromophenol blue, dH2O) supplemented with 2mM biotin and 20mM DTT for 10 
minutes at 110°C. Samples were vortexed, cooled on ice and then centrifuged at 13,000g at 
room temperature. The samples were placed back on to the magnetic rack in order to 
separate the eluate and streptavidin beads. Collected eluate was kept at -20°C before use.  
2.3.4. Immunoprecipitation 
2.3.4.1. FLAG IP 
Immunoprecipitation (IP) of FLAG-tagged protein complexes were achieved using anti-
FLAG M2 Affinity Gel (Sigma, A2220), which consists of 4% agarose beads covalently 
attached to mouse monoclonal anti-FLAG antibody. These beads were prepared via three 
sequential washes with YP-IP buffer (0.1% NP40 (v/w), 25mM Tris (pH 7.5), 150mM NaCl, 
dH2O) at 6000g for 30 seconds per wash.   
Cells transfected with FLAG-tagged APEX2-Ras were lysed with NP40 (as mentioned 
above in section 2.3.2). 0.8mg of lysate was made up to a volume of 800µl using NP40 lysis 
buffer then incubated with 40µl anti-FLAG beads for 2 hours at 4°C on a rotator (15rpm). 
Beads were pelleted at 6000g for 2 minutes and supernatant was stored at -20°C. Then beads 
were washed four times with YP-IP wash buffer. FLAG-tagged proteins were eluted from 
the beads by boiling the beads with 20µl 2X sample buffer (125mM Tris-HCl (pH 6.8), 4% 
SDS, 20% glycerol, 0.004% bromophenol blue, dH2O) at 95°C. Samples were centrifuged 
at 8200g for 30 seconds, allowing separation of FLAG-tagged proteins from the anti-FLAG 
beads. Supernatant was stored at -20°C until use.     
2.3.4.2. GFP IP 
20µl of GFP-NanoTrap beads (made in house) were washed three times with dH2O at 
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15,000g for 30 seconds per wash. Once prepared, 1mg/ml lysate of GFP-tagged annexin 
transfected cells was added to the beads and spun at 15rpm for 30 minutes at 4°C. Following 
the incubation, beads were pelleted at 15,000g for 30 seconds. Then washed three times with 
ice cold YP-IP buffer and once with 10mM Tris pH (pH 7.5). GFP-tagged proteins were 
eluted by boiling samples with 20µl of 2X sample buffer at 95°C for 5 minutes.       
2.3.5. SDS-PAGE 
Protein samples were prepared for loading on to precast NuPAGE 4-12% Bis-Tris gels 
(Thermo Fisher Scientific) with 5X sample buffer, then heated to 95°C for 5 minutes. The 
precast gel was placed into a NuPAGE gel tank and submerged with 1X NuPAGE MOPS 
SDS running buffer (diluted from 20X (Thermo Fisher Scientific, NP000102).  
Typically, 15-20µg of protein was loaded into each well, whereas for pulldowns, the total 
eluate volume was loaded. Molecular weight was measured using the Full range 
Amersham™ ECL™ Rainbow™ Marker (Sigma-Aldrich, RPN800E) alongside the 
samples. The protein gels were ran at an initial voltage of 100V until samples had passed 
from the wells into the gel, then raised to 180V for the remaining 50-60 minutes.       
2.3.6. Western blotting 
Proteins from the polyacrylamide gel were transferred on to Amersham™ Protran® Western 
blotting nitrocellulose membranes (Sigma-Aldrich, GE10600002) using a Royal Genie 
Blotter (Idea Scientific, 4020) containing transfer buffer (25mM Tris-Glycine, 20% 
methanol). This was ran at a constant 0.8A (~30V) for 1 hour and 10 minutes. The efficiency 
of the transfer and quality of the samples were assessed by staining the nitrocellulose 
membrane with Ponceau-S stain (Sigma-Aldrich, P7170). This stain was removed with 
multiple washes using H2O before subsequent blocking and incubation steps.  
All the following incubations were done with gentle agitation. The nitrocellulose membrane 
was placed in block, either 5% bovine serum albumin (BSA) or 5% milk (Marvel) in Tris-
buffered saline with Tween (TBST (10mM Tris, 150mM NaCl, 0.1% Tween 20, pH 7.4)) 
for 1 hour at room temperature. Then replaced with appropriate primary antibody (in block) 
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overnight at 4°C (see Table 2.4). The primary antibody was removed after incubation and 
any unbound antibody was washed off using three 5-minute TBST washes. Then incubated 
with the respective IRDye conjugate-secondary antibodies (LI-COR BioSciences) for 1 hour 
at room temperature. Lastly, the membrane was washed again twice in TBST (5-minutes 
per wash) and once with TBS (10mM Tris, 150mM NaCl, pH 7.4). The membrane was 
visualised on the LI-COR Odyssey Imaging System.     
2.3.7. Antibodies  
Antibody Company Catalog No. Dilution 
Anti-Pan Ras (rabbit) Abcam ab52939 1/5000 in 5% BSA 
Anti-FLAG (rabbit) Sigma-Aldrich F4725 1:1000 in 5% BSA 
Anti-NRAS (mouse) Cell Signalling F155 1/200 in 5% BSA 
Anti-ERK (rabbit) Cell Signalling 4695 1/1000 in 5% BSA 
Anti-B-Raf (mouse) Cell Signalling L12G7 1/1000 in 5% BSA 
Anti-PI3K-p110α (rabbit) Cell Signalling C73F8 1/1000 in 5% BSA 
Anti-pERK 1/2 (rabbit) Cell Signalling 4370S 1/2000 in 5% milk 
Anti-pMEK 1/2 (rabbit) Cell Signalling 9154S 1/1000 in 5% milk 
Anti-pAKT (rabbit) Cell Signalling 4060S 1/2000 in 5% milk 
Anti-beta actin (mouse) Abcam ab6276 1/10000 in 5% BSA  
Anti-annexin A1 (rabbit) Abcam ab214486 1/2000 in 5% BSA 
Anti-annexin A2 (rabbit) Abcam ab41803 1/5000 in 5% BSA/milk 
Anti-annexin A5 (mouse) Abcam ab54775 1/500 in 5% BSA 
Anti-annexin A6 (rabbit) Abcam ab201024 1/1000 in 5% BSA/milk 
Anti-annexin A7 (rabbit) Abcam ab197586 1/2000 in 5% BSA/milk 
Anti-annexin A11 (rabbit) Abcam ab137424 1/2000 in 5% BSA 
Anti-septin 2 (rabbit) Abcam ab58657 1:500 in 5% BSA 
Anti-GFP (sheep) Made in house by Prof. Prior. 1:5000 in 5% milk 
IRDye® 680LT Donkey anti-
Mouse IgG (H + L) 
LI-COR 
Biosciences 
926-68022 1:10000 in 5% BSA 
IRDye® 800CW Donkey anti-
Rabbit IgG (H + L) 
LI-COR 
Biosciences 
925-32212 1:15000 in 5% BSA 
IRDye® 800CW Streptavidin LI-COR 
Biosciences 
926-32230 1:10000 in 5% BSA 
Table 2.4| List of primary and secondary antibodies used for western blots. 
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2.3.8. Statistical analysis 
Statistical analyses were performed when appropriate for experiments with at least three 
independent repeats using GraphPad Prism 8.0. To determine the type of statistical test 
required, a normality test was performed to check the distribution of the data so that a 
statistical test could be chosen accordingly.  
2.4. PROTEOMICS 
2.4.1. In-gel digest  
Eluted samples were loaded into Novex precast gels (4-12% gradient, 10 well, 1.5mm) and 
ran at 100V for 15 minutes. The gel was fixed with 10% acetic acid and 50% methanol for 
10 minutes on a rocker. Once fixed, the gel was washed twice with water then each 
lane/sample was divided into top and bottom pieces. These pieces were further subdivided 
into 1mm2 square gel pieces. Resulting gel pieces were destained with 50mM ammonium 
bicarbonate (ambic (Sigma-Aldrich, 09830))/acetonitrile (ACN (VWR, 20060320)) at 37°C 
for 10 minutes at 900rpm. This step was repeated until gel pieces were opaque. Then, gel 
pieces were dehydrated with ACN for 5 minutes (900rpm, room temperature) before being 
placed into a speed vacuum for 5 minutes. Subsequent samples were reduced and alkylated 
using DTT (1hr, 900rpm, 56°C) and IAA (30 mins, 900rpm, room temperature (Sigma-
Aldrich, T-6125)), respectively. Then washed with 100mM ambic followed by 50mM 
ambic/ACN, both at room temperature for 15 minutes at 900rpm. Followed by dehydration 
using ACN and the speed vacuum. The dehydrated gel pieces were submerged in trypsin 
gold (Promega, V5280) for over 16 hours.  
The following day all supernatants were retained from the samples as well as from a series 
of incubations with ACN (30 mins, 900rpm, 30°C), 1% formic acid (20 mins at room 
temperature, repeated twice) and ACN again (10 mins, 900rpm, RT). Collected supernatant 
was dried in the speed vacuum until no liquid was present. For KRAS and NRAS, samples 
were processed by Dr Emma Rusilowicz-Jones on the LTP-Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific) based at the University of Liverpool. The dried peptides of the 
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remaining samples were resuspended in buffer A (0.5% acetic acid) then loaded on to 
previously made C18 stage tips that had been prewashed in methanol, buffer B (0.5% acetic 
acid and 80% ACN) and buffer A. The collected flowthrough was passed through the C18 
columns again. Then these columns were washed twice with buffer A, before samples were 
eluted in 60% ACN. The eluted samples were then further processed and analysed at the 
Proteomics Research Technology Platform in University of Warwick on the Orbitrap Fusion 
with UltiMate 3000 RSLCnano System (Thermo Fisher Scientific).     
2.4.2. Mass spectrometry data processing 
Mass spectrometry data was processed using MaxQuant 1.5.3.8. Group specific parameters 
were changed to label-free quantification as well as to include variable modifications: 
oxidation, acetylation, phosphorylation and biotinylation. In addition, carbamidomethyl 
fixed modification was also added.   
Data generated by MaxQuant were exported to Excel. Using the label-free quantification 
(LFQ) intensities, ratios were calculated using the no H2O2 control. These ratios were 
averaged between the two independent repeats. Then log2 transformed for shortlisting. To 
categorise whether proteins were specifically enriched i.e., biotinylated proteins, a two-fold 
threshold was implemented. Therefore, values greater than two-fold change of biotinylation 
control (i.e., no H2O2) in KRAS, HRAS and/or NRAS samples were termed ‘specific’, 
whereas proteins with values less than two-fold were termed ‘non-specific’. 
2.5. IMAGING 
2.5.1. Immunofluorescence  
Antibody Company Catalog no. Dilution 
Pan-Ras (rabbit) Abcam ab52939 1:100 in 3% BSA 
Anti-FLAG (mouse) Sigma-Aldrich F1804 1:500 in 3% BSA 
Anti-mouse Alexa-Fluor™ 488 Thermo Fisher Scientific A28175 1:500 in 3% BSA 
Anti-rabbit Alexa-Fluor™ 594 Thermo Fisher Scientific A]11012 1:500 in 3% BSA 
Streptavidin Alexa Fluor™ 647 Thermo Fisher Scientific S21374 1:500 in 3% BSA 
Table 2.5| List of primary and secondary antibodies used for immunofluorescence. 
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Cells were seeded at a cell density of 1.8-2x105 cells per well containing sterile coverslips 
(6 well plate), which were transfected the next day. Following 24 hours after transfection, 
cells were washed twice with ice cold PBS. Then cells were fixed in ice cold methanol for 
10 minutes followed by 1 minute with acetone, both steps at -20°C.  
The following steps were all performed at room temperature. Cells were washed twice with 
PBS then blocked with 3% BSA for 30 minutes. Next, the fixed cells were incubated with 
their primary antibodies in 3% BSA for 2 hours (see Table 2.5). The primary antibody was 
removed via three washes with PBS, each 5 minutes. Then cells were incubated with their 
secondary antibody (see Table 2.5) for 30 minutes before repeating wash steps with PBS. 
The coverslips were then removed and placed on to slides using MOWIOL 4-88 reagent 
(Merck, 475904) with added DAPI. Slides were left to dry overnight, then visualised on the 
Zeiss LSM 800 confocal microscope. Images were processed using FIJI.      
2.5.2. Fluorescence Resonance Emission Transfer 
2.5.2.1. Sample preparation 
HeLa S3 cells were seeded at a cell density of 5x104 cells per compartment in a glass bottom, 
four compartment 35mm dish (Greiner, 627975). The following day, 25µl Opti-MEM, 
0.75µl GeneJuice and 0.5µg DNA was added to each compartment for a single transfection. 
For co-transfections, the GeneJuice volume was doubled to account for the total combined 
DNA amount of 1µg. Here, cells were either transfected with GFP-annexins and/or 
mCherry-Ras.  
After 24 hours of transfection, cells were placed in a humidified warm (37°C) chamber 
containing 5% CO2 to be visualised on the Zeiss LSM 780 confocal microscope using the 
ZEN software. Images were collected with Dr James Boyd at the Liverpool Centre for Cell 
Imaging, who also calculated the FRET efficiency using MATLAB.      
2.5.2.2. Sensitised emission  
Cells were visualised and captured in three different channels: the GFP donor (488nm 
excitation, 490-535nm emission), the mCherry acceptor (560nm excitation, 595-645nm 
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emission) and FRET (488nm excitation, 595-645nm emission). The FRET efficiency (see 
below) was calculated in MATLAB, whereby each pixel intensity detected in the FRET 
channel was corrected using intensity values generated by cross-excitation and bleed-
through.  
FRET ε (%) = [(Fi – (β x Di) – (γ x Ai))/Ai] x 100 
Fε = FRET efficiency channel                β = Pixel intensity in bleedthrough channel 
Fi = Pixel intensity in FRET channel γ = Pixel intensity in cross-excitation channel 
Di = Pixel intensity in donor channel Ai = Pixel intensity in acceptor channel 
2.5.2.3. Photoacceptor bleaching 
For photoacceptor bleaching analysis, images of the cells were collected for both channels: 
GFP and mCherry for three frames prebleach. Then acceptor bleaching was initiated 
followed by dual channel imaging for a further three frames. Intensities of both channels 
was measured for whole cells using FIJI, then processed using Microsoft Excel to express 
values as a percentage of the initial donor/acceptor fluorescence.  
2.5.3. Transmission Electron Microscopy    
2.5.3.1. Grid preparation 
Glass slides were cleaned and dipped into 0.3% pioloform dissolved in chloroform, then left 
to dry. A razor blade was used to score along the glass slide before moisture was applied 
and immediately submerged vertically into dH2O in order to form a pioloform film. 3.05mm 
Copper Mesh hexagonal grids (G2450C, Agar Scientific) were gently placed on the floating 
pioloform sheet and collected using a white sticker covered clean glass slide. Slides were 
stored in a desiccator before use.   
2.5.3.2. Single gold labelling 
For each sample, 180,000 cells were seeded on a 3cm dish containing 13mm coverslips. Cell 
were transfected the following day with either mutant (G12V) or WT mCherry-HRAS. For 
samples with A6, cells were also co-transfected with eGFP-A6.  
52 
 
Previously prepared grids were treated with poly-l-lysine for 10 minutes and subjected to 
two washes in water before being left to dry for 10 minutes. Coverslips with the adherent 
cells were removed from the dishes after 24 hours post-transfection and placed cell side 
down on top of two grids. Filter paper was placed on top and pressure was applied using a 
rubber bung. KOAC buffer (250mM HEPES, 1.15M Potassium acetate, 25mM MgCl2) was 
added gently to the coverslips to allow for grids to float and subsequently be attached to 
membrane ‘rip offs’.  
Grids were removed and placed in the following solutions: fix (4% PFA, 0.1% 
glutaraldehyde in KOAC solution) for 10 minutes, 50mM glycine for 3 minutes (x3), block 
(0.2% BSA, 0.2% fish skin gelatine in PBS) for 20 minutes, gold-conjugated antibody 
(3.5nm anti-RFP gold) for 30 minutes, block for 3 minutes (x3) and dH2O for 1 minute (x3). 
Lastly, the grids were submerged in methylcellulose/uranyl acetate solution (3% uranyl 
acetate in methylcellulose) and captured using a loop; excess was removed at an angle using 
filter paper. These were left to dry at room temperature. Once dried, the grids were carefully 
removed from the loops, then stored for imaging. Grids were imaged at 87,000X 
magnification on the transmission electron microscope (TEM). Training and assistance for 
the preparation and visualisation of EM samples were provided by Professor Ian Prior, Miss 
Alison Beckett and Miss Jo Isherwood.  
2.5.3.3. Analysis 
Firstly, digital images acquired from the TEM were cropped (765x765nm) and processed to 
remove background in order to acquire x and y co-ordinates of gold particles using Adobe 
Photoshop and ImageJ, respectively. These co-ordinates were used for univariate point 
pattern analysis, which facilitates Ripley’s K function (see formula below) to determine the 
distribution of these gold particles by comparing the calculated number of points within a 
unit area with the expected normal distribution.  
Nanoclustering analysis of processed images (HRAS WT – 21 images, HRAS WT + A6 – 
14 images, HG12V – 10 images, HG12V + A6 – 11 images) were carried out by Dr Yong 
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Zhou (University of Texas) using macros on Microsoft Excel. Additional statistical analyses 
were performed using GraphPad Prism v8.0.  
K(r) = An-2 ∑i ≠j wij1 (|| xi - xj || ≤ r) 
L(r) – r = √(K(r)/ π) – r 
K(r) = Univariate K function r = Radius (1-240nm, 1nm increment) 
A = Area n = Number of points 
wij = Correction for edge effect ||xi-xj|| = Euclidean distance 















Protein-protein interactions regulate the structural and signalling processes underlying the 
functions of a living cell. The ‘undruggable’ status of Ras makes it increasingly important 
to map these interactions to further understand Ras biology and to identify potential targets 
for Ras-associated cancer therapeutics (Cox et al., 2014).  
Since the discovery of Ras, many efforts have been focussed into identifying proteins 
involved in the Ras signalling pathways. Genetic and biochemical techniques such as yeast-
2-hybrid (Vojtek, Hollenberg and Cooper, 1993; Hofer et al., 1994) and co-
immunoprecipitations (IP) (Koide et al., 1993; Warne, Vician and Downward, 1993) have 
been key tools in identifying some of the most well-known Ras interactors. Raf was the first 
Ras effector to be discovered, whereby initial genetic analyses of Drosophila melanogaster 
(Dickson et al., 1992) and Caenorhabditis elegans (C. elegans) (Han et al., 1993) 
highlighted Raf as a downstream component of Ras signalling. It was later shown in 
mammalian cells that Raf could be co-immunoprecipitated with Ras (Koide et al., 1993), 
which was then confirmed to be a direct interaction  (Warne, Vician and Downward, 1993). 
Another Ras effector, PI3K was also discovered via co-IP experiments whereby PI3K was 
present in anti-Ras (Y13-259) immunoprecipitates, which increased in stimulated cells and 
diminished when blocked with an anti-Ras antibody (Sjölander et al., 1991). In the past few 
decades, several direct interactors of active Ras other than Raf and PI3K have been 
identified such as RalGDS, Tiam1, p120GAP, NF1 and PKCζ (Rajalingam et al., 2007)  
Aside from Ras effectors, many Ras regulators have also been identified. Similar genetic 
studies using Drosophila and C.elegans were fundamental in the discovery of Kinase 
Suppressor of Ras (KSR) (Sundaram and Han, 1995; Therrien et al., 1995) and SHOC2 
(Sieburth, Sun and Han, 1998), which are scaffold proteins that positively regulate signalling 
by aiding the assembly of signalling complexes to Ras (Nguyen et al., 2002; Matsunaga-
Udagawa et al., 2010). Another type of regulator that aids Ras localisation at the inner 
plasma membrane were found using techniques such as co-IP and affinity purification. 
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These include galectin-1 (Ashery et al., 2006) and caveolin-1 (Song et al., 1996), 
respectively, which both regulate isoform-dependent spatial organisation of Ras at the 
plasma membrane.   
Although these techniques have provided key insight into the discovery of direct and indirect 
Ras interactors, they do however carry fundamental limitations of the identification of 
predominantly stable and high-affinity protein-protein interactions due to the harsh 
procedures involved in cell lysis. Additionally, often these experiments are performed in 
vitro, so do not provide physiologically relevant conditions. However, in more recent years, 
newer techniques that bypass these problems have been developed to map protein-protein 
interactions such as proximity labelling methods coupled with mass spectrometry (Jiang et 
al., 2012; Roux et al., 2012; H.-W. Rhee et al., 2013).  
Currently, there are three main proximity labelling methods based on the enzymes: 
horseradish peroxidase (HRP) (Jiang et al., 2012), biotin ligase (BirA) (Roux et al., 2012) 
and ascorbate peroxidase (APEX) (H. Rhee et al., 2013). The advantage of this type of 
methodology is that the process occurs in living cells and therefore maintains a 
physiologically relevant microenvironment. In addition, it has the capacity to detect 
transient and weak interactions.  
The general principle of proximity labelling relies on the fusion of the protein of interest 
with an enzyme that can convert a substrate into a highly reactive radical that can covalently 
tag a neighbouring protein with an enzyme substrate. These enzyme substrates are often 
small, e.g. biotin is 244.31g/mol, to lessen the possibility of modifying the activity or 
localisation of the protein (Jiang et al., 2012; Roux et al., 2012; H.-W. Rhee et al., 2013). 
The strong covalent bond between biotin and other proteins are preserved during cell lysis, 
therefore reducing the number of artefacts (Chapman-Smith and Cronan, 1999). These 
labelled proteins undergo various stringent washes to remove any non-specific interactions 
and are enriched for their enzyme substrate tag. Protein elutes can then be used for either 
western blotting for initial queries or alternatively be used for mass spectrometry to broadly 
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screen the spatially proximal proteome (Jiang et al., 2012; Roux et al., 2012; H.-W. Rhee et 
al., 2013).  
HRP is a 44kDa heme peroxidase tag. In the presence of H2O2, it can convert phenolic 
compounds like tyramine (selective proteomic proximity labelling assay using tyramide, 
SPPLAT) (Li et al., 2014) or phenolic aryl azide derivatives (enzyme-mediated activation 
of radical source, EMARS) (Honke and Kotani, 2012) into tyramide-biotin or fluorescein 
arylazide/biotin arylazide respectively, which bind electron-rich amino acids of 
neighbouring proteins. HRP has been used to map the surface of living cells due to its 
optimal activity in oxidising environments such as extracellular regions or the lumen of the 
ER or Golgi. Its structurally essential disulphide bonds and Ca2+ ion-binding sites are unable 
to form in reducing environments such as the cytosol, therefore HRP is limited to secretory 
pathways and extracellular interactomes (Jiang et al., 2012).  
Proximity-dependent biotin identification (BioID) uses a promiscuous 35kDa Escherichia 
coli-derived biotin ligase (BirA*). Normally, BirA catalyses the conversion of biotin to a 
reactive biotinoyl-5’-AMP (bioAMP) in the presence of ATP and strongly retains the 
intermediate in its active site until its substrate, acetyl-CoA carboxylase or a short acceptor 
peptide is available. However, engineered biotin ligase, BirA* harbours a R118G mutation 
in its catalytic site which reduces its affinity for bioAMP and thus dissociates easier to bind 
to lysine residues of neighbouring proteins (Roux et al., 2012). In water, the half-life of 
bioAMP has been estimated to be approximately 30 minutes (Xu and Beckett, 1994), 
however this has shown to be less inside cells, possibly due to the presence of intracellular 
nucleophiles (Kim et al., 2014).  
The application of BioID in the nuclear pore complex has shown that the labelling radius of 
BioID to be approximately 10nm (Kim et al., 2014), although this can be context-dependent 
and vary with the length of the flexible linker (Kim et al., 2016). However, BioID has 
relatively slow kinetics as it requires 15-24 hours of labelling time with biotin 
supplementation for sufficient biotinylation. BioID was originally used to study a well-
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characterised component of the nuclear envelope, an intermediate filament protein called 
lamin-A (LaA). The method was able to identify known interactors of LaA as well as a novel 
interacting protein, SLAP75, which was later found to associate with the nuclear envelope 
(Roux et al., 2012). Following its initial success for screening direct and indirect protein-
protein interactions of the nuclear envelope, it has since been applied to studies of previously 
difficult to investigate insoluble structures such as cell junction complexes (Van Itallie et 
al., 2014; Fredriksson et al., 2015) and centrosomes (Firat-Karalar et al., 2014; Dong et al., 
2016) in mammalian cells. 
The smallest enzyme used for proximity labelling, APEX, is 27kDa and is derived from 
either pea (APEX, first generation) (H.-W. Rhee et al., 2013) or soybean (APEX2, second 
generation) (Lam et al., 2015). This class I cytosolic plant peroxidase was first engineered 
to be used in EM, as an alternative to HRP that could be used in reducing 
microenvironments. APEX catalyses the production of diaminobenzidine (DAB), which in 
return recruits osmium to produce the high contrast required for high resolution EM images 
(Martell et al., 2012). In addition to its use for EM, it can also be used as a tool for proteomic 
mapping. The first-generation APEX has three mutations: K14D, W41F and E112K (H.-W. 
Rhee et al., 2013), whereas the second generation was developed by yeast display and yields 
an additional mutation (A134P), which improves its catalytic efficiency and sensitivity (Lam 
et al., 2015). Similar to the other enzymes, the engineered monomeric APEX catalyses the 
production of biotin-phenoxyl radicals in the presence of H2O2 and its substrate, BP. These 
free radicals are short-lived (<1ms) (Mortensen and Skibsted, 1997) and attach to tyrosine 
side chains (H.-W. Rhee et al., 2013) and potentially other electron-rich amino acids such 
as tryptophan (Bhaskar et al., 2003), cysteine (Rogers et al., 2008) and histidine (Amini, 
Kodadek and Brown, 2002).  
Initial studies in mitochondria demonstrated the use of APEX for proteomic mapping. The 
first experiment highlighted proteins associated with the human mitochondrial matrix and 
was able to distinguish proteins between whether they were inner membrane proteins facing 
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the matrix or the intermembrane space (H.-W. Rhee et al., 2013). Whereas the second 
experiment focussed on mapping the proteome of a previously impossible to isolate 
component, the mitochondrial intermembrane space, which aided the identification of 9 
novel mitochondrial proteins (Hung et al., 2014). Following the success of these studies 
based in bound organelles, APEX was later used to map proteomes of open compartments 
like in primary cilia (Mick et al., 2015) and G-protein coupled receptors (GPCRs) on the 
plasma membrane (Lobingier et al., 2017; Paek et al., 2017). 
The primary aim of this project is to identify regulators of Ras nanoclustering and in the 
context of different Ras isoforms and activation states. Therefore, it is advantageous to use 
the novel proximity labelling method to widely screen the different Ras microenvironments, 
as this technique has the potential to capture transient interactions in live cells and without 
the need to biochemically isolate the plasma membrane. The choice of labelling enzyme was 
dependent on which enzyme was most suitable for capturing the dynamic nature of the 
nanoclustering events that range from 0.1-1 seconds occurring at the inner membrane leaflet 
(Zhou and Hancock, 2015). At this location, HRP would be inactive and thus, unsuitable for 
investigating the Ras interactome in this context, whereas APEX2 could tolerate such 
conditions. Additionally, APEX2 has a faster labelling duration than BirA*, 1 minute (Lam 
et al., 2015) versus 18-24 hours (Roux et al., 2012). Therefore, APEX2 is more likely to 
capture more dynamic interactions, whereas BirA* would detect steady state interactions. 
Furthermore, APEX2 has less potential of interfering with the function and localisation of 
Ras as it is a smaller enzyme tag than BirA* (27kDa vs 35kDa).  Henceforth, the 
catalytically improved second generation APEX2 will be the labelling enzyme used in this 
project to spatially map the Ras interactome (Fig.3.1a).    
3.2. AIMS 
3.2.1. To establish the APEX2 method for the study of Ras 
The first objective for this project will be to establish APEX2 as a proteomic tool. Therefore, 
it will require APEX2 to be fused to the protein of interest, Ras. Since different Ras isoforms 
60 
 
will be investigated, several APEX2-Ras fusion constructs need to be generated. Then, 
multiple steps involved in the APEX2 method (Fig.3.1b) will be optimised for the study of 
Ras.  
 
Figure 3.1| Proximity labelling using APEX2 – a) Schematic of the APEX2 reaction. The addition 
of its substrate: BP (30 minutes) followed by H2O2 (1 minute) treatment allows for proteins in close 
proximity with Ras to be covalently tagged with biotin. (b) The APEX2 methodology involves HeLa 
S3 cells to be seeded and transfected with FLAG-tagged APEX2-Ras. Cells were lysed and tested 
initially using western blot. Further experiments using streptavidin bead pulldown were used to 
enrich for biotinylated proteins, then analysed either by western blot or mass spectrometry.  
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3.2.2. To identify whether the APEX2 method would be a suitable tool for 
screening the Ras proteome microenvironment.  
The APEX2 method has been used to successfully map the proteome microenvironment of 
many cellular regions of interest such as the synaptic cleft and mitochondrial intermembrane 
space. Here, this methodology will be assessed by identifying whether APEX2 can be used 
to widely screen the Ras proteome without affecting its normal activity and localisation.   
3.3. PRODUCTION OF APEX2-TAGGED RAS 
In order to perform the APEX2 experiments, a panel of fusion constructs consisting of 
APEX2 and Ras: KRAS WT (K WT), KG12V, HRAS WT (H WT), HG12V, NRAS WT 
(N WT) and NG12V were generated (Appendix 1). Here, different APEX2-Ras isoforms 
and their G12V mutants were created so that in later experiments, comparisons can be made 
between the proteome microenvironments of these various conditions.   
An overview of the cloning process can be seen in Figure 3.2. The first step consisted of 
using APEX2-actin in pEGFP as a template DNA of APEX2. This plasmid consisted of an 
N-terminal FLAG epitope tag (DYKDDDDK) and APEX2 (soybean), which contains 4 
mutations: K14D, W41F, E112K and A134P. Next, N-terminal and C-terminal primers were 
designed to amplify the FLAG-tagged APEX2 as well as to add restriction sites: NheI and 
BglII, respectively. The C-terminal primer also contained an additional 13 amino acid linker 
consisting of glycine and serine residues between the APEX2 and BglII sequence. This short 
linker was included to minimise the effect of APEX2 on the targeting moiety of Ras. A 
number of bases were also added before the BglII sequence to alter the frame of the APEX2 
insert so that it could be cloned into the appropriate pEGFP-C1/C2/C3 vector.  
These amplified inserts were later ligated into an intermediate vector, pCR 4 Blunt TOPO. 
Once confirmed by DNA sequencing, the APEX2-TOPO plasmids were digested by NheI 
and BglII for either subcloning into pEGFP-C1/C2/C3 or for direct cloning into pEGFP-tK 
or -tH. In both cases, pEGFP was replaced with APEX2. For the full-length Ras APEX2 
constructs, pEGFP-KRAS WT/KG12V/HRAS WT/HG12V/NRAS WT/NG12V and 
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APEX2-C1/C2/C3 underwent the appropriate restriction enzyme digest to generate different 
Ras isoform inserts that could be subcloned into the multiple cloning sites of the respective 
APEX2 vectors. In all APEX2-Ras constructs, APEX2 was specifically tagged to the N-
termini of Ras to prevent alterations to the C-termini, which is fundamental for its 
localisation (Prior and Hancock, 2012)     
 
Figure 3.2| Schematic of APEX2-Ras cloning - Using designed primers and PCR, the APEX2 
sequence from the template: APEX2-Actin in a pEGFP vector was amplified. The APEX2 insert was 
subcloned into a TOPO vector for sequencing. Then using REs, the APEX2 insert was removed from 
the TOPO-APEX2 and was inserted into the position of the EGFP sequence of the pEGFP-C1/C2/C3 
vectors. Then the respective full-length Ras sequences were inserted into the multiple cloning sites 
of these APEX2-C1/C2/C3 vectors in order to generate APEX2-Ras.    
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3.4. CHARACTERISATION OF APEX2-RAS LOCALISATION 
AND ACTIVITY  
3.4.1. Expression of APEX2-Ras in vitro 
Having generated a panel of different APEX2-Ras constructs, it was important to check 
whether cells could efficiently express these constructs and consequently able to biotinylate 
proteins. Therefore, the presence of FLAG (the N-terminus tag of APEX2-Ras) and biotin 
were investigated in whole cell lysates.   
 
Figure 3.3| Western blot of APEX2-Ras transfected cells – Hela S3 cells were transfected with 
either APEX2-K WT, -KG12V, -H WT, -HG12V, -N WT or -NG12V. Controls included 
untransfected (U) and APEX2 only (A). Each condition was subjected to 30 minutes of BP, followed 
by either with (+) or without (-) H2O2 treatment for 1 minute. Cell lysates were blotted for the 
presence of FLAG (red arrows), biotin and actin (loading control). Data representative of 3 
biological repeats.  
HeLa S3 cells were transiently transfected with either APEX2 only or APEX2-Ras fusion 
constructs: KRAS WT, KG12V, HRAS WT, HG12V, NRAS WT and NG12V for 24 hours. 
As a control, untransfected (U) HeLa S3 cells were used. Then for each sample, the media 
was replaced with media supplemented with BP. After 30 minutes, half of the samples were 
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treated with H2O2 for 1 minute. The reaction was halted by a number of washes with 
quencher solution, followed by cell lysis. 10µg of total cell lysate from individual samples 
were ran on an SDS PAGE gel and transferred to a nitrocellulose membrane. Followed by 
immunoblotting for FLAG, biotin, and actin (loading control).  
As expected, FLAG was present only in the transfected samples, i.e., the APEX2 only 
control and in the APEX2-Ras samples: K WT, KG12V, H WT, HG12V, N WT and NG12V 
(indicated by the red arrows in the top blot), but not in the untransfected control (Fig.3.3). 
The difference between the detection of a lower (~30kDa) and upper FLAG band (~53kDa) 
is due to the presence of the Ras protein in the APEX2-Ras samples and therefore making 
it a higher molecular weight. It also appears that there might be slight discrepancies in 
protein expression levels, since KRAS WT and KG12V have lower expression compared to 
other isoforms. Overall, it was evident that HeLa S3 cells can be efficiently transfected with 
the APEX2-Ras constructs, and therefore able to express the APEX2-Ras fusion protein of 
which biotinylated proteins in the presence of BP and H2O2. 
Next, it was assessed whether the expressed APEX2-Ras protein could biotinylate proteins. 
To test this, samples were either untreated (BP only) or treated with H2O2 and later whole 
cell lysates were immunoblotted for biotin. As shown in Figure 3.3 (lower blot), three 
predominant bands appear at 130kDa, 75kDa and 72kDa in all samples. These are likely to 
represent naturally biotinylated proteins in humans, in which biotin is a crucial co-factor for 
metabolic enzymes such as carboxylase and decarboxylases, where post-translation 
modifications occur via biotin ligase (Hung et al., 2016). In the untransfected controls, less 
biotinylation can be observed. Whilst in all H2O2-treated APEX2 samples, additional bands 
were present across a large molecular-weight range due to the presence of APEX2-
biotinylated proteins. These proteins were likely to represent proteins that were in close 
proximity to APEX2 or APEX2-Ras. Since APEX2 alone is not specifically targeted to any 
cellular region, it is likely that these detected proteins represent a population of randomly 
labelled proteins encountered by APEX2 within the cell. In general, the addition of the 
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APEX2 enzyme to Ras does not appear to affect its enzymatic activity and the biotinylation 
of endogenous proteins (with the exception of the three naturally occurring biotinylated 
proteins) is dependent on the presence of the APEX2 enzyme, BP and H2O2. 
3.4.2. Localisation of APEX2-Ras in vitro 
Ras predominantly localises at the plasma membrane and fundamental for this correct 
localisation is the HVR (Prior and Hancock, 2012). Using immunofluorescence (IF), the 
localisation of APEX2-Ras within the cell could be investigated to see whether the 
attachment of APEX2 to the Ras protein affected its localisation to the plasma membrane.  
Cells were prepared like previous, supplemented with BP and H2O2 then reaction was 
quenched before preparation for imaging. Here, cells were stained with multiple antibodies: 
anti-FLAG antibody to detect APEX2-Ras, Pan-Ras antibody to visualise total Ras 
expression, streptavidin-conjugated Alexa Fluor to check for biotinylation and DAPI for 
nuclear staining (Fig.3.4). As expected, FLAG was present in all APEX2-Ras transfected 
samples and its pattern of expression was very similar to the expression of Ras, therefore 
highlighting that most of the Ras detected in the cell is from the exogenous expression of 
the FLAG-Ras construct. This is further supported by the negative controls, where little 
Ras/FLAG expression appeared in the untransfected sample. Similarly, in the APEX2 only 
control, FLAG can be seen due to its presence in the APEX2 construct. However, Ras 
expression is considerably lower compared to samples containing APEX2-Ras and is likely 
to reflect the normal levels of endogenous Ras present within the cells.  
Majority of the APEX2-Ras fusion proteins: KRAS WT, KG12V, HRAS WT, HG12V and 
NRAS WT localised predominantly in the plasma membrane, indicating that the attachment 
of APEX2 to Ras does not appear to affect its localisation. This is reassured by the APEX2 
only control, which shows a different pattern of APEX2 localisation, where its expression 
is mainly cytosolic. APEX2-NG12V is less membrane-bound and more cytosolic than the 
other isoforms and this could be due to the dynamic cycling between palmitoylated and 




Figure 3.4| Localisation of APEX2-Ras – Representative confocal fluorescent images of cells (n=3) 
expressing either APEX2-K WT, -KG12V, -H WT, -HG12V, -N WT, -NG12V or APEX2 only. 
Expression of Ras, APEX2-Ras and biotinylation was visualised using anti-Ras, anti-FLAG, and 
streptavidin-Alexa Fluor 647 antibodies, respectively. DAPI used as a nuclear stain. Scale bar, 10µm.  
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Biotinylation was seen in all samples, which is not surprising since this type of assay does 
not distinguish between endogenously biotinylated proteins and APEX2-biotinylated 
proteins. However, it can be speculated that there is a higher expression of biotinylated 
proteins in some of the Ras samples compared to control. Although in some samples the 
pattern of biotinylation follows the expression of FLAG and Ras, there are some that do not. 
This could be due to the diffusion of biotinylated proteins from the APEX2-Ras during the 
H2O2 reaction window since Ras is not present in a compartmentalised part of the cell. 
Overall, the IF experiments have shown that the APEX2-Ras fusion proteins can localise 
correctly to the plasma membrane.    
3.5. OPTIMISATION OF THE APEX2 TECHNIQUE 
3.5.1. Stimulation of Ras activity 
The aim of this project is to investigate the different Ras isoform interactomes in both their 
active and non-active states since it has been previously highlighted that GDP- and GTP-
bound Ras occupy distinct transient nanoclusters on the plasma membrane for each isoform. 
Therefore, the assumption would be that the proteome microenvironment would differ 
between these states. In order to capture the snapshots of these different Ras events, the 
optimal stimulation for Ras effector activity would be required to establish the conditions 
that would model Ras in its active form.  
HeLa S3 cells expressing APEX2-NRAS WT were firstly serum-starved for 5 hours then 
stimulated with FBS (20%) for different durations (0.5, 1, 2, 3, 4, 5, 10, 20, 30 minutes) 
before lysis. In addition, there was a serum-starved (SS) control and normal serum 
supplemented (20% FBS) with no starvation (CON) control. FBS was chosen to stimulate 
various growth factor pathways such as EGF, which induces Ras activation. Western blots 
were performed on the resulting lysates and the phosphorylation of three well-known Ras 
effectors: MEK, ERK and Akt were immunoblotted along with biotin and actin as loading 
control (Fig.3.5). Bands observed for the three experimental repeats were quantified then 




Figure 3.5| Optimisation of Ras stimulation – Different durations of FBS stimulation (0-30 mins) 
were tested on APEX2-NRAS WT transfected cells. Lysates were blotted for pMEK (S217/S221), 
pERK (T202/Y204), pAkt (S473), biotin and actin. Bottom graphs show the cumulative pMEK, 
pERK and pAkt activity of three independent experiments, error bars displayed as mean+SD. 
Results indicated that pERK activity increased following stimulation and reached its highest 
level (mean = 2.03 and 1.79) between 4-5 minutes and similarly, pMEK levels peaked at 4-
5 minutes (mean = 1.83 and 1.78) before declining. Whereas pAkt activity displays a 
prolonged increase following stimulation (Fig. 3.5). Since peak pERK and pMEK activity 
occurred between 4-5 minutes, it seemed that this would be the optimal duration to stimulate 
cells to model active Ras. Although peak pAkt did not occur during these timepoints, the 
pAkt levels (mean = 2.01 and 2.07, respectively) observed were still double the levels for 
SS (mean = 1). Therefore, in combination with current literature, 5 minutes of FBS 
stimulation should be an appropriate duration to represent active Ras, since levels of 
activated MEK, ERK and Akt are noticeably higher than the SS control. In addition to testing 
Ras activity, biotinylation was also checked to see if FBS stimulation resulted in any 
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changes. As shown from the blot, the biotinylation pattern remained fairly constant amongst 
the different timepoints and therefore was unaffected by the FBS stimulation.    
3.5.2. Duration of biotinylation reaction 
The application of APEX has predominantly been used in enclosed membrane-bound 
compartments. The original protocol suggests that the biotinylation reaction, i.e., H2O2 
incubation, should occur for 1 minute. However, since Ras localises at the inner leaflet of 
the plasma membrane, the labelled proteome microenvironment will be relatively larger due 
to the wider open region and thus a higher chance of non-specific labelling of proteins that 
are not part of the Ras interactome. The assumption is that the longer the reaction, the larger 
the biotinylation radius and as a result the more proteins being biotinylated (Fig. 3.6a).  
Therefore, the duration of the reaction is an important factor to consider.  
To determine the duration of biotinylation that would produce minimal labelling of non-
specific proteins, different durations of H2O2 incubation was investigated using western 
blotting. Durations (0, 15, 30, 45, 60, 120 and 240 seconds) of H2O2 were tested in APEX2-
NRAS WT transfected cells. In addition, untransfected and APEX2-only were used as 
controls. Figure. 3.6b shows that the cells expressed APEX2-NRAS WT, as represented by 
the bands in the lower blot immunoblotted for FLAG (~53kDa). From the three independent 
repeats, it is evident that there is a time-dependent increase in biotinylation. Whereby the 
highest level of biotinylation occurred with the longest incubation of 240 seconds, which is 
comparable to the levels seen for the non-targeted APEX2-only control. However, 240 
seconds would not be a suitable timepoint as this might cause cellular toxicity and it could 
also be speculated that a longer reaction could result in the labelling of more distal proteins. 
Therefore, an ideal timepoint would be at the shortest duration that results in sufficient 
biotinylation. Although, biotinylation could be observed from as early as 15 seconds, this 
would be problematic from a practical perspective and thus 30 seconds was chosen for 
subsequent experiments instead, which showed to have similar levels of biotinylation as 




Figure 3.6| Optimisation of the duration of the biotinylation reaction – a) Schematic of the 
hypothesised relationship between biotinylation radius and duration of H2O2 incubation. b) 
Representative western blot and bar graph summary (n=3) displaying the time-dependent increase in 
biotinylation (0-240s). Untransfected and APEX2 only controls were either untreated or treated with 
H2O2 for 60s. Actin was used as a loading control. Error bars are mean+SD. 
3.5.3. Titration of streptavidin beads used for pulldown  
For mass spectrometry experiments, biotinylated proteins need to be enriched using 
streptavidin beads. The original protocol suggests to incubate 360µg whole cell lysates with 
30µl streptavidin beads for 1 hour at room temperature (Hung et al., 2016). Using this as a 
guideline, the amount of streptavidin beads needed for optimal purification of biotinylated 
proteins in these experiments was tested. 
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Using the originally stated protein concentration, 360µg total cell lysate of APEX2-NRAS 
WT transfected cells was incubated with either 20, 30 or 40µl streptavidin beads for 2 hours 
at room temperature. Flowthrough was retained to check for any unbound biotinylated 
proteins. The beads underwent a series of washes in different buffers containing high-salt, -
pH and -urea to remove non-biotinylated protein before proteins were eluted. Both 
flowthrough, eluted proteins and no-bead controls were used for western blotting and the 
presence of biotinylated proteins was checked.  
 
Figure 3.7| Streptavidin bead titration – Optimisation of the amount of streptavidin beads (20, 30, 
40µl) required for enrichment of biotinylated proteins. Whole cell lysates (input, 1:36), flowthrough 
(1:36) and pulldown samples were immunoblotted for biotin. Actin was used as a loading control.   
The higher amount of streptavidin beads used resulted in greater enrichment of biotinylated 
proteins. However, it is evident from Figure 3.7 that 40µl streptavidin beads might be overly 
saturated as no biotinylated proteins were present in the flowthrough compared to the no 
beads control, which indicated that even the naturally occurring endogenous biotinylated 
proteins were being pulled down. It is also possible that a larger volume of beads provides 
an increased surface area for non-specific binders and thus increases the background signal.  
The smallest volume of streptavidin beads (20µl) resulted in the least enrichment of 
biotinylated proteins, which could potentially lead to suboptimal purification of potential 
proteins. So, for that reason, 30µl streptavidin beads per 360µg protein lysate was chosen to 
minimise the risk of either low detection or too many non-specific binders and therefore 
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optimally enriches for specifically labelled proteins generated by APEX2-Ras. Meanwhile, 
actin was absent from the eluates indicating the specificity of APEX2-Ras as well as the 
efficiency of the purification steps to achieve the biotinylated fraction.    
3.5.4. APEX2 biotinylates Ras effectors  
Previous results confirmed efficient transfection of the APEX2-Ras construct into HeLa S3 
cells, which was then expressed as fusion proteins that were capable of biotinylation once 
supplemented with BP and H2O2. However, the specificity of this biotinylation reaction is 
still unknown. To test whether this biotinylation is not random and occurs predominantly 
within the close vicinity of Ras, detection of proteins associated with Ras were used as 
positive markers. Using the previously optimised conditions, biotinylation of Ras effectors: 
PI3K and B-Raf were tested.  
 
Figure 3.8| Specific biotinylation of Raf and PI3K – Lysates from serum-starved and stimulated 
APEX2-NRAS WT transfected cells underwent enrichment for biotinylated proteins. Input (I), 
flowthrough (F) and pulldown (P) samples were blotted for PI3K, B-Raf and NRAS (left). Schematic 
(right) shows the biotinylation reaction within 30 seconds.  
As shown by Figure 3.8, pulldown of well-known Ras effectors: PI3K and B-Raf indicated 
that the APEX2-NRAS WT fusion protein was able to biotinylate relevant proteins that 
interact with Ras. The pulldown lanes show that within the enrichment of biotinylated 
proteins that NRAS was detected and therefore reaffirming that the neighbouring APEX2 
enzyme was close enough to biotinylate Ras. Additionally, Ras effectors such as PI3K and 
Raf were also biotinylated and appear to be more abundant in the stimulated samples versus 
serum-starved, which is to be expected since recruitment of Ras effectors occurs following 
Ras activation. From this experiment, there is confidence that the APEX2-Ras fusion 
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proteins are functioning correctly, and the previously optimised conditions would be suitable 
for a larger-scale application to different Ras isoforms and active states. 
3.6. DISCUSSION 
In recent years, proximity labelling has been a popular technique for studying protein-
protein interactions. They carry advantages over conventional methods as they preserve 
interactions within a living cell and allow for the detection of transient and weak interactions 
as well as associated proteins. At the beginning of this project, no studies had used proximity 
labelling to investigate the Ras interactome, therefore it was of interest to use this novel 
approach to provide insights into potential interactions that have been previously missed by 
conventional methods. The benefits of it being a wide screening tool makes it easier to 
investigate multiple conditions such as different isoforms and activation states. More 
importantly, it has the capability to capture interactions at the plasma membrane which are 
fundamental for Ras signalling but are normally disrupted due to cell lysis.  
In this chapter, the APEX2 technique was established to study the Ras interactome at the 
plasma membrane with aims to highlight any potential regulators of Ras nanoclustering. 
Here, it has been demonstrated via sequencing as well as on a protein-level that all designed 
constructs were functional and correctly targeted in living cells. This was facilitated in the 
following experiments that were required to optimise the methodology. The first set of 
experiments sought to generate a model that represented ‘active’ Ras to allow for 
comparisons between both active and non-active Ras protein microenvironments to then 
identify any specific proteins which regulate the different signalling platforms on the plasma 
membrane. In this experiment, FBS was used as it consists of multiple growth factors, which 
activate Ras via the RTK pathway (Gstraunthaler, 2003). High activity levels of Ras 
effectors: ERK, MEK and Akt were observed at 5 minutes, suggesting this timepoint to be 
the optimal model for ‘active’ Ras. This is similar to previously reported, where peak MEK 
and Akt activity occurred after 5 minutes of EGF stimulation in PC12 cells and HEK293 
cells, respectively (Traverse et al., 1992; Borisov et al., 2009). Aside from static snapshots 
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of effector activity using western blots, single-cell analysis has also demonstrated that the 
average pERK activity similarly reaches a maximum between 5-10 minutes in PC12 cells. 
Interestingly, it  highlighted heterogeneity in activity occurred amongst the cells in response 
to EGF stimulation (Ryu et al., 2015). Overall, current literature in support with data 
generated here provides evidence that the 5-minute stimulation will be sufficient to capture 
the active state of Ras during the transient activation period. It is also important to note that 
the concentration and composition of different growth factors affect the stimulation 
dynamics, therefore the same batch of FBS should be used for subsequent experiments.   
Initially, APEX was recommended for the study of compartments within mammalian cells 
and many original papers were indeed done in membrane-enclosed organelles such as 
mitochondria and ER (Hung et al., 2017). However, over the years its use has expanded to 
different model organisms such as yeast (Hwang and Espenshade, 2016) and Drosophila 
(Mannix et al., 2019), as well as in non-membrane enclosed regions like the primary cilia 
(Mick et al., 2015) and mitochondria nucleoid (Han et al., 2017). The success of APEX in 
non-enclosed regions showed promise for its use to study Ras at the plasma membrane. 
However, this required alterations to the original APEX2 method previously described by 
Hung et al, so that it would be suitable for studying open regions (Hung et al., 2016). 
Modifications to the biotinylation process was needed due to the likelihood of more non-
specific labelling as a result of the larger proteome microenvironment. Despite most APEX2 
protocols using 1 minute reaction windows (Hung et al., 2016; Han et al., 2017), it was 
shown here that 30 seconds of H2O2 generated sufficient biotinylation. The same duration 
was used in the study of GPCRs, where they were also investigating dynamic events 
(Lobingier et al., 2017). It is postulated that shorter reactions would result in a smaller 
population of biotinylated proteins and consequently reduce the number of non-Ras 
associated binders. Additionally, it could be speculated that reducing the incubation time 
would give a better snapshot of the dynamic events during nanoclustering. Given the 
shortened reaction window and thus reduced number of biotinylated proteins, it was 
expected that there would also be a change to the ratio of streptavidin beads to lysate. 
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However, further experimentation indicated that the originally stated amount would be 
optimal. Lastly, using the optimised conditions, a preliminary small-scale enrichment was 
carried out to test if known Ras interactors were present in the selectively isolated population 
of biotinylated proteins. The results demonstrated that PI3K and B-Raf were efficiently 
detected and differences could be seen between the unstimulated and stimulated Ras. 
These initial experiments have demonstrated that the fusion of APEX2 to Ras does not 
appear to affect Ras localisation or activity and vice versa, Ras does not seem to alter APEX2 
function. Having generated a number of APEX2-Ras constructs consisting of the three Ras 
isoforms in both their WT and G12V mutant forms, as well as a model for active and non-
active Ras, the different conditions required for large-scale experiments to investigate the 
proximity proteome had been established. Furthermore, modifications were made to the 
APEX2 method so that it was more applicable for the study of open regions. Preliminary 
results showed that APEX2 was able to biotinylate known interactors of Ras, indicating that 
APEX2 is a suitable enzyme to screen the Ras interactome and has the potential to capture 




























Ras nanocluster formation result from the complex interplay between the plasma membrane 
and Ras. Here, Ras isoforms laterally segregate into non-overlapping nanoclusters, which 
are also GDP/GTP-dependent (Janosi et al., 2012). This process is required to expose Ras 
to a suitable proteome and lipidome microenvironment, which favour interactions that lead 
to downstream Ras signalling (Prior et al., 2003). The plasma membrane is highly 
heterogenic and consists of different microdomains such as lipid rafts (Prior et al., 2001) or 
caveolae (Ariotti et al., 2014), which have shown to be important for Ras nanoclustering. 
Other components such as scaffold proteins, lipid composition and actin also affect 
nanocluster formation and therefore are crucial determinants of Ras signalling (Plowman et 
al., 2005; Zhou et al., 2014).  
Actin aids Ras nanoclustering via its interaction with the plasma membrane, whereby it 
facilitates the formation and maintenance of these nanodomains (Plowman et al., 2005). 
Similarly, cholesterol is another vital component of Ras nanoclustering, its presence has 
shown to be required for the localisation of HRAS-GTP and NRAS-GDP, whereas HRAS-
GDP and NRAS-GTP is cholesterol-independent (Prior et al., 2001). Other lipid species that 
make up the plasma membrane also vary depending on the isoform and nucleotide state. 
Examples include: PS, PA, PIP2, PIP3, PI3P and PI4P (Zhou et al., 2014). One study 
highlighted that all these lipids were present in KG12V, HG12V and tH nanoclusters. PS 
and PI4P were more associated with HRAS, whilst tH appeared to be more enriched for PIP2 
and PI3P than HG12V. Also, PA was more abundant in HG12V nanoclusters. Whereas, 
KG12V nanoclusters displayed lower concentrations of PS and PI4P compared to HRAS but 
higher amounts of PA (Zhou et al., 2014). Therefore, highlighting the complexity of the 
lipid microenvironment of Ras.     
In terms of scaffold proteins, a few have been identified for the Ras pathway such as KSR 
(Therrien et al., 1995, 1996), AF6 (Kuriyama et al., 1996) and IQGAP1 (Matsunaga et al., 
2014). However, only a few scaffold proteins like Gal-1 (Belanis et al., 2008), Gal-3 
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(Shalom-Feuerstein et al., 2008), NPM (Inder et al., 2009) and ASPP2 (Posada et al., 2016) 
have shown to affect Ras nanoclustering. Gal-1 is recruited to the plasma membrane where 
it interacts with activated HRAS and plays an integral nanocluster component that stabilises 
the HRAS-GTP nanoclusters (Belanis et al., 2008). Similarly, Gal-3 is recruited from the 
cytosol to the plasma membrane by KRAS-GTP, where it is involved in the formation and 
stabilisation of KRAS-GTP nanoclusters (Elad-Sfadia et al., 2004; Shalom-Feuerstein et al., 
2008). NPM also specifically interacts with KRAS at the plasma membrane, where it 
enhances KRAS clustering and activation of MAPK (Inder et al., 2009).  Whilst, pan-Ras 
scaffold protein, ASPP2 increases nanoclustering of all oncogenic Ras G12V isoforms 
(Posada et al., 2016).  
Evidently, Ras nanocluster formation requires input from different types of lipid and protein. 
These vary depending on the type of Ras isoform present and whether GDP or GTP-bound 
(Prior et al., 2003). To date, regulation of Ras nanoclustering at the plasma membrane is not 
very well understood. Since localisation is key to Ras activity, which is fundamental for 
certain cancer types (Mo, Coulson and Prior, 2018), its crucial to understand its localisation 
at the plasma membrane and identify regulators that are involved. Elucidating the different 
protein microenvironments in which these nanoclusters function would provide insight into 
potential regulators of Ras nanoclustering and subsequently, Ras signalling. The 
identification of such regulators could be beneficial as alternative pharmacological targets 
that prevent Ras signalling via abrogation of Ras nanoclustering, since direct inhibition of 
Ras has shown to be problematic (Brock et al., 2016). 
Previous to the use of proximity labelling methods, it would have been likely that 
purification of the plasma membrane would be required to investigate these types of 
interactions (Roy et al., 1999; Prior et al., 2001). However, the purification process often 
introduces contaminants and disrupts interactions. Whereas, traditional methods of 
proteomic analysis of co-IP carries a bias for strong interactions (Koide et al., 1993; Song 
et al., 1996a). Therefore, the availability of proximity labelling methods such as APEX2 has 
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been beneficial as it allows for an unbiased proteomic screen of proteins in close proximity 
of Ras in intact living cells, therefore allowing detection of both weak and strong, direct and 
indirect interactors (Lam et al., 2015).  
To identify the different Ras proteome microenvironments, the three Ras isoforms: KRAS, 
HRAS and NRAS were studied using the conditions optimised from the previous chapter. 
The ease of APEX2 to widely screen the proteome makes it possible to compare multiple 
conditions. This is advantageous as evidently from previous studies, different Ras isoforms 
and activation states dictate the type of nanocluster formed. Therefore, different models will 
be generated to represent these conditions. Ras isoforms: KRAS4B WT, HRAS WT and 
NRAS WT as well as their G12V mutant forms will be used. In addition, for each WT 
condition, to mimic the effects of being GDP or GTP-bound, Ras will be either serum-
starved or stimulated with FBS. The large number of samples as a result from the different 
conditions meant it would not be possible to do stable isotope labelling by amino acids in 
cell culture (SILAC) and therefore label-free mass spectrometry will be used instead.  
As a main control, each Ras WT isoform sample will also only be treated with BP and not 
with H2O2, i.e., no biotinylation reaction, to account for any non-specific binders. For 
additional controls, to aid the identification of predominantly plasma membrane proteins, 
APEX2 only and tK and tH were used to produce proximity lists of cytosolic and membrane 
proteins, respectively. Specifically, tK and tH localise in cholesterol-independent and 
cholesterol-dependent nanoclusters, respectively (Janosi and Gorfe, 2010; Janosi et al., 
2012). In this chapter, different Ras proximity proteomes will be investigated with APEX2 
to generate a list of hits that could aid the elucidation of possible Ras nanocluster regulators.    
4.2. AIMS 
4.2.1. To validate APEX2 as a method for screening the Ras interactome.    
Preliminary data from the small-scale experiments illustrated that APEX2 could be a 
suitable tool to screen the Ras interactome, therefore it will be reviewed whether this will 
be reflected among the mass spectrometry data. 
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4.2.2. To observe protein networks of different Ras isoforms and active states. 
Protein lists generated from the multiple conditions will allow for comparisons between the 
different protein microenvironments to identify any isoform- or active-specific proteins 
and/or universal proteins that are relevant for the general Ras interactome.  
4.2.3. To produce a shortlist of potential regulators of Ras localisation. 
Amongst the generated data, top hits will be selected to shortlist proteins that could 
potentially regulate Ras localisation and therefore be used for further analysis.  
4.2.4. To compare APEX2 to BioID studies. 
Validation of the APEX2 dataset generated here via comparisons with other Ras 
interactomes produced by other proteomic studies could provide insight to the accuracy of 
the APEX2 data as well as an evaluation of the proximity labelling methods.  
4.3. APEX2 AS A METHOD 
4.3.1. Experimental setup 
For the large-scale experiment, 21 samples were prepped using different Ras isoform 
constructs and conditions for mass spectrometry (Fig. 4.1). Samples included APEX2-
tagged KRAS WT, KG12V, HRAS WT, HG12V, NRAS WT and NG12V. In addition, 
APEX2 alone and APEX2-tagged tK and tH were used as controls.  
The main control used for these mass spectrometry experiments was the no H2O2 control, 
which distinguishes between biotinylated and non-biotinylated proteins. In addition, other 
potential controls: APEX2 only, tK and tH were tested. These controls would essentially act 
as negative and positive markers respectively and therefore help narrow the shortlisting 
process to produce a list of membrane-enriched proteins that associate with Ras. The free-
flowing APEX2 would act as a negative control and eliminate any non-plasma membrane 
targeted cytosolic proteins, whereas the tK and tH would act as positive markers of the 
plasma membrane where the respective Ras molecules localise.   
For each Ras isoform, there were 4 conditions: WT control (no H2O2 treatment, i.e., no 
81 
 
biotinylation, CON), WT serum-starved (no serum media for 5 hours prior lysis, SS), WT 
stimulated (serum-starved for 5 hours followed by 5-minute stimulation with 20% FBS 
before lysis, STIM) and G12V (the mutant G12V form of the Ras isoform in normal 20% 
FBS supplemented media, G12V). Each sample underwent transfection, treatment with BP 
and H2O2 (or without for control) followed by cell lysis. Resulting lysates were subjected to 
avidin-based pulldown and ran on a polyacrylamide gel. Peptides were extracted using in-
gel digest and analysed by mass spectrometry.  
 
Figure 4.1| Schematic of the sample preparation workflow for mass spectrometry – Three different 
Ras isoforms (WT) along with controls: APEX2 only, tK and tH were transfected into HeLa S3 cells 
and treated accordingly to generate the conditions: control, serum-starved (no serum for 5hrs) and 
stimulated (no serum for 5hrs followed by 5 min FBS stimulation). The G12V mutant-transfected cells 
were kept in normal media supplemented with 20% FBS.    
4.3.2. Data processing of mass spectrometry data 
To analyse the differences between interactomes, the data was processed to a finalised list 
of proteins detected in each sample. In brief, the LFQ intensities were normalised to the non-
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biotinylated samples to identify biotinylated proteins, which were then averaged between 
the two repeats. These values were log2-transformed to model any changes in expression 
proportionately. Then a two-fold limit was set to stringently categorise specifically enriched 
i.e., biotinylated proteins from non-specifically labelled proteins. Note, with this assay, only 
increase fold changes were considered and not decreases due to the nature of the no H2O2 
control. Therefore, any proteins with a value 2-fold greater than control in the KRAS, HRAS 
and NRAS protein lists were termed ‘specific’ and listed as a protein present in that specific 
interactome. Whereas hits with values less than 2-fold were termed ‘non-specific’. 
 
Figure 4.2| Data processing workflow for mass spectrometry results – LFQ intensities generated 
from MaxQuant used to produce shortlists of specific proteins (>2-fold change compared to no H2O2), 
which were categorised by Ras isoform followed by activation status. 
4.3.3. Reproducibility 
A total of 5200 proteins (excluding common contaminants) were detected from the two 
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independent repeats of the 21 samples tested. To check the overall quality of the data, the 
LFQ intensities between the two experimental repeats were analysed. The graph shown in 
Figure 4.3a displays a strong correlation (Pearson’s correlation = 0.942) between the two 
sets of LFQ intensities. The little variability between the datasets provides a good indication 
that the datasets are similar and reproducible.  However, only two experimental repeats were 
performed here due to the time-constraints so further repeats would be needed. 
4.3.4. Specificity 
Mass spectrometry analysis revealed a total of 5200 hits were detected, in terms of K, H and 
N, 2212 of these proteins were non-specific i.e., proteins detected in the no H2O2 control and 
2988 proteins were found to be specific for K, H or N (Fig. 4.3b). In order to classify whether 
a hit was specific for a particular isoform, a 2-fold change in either one of the conditions: 
serum-starved, stimulated or G12V was required. Due to the classification of non-specific 
hits as less than 2-fold change, it is difficult to speculate whether there were a high number 
of non-biotinylated binders during the pulldown process or that many biotinylated binders 
were not considered to be ‘specific’ due to being lower than the chosen threshold.  
The total number of specific hits for each Ras isoform and controls are displayed in Figure 
4.3c. KRAS and NRAS have a similar number of hits (1610 and 1493, respectively), 
whereas fewer proteins were detected in HRAS (1117). As expected, a smaller number of 
proteins were detected in the truncated versions of KRAS (1117) and HRAS (903). The least 
number of proteins was detected in the APEX2 only control (888). The specific hits can be 
further subcategorised into whether these hits were distinctive to one Ras isoform or shared 
amongst the other isoforms (Fig. 4.3b). Interestingly, KRAS and NRAS samples shared 
more associated proteins than with HRAS, which seems to be more linked to KRAS than 
NRAS. Out of the 2988 proteins detected, only 199 proteins were common to all three Ras 
isoforms, in fact, majority (42-55%) of the proteins were present only in one Ras isoform. 





Figure 4.3| Overview of APEX2 mass spectrometry results – a) Reproducibility between the two 
experimental repeats. b) Detected proteins processed into two categories: specific (> 2-fold change 
compared to control) and non-specific. Specific proteins consist of KRAS-, HRAS- and NRAS-
associated proteins, which can be further subdivided into their subsequent conditions: serum-starved, 
stimulated or G12V mutant. c) Total number of specific hits for each Ras isoform and control.  
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Each Ras isoform proximity interactome is divided into the three conditions: serum starved, 
stimulated and G12V mutant (Fig. 4.3b). Results showed that 27.0%, 30.3% and 22.7% of 
the total hits were shared by all the conditions in KRAS, HRAS and NRAS, respectively. 
This indicates that these hits could potentially form the core interactome for each of the Ras 
isoforms. It was predicted that G12V and stimulated would share a higher proportion of the 
interactome, which appears to be the case in HRAS and NRAS but not in KRAS, whereby 
more similarities were seen between serum-starved and stimulated. NRAS displayed the 
most commonality between the G12V and stimulated condition (212). This suggests that 
despite both conditions being a model of ‘active’ Ras, these two interactomes are more 
diverse than expected.  
In addition, there were fewer proteins present in the stimulated condition than in the serum 
starved and G12V samples in KRAS, which was surprising as it would be expected that 
more proteins would be recruited when active. However, the opposite was true for NRAS, 
whereby the stimulated condition generated more hits than the other two conditions. 
Whereas, for HRAS, a similar number of unique proteins were detected per condition. 
Therefore, as a gross overview, it appears that the proximity interactome varies by different 
degrees dependent on the isoform and condition. For example, mutant KRAS and inactive 
KRAS proteomes share more similarities, whilst mutant HRAS and NRAS are more alike 
to stimulated HRAS and NRAS, respectively.     
4.3.5. Ras interactors 
To check the validity of the dataset, a list of Ras interactors was generated using STRING. 
The top 50 interactors with high confidence (score >= 0.7) for KRAS, HRAS and NRAS in 
humans using experiment and database sources were compiled into a list of 76 unique Ras 
interactors. From this list, 42 interactors were found in our dataset (55.3%), of which 29 
were specific for K, H or N and 13 were either non-specific or detected in only controls: tK 
and/or tH (Fig. 4.4a). The breakdown of the number of identified Ras interactors in each 




Figure 4.4| Identification of Ras interactors within the Ras-proximal proteome network – Bar 
charts displaying number of Ras interactors identified in a) STRING versus different protein lists 
generated here as well as b) a breakdown of these for the different samples. c) Schematic of known Ras 
interactors detected in the mass spectrometry data. Those listed in black highlight the presence of Ras 
interactors within the specific K, H, N databases versus hits that were non-specific (grey). 
The first key observation is that KRAS, HRAS and NRAS were detected in their respective 
samples and therefore APEX2 was correctly localised close to Ras in these samples. 
Secondly, Ras interactors were identified in the dataset and thus relevant proteins were 
biotinylated in these APEX2 experiments. Thirdly, the Ras isoforms and truncated Ras 
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markers all consisted of a higher number of Ras interactors compared to the negative non-
Ras control, APEX2 only. Although, it is interesting to note that BRAF, PI3KCG, RAC1, 
PAK2, MAP2K1, MLLT4, RASA2 were all present in the APEX2 only sample, which could 
suggest its wide presence within the cell might not make it a suitable negative control as it 
might eliminate potential candidate proteins. Nevertheless, Ras was not detected in the 
APEX2 control, which indicates that the specific localisation of Ras might have minimised 
its chances of being non-specifically labelled by free APEX2.  
All three Ras isoforms were present in the KRAS sample. But for HRAS and NRAS, only 
two Ras isoforms were detected in each sample, KRAS and HRAS in the HRAS only 
sample; HRAS and NRAS in the NRAS only sample. Intriguingly, both HRAS and NRAS 
were detected in the tK and tH controls, but KRAS was not present in either. Since KRAS 
was not labelled in the tK control but in the vicinity of the other two Ras isoforms, it is 
possible that precise localisation of KRAS requires the additional signals that could be 
provided by its full-length sequence. Identification of the respective Ras isoform and 
interactors in each sample confirmed that Ras has been efficiently biotinylated, which 
subsequently should lead to the specific labelling of relevant proteins within the vicinity. 
4.3.6. Proteome enriched for Ras signalling and plasma membrane proteins 
The detection of known Ras interactors highlighted the potential for the enrichment of other 
Ras-associated proteins in the detected proteomes for each of the Ras isoforms, Here, 
biological processes and cellular components associated with the total specific datasets were 
investigated via Gene Ontology (GO) enrichment analysis using the DAVID 6.7 database 
with an ease score of 0.1 and count of 2. The total specific dataset lists (T) were used here to 
give an overview of the overall function and localisation of the Ras isoforms, whereas later, 
assessment of hits present in only one of the isoforms (O) was used to identify 
proteins/functions/localisation unique to that isoform.    
The total specific datasets of KRAS (KT), HRAS (HT) and NRAS (NT) revealed that all three 
Ras isoforms were enriched for Ras protein signalling as well as other processes that might 
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be relevant to nanocluster formation such as actin cytoskeleton and membrane organisation 
proteins. Similarly, small GTPase mediated signalling was also found to be a significant 
biological process in KRAS and NRAS, in particular, components involved in Rho protein 
signalling were detected in KRAS. The absence of these pathways in the APEX2 only 
control signifies that the enrichment of Ras-related proteins is only present in the relevant 
Ras samples. Aside from these Ras-related roles, more general processes such as DNA 
replication, translation, protein transport and stress response were also enriched in all three 
Ras isoforms. In general, the enriched biological processes appear to be very similar 
amongst the different isoforms, with the exception of small GTPase mediated signalling, 
which was absent in HRAS. Additionally, Rho protein signalling, and protein ubiquitination 
were only present in KRAS and NRAS, respectively. The detected interactomes of tH and 
tK had similar enrichments as their full-length counterparts, however Ras protein signalling 
was not present in tK. As shown previously, KRAS was not present in tK, therefore it could 
be speculated that the lack of KRAS could result in inaccurate localisation and subsequently, 
an absence of relevant Ras signalling proteins. Nevertheless, APEX2-labelling has shown 
to effectively capture the functionality of the Ras interactomes. 
Fundamentally for this project, the aim is to identify regulators of Ras nanoclustering at the 
plasma membrane, therefore it is crucial to detect proteins associated with the plasma 
membrane. Using GO analysis, the cellular localisation of the detected proteins was 
assessed. As shown by Figure 4.5, the labelled proteins were detected widely around the cell 
and found to be significantly associated with several components of the cell: plasma 
membrane, cytoskeleton, cytosol, mitochondria, ER, ribosomes, and nucleoli. Its ubiquitous 
expression within the cell is not surprising, since it is known that Ras can traffic and signal 
from various endomembranes (Choy et al., 1999; Rebollo, Pérez-Sala and Martínez-A, 
1999; Chiu et al., 2002; Lu et al., 2009). Therefore, it is possible that APEX2 labelling 
occurs at various timepoints among these locations. The result showed a significant 
enrichment of endosomal and ER proteins in KRAS and NRAS. It is interesting that these 
proteins were not as abundant in HRAS, since there is substantial evidence that HRAS can 
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localise and signal from these different endomembranes (Apolloni et al., 2000; Chiu et al., 
2002; Roy, Wyse and Hancock, 2002). More surprisingly, for all three Ras isoforms, 
proteins associated with the Golgi apparatus appeared to be absent, which is particularly 
unexpected for HRAS and NRAS, since these isoforms are commonly known to be 
palmitoylated in the Golgi (Laude and Prior, 2008).  
 
Figure 4.5| GO enrichment analysis of the total specific hits – Datasets of total specific hits (T) of 
all three Ras isoforms and the controls: A, tK and tH were represented by their a) biological function 
and b) cellular components. Colour intensity represents the enrichment p value.  
To conclude, there was a significant enrichment of plasma membrane proteins amongst the 
total specific datasets, which indicates that a large proportion of APEX2-Ras molecules 
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localised to the plasma membrane where interactions with potential regulators could have 
been detected. The GO analysis did however also reveal the noise associated with this type 
of methodology, which would need to be addressed with additional localisation controls in 
future experiments.   
4.4. PROFILING THE RAS INTERACTOMES 
Preliminary analysis has shown promising results that APEX2-Ras labels proteins in the 
vicinity, which are relevant to Ras biology. Despite the widespread labelling throughout the 
cell, there was still an enrichment of plasma membrane proteins in the Ras samples, which 
could be potential regulators. The three Ras isoforms have different signalling platforms on 
the plasma membrane, which aside from the G-domain and C-terminal membrane anchors, 
also require additional proteins to facilitate their specific localisation (Belanis et al., 2008; 
Shalom-Feuerstein et al., 2008; Posada et al., 2016). Dissection of the different Ras 
interactomes could elucidate proteins unique to each isoform and/or condition. This will aid 
the shortlisting process to highlight potential hits that could play a role in Ras localisation.  
4.4.1. Isoform-dependent interactomes 
In the previous section, total hits in each isoform i.e., any hits identified in that isoform 
irrespective of appearing in other isoforms were used for analysis. However, to investigate 
the isoform-specific hits (denoted by o), the total hits were categorised into hits that occurred 
exclusively in one isoform. Hits present in two or all three isoforms were also displayed to 
show the full dissection of the dataset (Fig.4.6). With this breakdown, comparisons could 
be made between unique proteins present in each isoform (Ko, Ho, No) as well as any shared 
amongst two isoforms or common to all three isoforms.  
Analysis of the biological functions amongst these isoform-specific datasets revealed that 
the hits responsible for the Ras protein signalling enrichment seen previously in all three 
isoforms was not unique to each isoform and are due to the combinations of proteins found 
amongst the different Ras isoforms. Interestingly, Ko and Ho were significantly enriched for 
proteins involved in membrane organisation and more importantly, these proteins were 
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different between the two isoforms. This raises the question whether these differentially 
expressed proteins play a role in its localisation.  
 
Figure 4.6| Dissection of isoform-specific proximity proteins - Heatmap of GO enrichment analysis 
of hits present in one (o), two or all three Ras isoforms. 
The cellular component analysis revealed that proteins common to all three Ras isoforms 
were enriched for inner plasma membrane proteins. Significant enrichment of these types of 
proteins were also present exclusively in KRAS as well as in both KRAS and NRAS. From 
literature, it is known that HRAS and NRAS undergo an exocytic pathway to the plasma 
membrane via the ER and Golgi,  however, proteins associated with these components were 
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not present in either isoforms nor in the collective group of HRAS and NRAS (HN) (Choy 
et al., 1999; Apolloni et al., 2000). Overall, it appears that the majority of enriched plasma 
membrane proteins were shared amongst all isoforms, which could suggest that these 
different Ras molecules localise closely to each other at the plasma membrane. It is also 
possible that APEX2 does not have the resolution to distinguish the differences between the 
different nanoclusters due to their close proximity.    
4.4.2. Activation-dependent interactomes 
 
Figure 4.7| Interrogating proximity proteomes of different activation states – The effects of serum-
starvation, stimulation and the G12V mutation on Ras a) function and b) localisation was investigated 
using GO enrichment analysis.  
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Next, the effects of differential activation on Ras signalling and localisation were 
investigated. Similar to the isoform analysis, each isoform (T) was divided into unique hits 
for each of the conditions: serum-starved, stimulated and G12V (Fig. 4.7). As mentioned 
previously, the serum-starved condition represented inactive GDP-bound-Ras, whereas 
stimulated and G12V models active GTP-bound Ras.  
Initial findings show that all conditions in KRAS and HRAS were significantly enriched in 
Ras protein signalling. These hits do not appear to be unique to each of the individual 
conditions, therefore suggesting that the proteins enriched for Ras protein signalling were 
predominantly shared amongst both active and inactive Ras. It is possible that the expression 
levels of these proteins differ between the nucleotide states, however due to the nature of 
overexpression, exact quantification was limited. Unlike KRAS and HRAS, Ras protein 
signalling only appears to be significant in active Ras conditions in NRAS. This highlights 
a possibility that the NRAS proximity proteome varies more considerably with its state of 
activity compared to other isoforms.  
A significant association of inner plasma membrane proteins were present in the collective 
conditions for each Ras isoform, however none appeared to be unique to a specific condition 
(with the exception of serum-starved NRAS). Interestingly, there did not appear to be an 
increased enrichment of plasma membrane proteins in the activated conditions (i.e., STIM 
and G12V) compared to the serum-starved non-active samples, despite the knowledge that  
activation of Ras leads to the recruitment of additional proteins to the plasma membrane 
(Simanshu, Nissley and McCormick, 2017).   
4.4.3. Shortlisting of proteins for validation 
Analysis revealed that APEX2 in combination with a dynamic protein like Ras generated 
extensive labelling around the cell. Also, due to the nature of the experiment, accurate 
comparisons of protein expression levels could not be made. The majority of the enriched 
plasma membrane proteins did not appear to be isoform nor activation state specific and 
instead were commonly found to be shared amongst these conditions. The high amount of 
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labelling of these proteins and their presence in all conditions provided confidence that these 
proteins were likely to be in close proximity to Ras, where they might play a role in their 
biology. Therefore, to shortlist proteins that could be of potential interest to Ras 
nanoclustering, top hits specific for all different conditions were investigated. 
A total of 17 proteins were found to be specific for all Ras isoforms: KRAS, HRAS and 
NRAS, as well as for all three conditions: serum-starved, stimulated, and mutant (Fig. 4.8a). 
Amongst these hits, Ras-associated proteins: ezrin (EZR), galectin-3 (LGALS3/Gal-3) and 
Ras GTPase-activating protein-binding protein 2 (G3BP2) were present. Gal-3 is a KRAS 
scaffolding protein (Shalom-Feuerstein et al., 2008), whereas EZR aids the assembly of a 
protein complex with Ras and SOS (Geißler et al., 2013). Aside from these types of proteins, 
other hits included enzyme-, actin- and cell division-related proteins. More importantly, two 
members from the membrane-binding annexin (ANXA or A) family: ANXA11 and ANXA6 
(Grewal et al., 2005) were found to be highly present amongst the Ras proximity proteomes, 
in particular with KRAS and HRAS. Interestingly, other annexins have also appeared in the 
datasets. Therefore, annexins could be of interest due to its association with the plasma 
membrane and its observed proximity to Ras.  
In the overall dataset, eight types of annexins were detected: ANXA-1, -2, -3. -4, -5, -6, -7 
and -11 (Fig. 4.8b). All these annexins appeared to be most abundant in KRAS compared to 
the other two isoforms. Only ANXA6 and ANXA11 were detected in all Ras isoforms and 
conditions, whereas ANXA1 and ANXA2 were present in all Ras isoforms but not all 
conditions. The remaining annexins: ANXA-3, -4, -5 and -7 were primarily identified in 
KRAS, however the latter two annexins were also associated with NRAS. In most cases, the 
differences between the conditions for each of the Ras isoforms were often subtle. 
Altogether, it appears that APEX2 might lack the sensitivity and resolution which might be 
required for an in-depth quantitative comparison of the different isoforms and conditions. 
Nevertheless, it has been a valuable tool that has highlighted possible candidate proteins 




Figure 4.8| Identification of potential regulators of Ras nanoclusters – a) Proteins present in all Ras 
isoforms and activity states represented by their stimulated log2 value. b) Log2 values of each Ras 
isoform and condition are shown for each annexin detected within the APEX2 dataset.  
96 
 
4.4.4. Comparisons to other databases 
Proximity labelling has become increasingly popular for screening interactomes, in 
particular using BioID. In recent years, BioID has been used to study the Ras interactome 
(Ritchie et al., 2017; Adhikari and Counter, 2018; Kovalski et al., 2019), where these studies 
focused on identifying therapeutic targets in terms of Ras signalling. However, as of current, 
no studies have been published using APEX2 to investigate Ras. Therefore, it was of interest 
to compare the data generated here with the detected interactomes from BioID studies to 
provide insight into these two methodologies.     
Adhikari and Counter investigated the interactomes of oncogenic Ras (G12V) for KRAS, 
HRAS and NRAS in HEK 293T cells using BioID. In their study, a total of 3148 proteins 
were detected of which 476 were specifically labelled. Whereas 1984 specific proteins were 
identified amongst the G12V population in the APEX2 dataset. Between these two datasets, 
around 115 hits appeared to be common to both (Fig. 4.9a). These hits included members 
of the GTPase family: Rho, Rab and Arf as well as Raf. PIP5K1A was found to be important 
for KRAS oncogenicity in the BioID study. In concordance, PIP5K1A was also identified 
in the KG12V and NRAS WT samples in the APEX2 dataset. Therefore, highlighting the 
capacity of APEX2 to detect hits that were significant in BioID.  
The second BioID study by Kovalski et al identified the interactomes of KRAS WT/G12D, 
HRAS WT/G12V and NRAS WT/Q61K in colon (Caco-2)-, bladder (HT-1376)- and skin 
melanoma (CHL-1)-cancer cell lines, respectively. Here, using their isoform normalised 
log2 fold change scores with a cut-off of 4-fold change compared to BirA* control, 
comparisons were made between their WT data and the combined APEX2 data of serum-
starved and stimulated (representing WT Ras) (Fig. 4.9b). The overall analysis showed little 
overlap between the two datasets. Majority of shared proteins for KRAS WT and HRAS 
WT were related to more general biological processes, whereas hits shared amongst the two 
databases for NRAS WT were linked to the Ras signalling pathway and plasma membrane. 




Figure 4.9| APEX2 vs BioID – Comparisons made between the APEX2 data and three BioID studies: 
Adhikari & Counter, Kovalski et al and Go et al. a) Mutant G12V Ras isoforms. b) WT Ras isoforms. 
c) HG12V. d) KRAS WT vs tK. e) HG12V vs plasma membrane (PM) proteins.  
98 
 
Presence of the HG12V condition in two of the BioID studies made it possible to compare 
with the APEX2-generated HG12V dataset (Fig. 4.9c). Firstly, the results showed that a 
higher number of hits were present in APEX2 compared to BioID. Secondly, the two BioID 
studies displayed more commonality than with APEX2. Lastly, only 17 proteins were 
present in all three studies. These proteins included the Raf proteins: a-Raf and c-Raf, as 
well as caveolae component: flotillin-1 (FLOT1). A possible reasoning for the difference in 
results could be due to the lack of specific (i.e., greater than 2-fold change) labelling of 
HRAS in the APEX2-generated HG12V condition despite its presence in the dataset, which 
could ultimately affect the biotinylation of neighbouring proteins.  
Another important BioID study is by Go et al. Here, they produced a BioID-generated 
proximity map of HEK 293 Flp-In-T-REx cells using 192 marker proteins as a tool for others 
to interpret their biotinylation-based proximity labelling data. In their study, 22 bait proteins 
were used to map the microenvironment of the plasma membrane, which also included tK. 
Analysis revealed a high level of similarity between the protein lists of Kovalski et al and 
Go et al, whereas the APEX2 dataset appeared to be dissimilar (Fig.4.9d). Another 
interesting finding was that the HG12V data from the other two BioID studies were more 
enriched for the plasma membrane proteins detected in Go et al study compared to APEX2 
(Fig.4.9e). However, nearly a third (120 of the 378) of the plasma membrane proximity 
proteins generated by BioID were identified in the total specific hits found using APEX2 
(not shown).        
Overall, APEX2 appears to be a noisier method than BioID. The primary indication of this 
is the presence of considerably more proteins, yet fewer plasma membrane proteins. 
However, it is possible that the use of additional controls and more stringent cut-offs in other 
studies aided the deduction of background proteins. In addition, APEX2 captures more 
transient interactions of which could be more abundant than stable interactions that are 
thought to be detected by BioID. Nevertheless, differences also occurred between the BioID 
studies which highlights high variability amongst these types of methodology. The use of 
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different cell models could contribute to the disparities, such as the type of cell line used 
and whether expression was transient or stable. Although, it should also be noted that 
different types of analyses and cut-off points were performed for all studies, which would 
largely affect the observed final dataset. On the whole, results here have shown differences 
in protein lists generated by APEX2 and BioID, but a more accurate comparison would be 
needed whereby the same experimental setup and analyses are used. Nonetheless, it has 
demonstrated that APEX2 has the capacity to detect potential Ras interactors and/or 
regulators, however the use of carefully selected markers and controls are required to reduce 
the noise that is associated with this technique.  
4.5 DISCUSSION 
In this chapter, the use of APEX2 to profile the Ras interactome was demonstrated, which 
has not been previously shown before. Here, a large-scale APEX2 experiment was 
performed using an optimised protocol in combination with mass spectrometry. The overall 
dataset showed to be reproducible with an r score of 0.942, however further repeats would 
be needed. Nevertheless, the experiment generated a substantial database consisting of a 
total of 5200 hits of which 2988 hits were found to be specifically labelled with biotin. 
Biotinylation is relatively uncommon within a cell, mainly carboxylases are biotinylated 
(Chapman-Smith and Cronan, 1999), therefore it was with high confidence that the proteins 
detected were specifically biotinylated by APEX2-tagged Ras. Also, as shown by the IF 
images from the previous chapter, background biotinylation was modest and could be due 
to the combination of naturally biotinylated proteins and cell culture media. However, the 
high number of non-specific proteins present here which include proteins other than 
carboxylases indicates that these proteins may have resulted from processes further 
downstream of the APEX2 protocol. Although, the bead to lysate ratio was optimised 
previously, it is possible that the scaling-up process could have affected the purity of the 
enrichment. The large volume of beads may have resulted in suboptimal wash steps during 
the enrichment process and therefore would require further optimisation for future 
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experiments.    
The specific hits were later categorised into their isoform/s and condition/s, which was then 
used for GO analysis. Overall, the detected hits showed to be enriched for Ras signalling, 
membrane organisation and plasma membrane proteins. Additionally, known Ras 
interactors were also present. Together it was evident that relevant labelling occurred. 
However, GO analysis of the cellular components revealed that labelling was not occurring 
exclusively at the plasma membrane, but also in other subcellular regions within the cell in 
which Ras can traffic to. Since literature has shown that HRAS and NRAS move throughout 
the cell in a similar manner, it was of interest to see that there was little resemblance between 
their localisation profiles. Similarly, despite both stimulated and G12V conditions being 
active models of Ras, these were highly dissimilar in terms of proteins relating to biological 
function. Nonetheless, both conditions were enriched for plasma membrane proteins.     
Interestingly, more proximal proteins were detected in KRAS than in HRAS and NRAS, 
which could be due to transient transfection, whereby expression levels could vary. GO 
analysis was used to profile the functions and localisation of these different isoform protein 
lists. It appeared that KRAS in particular displayed distinctive proximal proteins for 
membrane organisation and the inner plasma membrane. In terms of the different active and 
non-active conditions, it did appear that majority of the conditions shared similar proteins 
for Ras protein signalling (except NRAS) and inner plasma membrane proteins, which might 
constitute as a core proteome that is supplemented with individually enriched unique 
proteins that are dependent on the condition.  
The level of biotinylation is an indication of its proximity to Ras, i.e., a protein that interacts 
with Ras should be labelled more than a protein that is in the distance. However, due to the 
number of conditions used for this experiment, it was not possible to use SILAC and instead 
the label-free approach was used. The downfall of label-free is that abundance is hard to 
quantify as the different expression levels cannot be accurately accounted for during 
analysis, so it was difficult to conclude comparisons made between isoforms without further 
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experimentation. Therefore, after initial analysis, it became apparent that the results should 
be interpreted more as an indication of whether a protein was present or not, and not for 
comparison of expression levels. Using the core set of proteins shared by all Ras isoforms 
and conditions, a shortlist of 17 proteins was generated. Amongst the list were Ras-related 
proteins, membrane associated proteins, actin-related proteins, and metabolic enzymes. 
Since the aim of the project is to identify regulators of Ras nanoclustering organisation at 
the plasma membrane, it was apparent that membrane proteins present within the list, 
annexins should be further followed up.  
For this project, APEX2 was used as the proximity-labelling method for analysing the Ras 
interactome, as it was more likely to capture more transient interactions due to the short 
labelling reaction. During the duration of this project, studies using BioID to investigate Ras 
were published (Ritchie et al., 2017; Adhikari and Counter, 2018; Go et al., 2019; Kovalski 
et al., 2019). It was of interest to compare the APEX2 and BioID datasets to understand how 
these proximity labelling methods differed. Overall, APEX2 generated largely different 
proximity proteomes compared to those in the BioID studies, which appeared to be more 
similar to one another. Additionally, more plasma membrane proximity proteins were 
detected in the BioID studies, although this could be biased as this list of proteins was 
established using BioID. Nevertheless, APEX2 was able to detect known Ras-related 
proteins as well as other proteins present in the BioID studies. These proteins are likely to 
be more stably expressed proteins, whereas the other detected proteins could reflect transient 
interactions.  
Further optimisation of the APEX2 method could reduce the number of non-specific 
proteins that bind to the streptavidin beads. Also, in light of the analysis, many hits were 
localised to different cellular components other than the plasma membrane. Markers of these 
regions could help eliminate proteins that are not localised at the plasma membrane in future 
experiments, thus reducing the noise to signal ratio.  
The observed differences amongst the datasets of the different BioID studies and APEX2 
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were not surprising, since the biochemistry of the labelling reactions differ. Firstly, the 
labelling duration determined whether stable or transient interactions were detected. 
Secondly, BioID labels lysine side chains (Roux et al., 2012), whereas APEX2 tags tyrosine 
side chains (Lam et al., 2015). Tyrosine is a less abundant amino acid than lysine (Tourasse 
and Li, 2000; Echols, 2002), which could lead to a bias in the protein population detected. 
In general, the addition of biotin may also alter the charge and structure of a protein, thus 
affecting its function. Thirdly, oxidative damage from H2O2 could have affected the cellular 
physiology such as signalling pathways or protein interactions, which could be likely as the 
GO analysis revealed that the samples were significantly enriched in stress response related 
proteins. Fourthly, it has been reported that BP is less membrane permeable, which in 
combination with its short half-life of the unstable free radicals could result in a smaller 
labelling radius (Hung et al., 2016). However, this might have been more beneficial for this 
study since regulators of Ras nanoclustering would be expected to be of very close 
proximity. Variation also occurred amongst the BioID studies, less than half of the total hits 
were shared between them despite the use of the same labelling duration of 24 hours. 
Although differences could be due to differences in experimental setup and/or data analysis. 
In general, it is important to note that the extent in which Ras is affected biochemically by 
the attachment of these proximity labelling enzymes is still unknown.   
Overall, proximity labelling has been an instrumental tool for the wide screening of different 
proteome microenvironments. Here, APEX2 was successfully used to map proteins 
proximal to Ras WT (both active and inactive forms) and G12V mutants. A significant 
number of hits were detected via mass spectrometry of which was used to shortlist annexins 
as possible regulators of Ras nanoclustering. Therefore, APEX2 has played an important 
role for this project. However, one of the biggest caveats of this technique is the number of 
non-plasma membrane proteins detected, which with further optimisation could be resolved. 
In addition, normalisation of expression via stable transfection in future studies would allow 












Annexins are a group of calcium- and acidic phospholipid-binding proteins (Crumpton and 
Dedman, 1990) that were first discovered in the late 1970s (Creutz, Pazoles and Pollard, 
1978). Since then, over 100 different annexin proteins have been identified in a wide range 
of species such as animals, plant and fungi (Morgan and Pilar Fernandez, 1997). In humans, 
12 members have been identified (A1-11, 13), which vary in size ranging from 15kb (A9) 
to 96kb (A10) (Morgan et al., 1999). A3, -8, -9, -10 and -13 are selectively expressed in 
neutrophils, skin, tongue, stomach, or small intestine, respectively. Whereas the remaining 
annexins are ubiquitously expressed (Moss and Morgan, 2004). Within the cell, they are 
predominantly cytosolic, however some members such as A2 (Eberhard et al., 2001) and 
A11 (Tomas and Moss, 2003) have been found to localise  in the nucleus.  
These annexins have high structural homology, where all share a conserved core domain at 
the C-terminus, which consists of four subunit repeats (except for A6 with eight repeats), 
each made up of around 70 amino acids (Fig. 5.1). The repeats assemble into a tight α-
helical disk. Its slightly curved shape gives it a convex surface that contains the calcium- 
and phospholipid-binding sites, as well as a concave side which associates with the N-
terminus and/or potential interactors (Huber, Römisch and Paques, 1990). These calcium-
binding sites vary in location and in numbers between the different annexin members. 
Similarly, the N-terminal domain is unique to each individual annexin, where length and 
sequence differ between them and mediates interaction with cytoplasmic binding partners 
like S100A10 (Morel and Gruenberg, 2007), Src (Hayes and Moss, 2009) and PKC 
(Kheifets et al., 2006). Additionally, the N-terminal domain has shown to modulate 
membrane association (Wang and Creutz, 1994; Hofmann et al., 2000) and act as a binding 
site for other annexins, leading to dimerization (Lizarbe et al., 2013).   
In general, annexins have shown to be involved in a wide range of processes such as 
membrane organisation, trafficking as well as extracellular functions. Its hydrophilic nature 
allows it to bind to negatively charged phospholipids in a reversible calcium-dependent 
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manner. Whereby, the sensitivity to calcium as well as specificity for particular phospholipid 
headgroups such as PA, PS or PI differ between each annexin member (Raynal and Pollard, 
1994). Typically, external stimuli triggers the release of intracellular calcium and results in 
the recruitment of annexins to the inner leaflet of the plasma membrane and/or other 
membranes of various organelles (Reviakine et al., 2000). This allows for annexin regulated 
membrane reorganisation of the cell in response to different stimuli. For example, A2 and 
A6 are recruited to sites of actin assembly, where they associate with lipid rafts and 
cytoskeleton in order to regulate the organisation of non-raft and raft microdomains in 
smooth muscle cell membranes (Babiychuk and Draeger, 2000). Interactions with the 
membrane can also be calcium-independent and instead, depend on pH (Gerke and Moss, 
2002). For example, the acidic pH in endosomes can induce conformational changes to A6, 
thus exposing hydrophobic regions to bind the plasma membrane (Golczak et al., 2004). 
 
Figure 5.1| Schematic of the annexin structure 
Aside from membrane organisation, annexins also play a role in both calcium-dependent 
and -independent regulated endocytotic and exocytotic events. Studies have shown A2 to be 
associated with early endosomes in a calcium-independent manner (Babiychuk and Draeger, 
2000) as well as the biogenesis of multivesicular endosomes (Mayran, Parton and 
Gruenberg, 2003). Its subcellular distribution appears to be regulated by cholesterol, as it 
binds to cholesterol-rich membranes (Mayran, Parton and Gruenberg, 2003). Similarly, A8 
has shown to be required for the regulation of late endosomal trafficking (Goebeler et al., 
2008). Whereas, A6 regulates the budding of clathrin-coated pits from the plasma membrane 
of human fibroblast cells (Lin, Südhof and Anderson, 1992).   
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The pathogenesis or progression of many human diseases have often been linked to 
annexins. In particular, annexins have been associated with various cancers such as breast 
(Du et al., 2018), ovarian (Song et al., 2009), gastric (Hua et al., 2018), liver (Sun et al., 
2018; Zhao et al., 2018) as well as head and neck cancers (Raulf et al., 2018). In gastric 
cancer, it has been reported that A11 promotes the proliferation, migration and invasion of 
cancerous cells via the Akt/GSK-3β pathway (Hua et al., 2018). Whereas, A5 has shown to 
aid the progression of hepatocarcinoma via the integrin and MEK-ERK pathway (Sun et al., 
2018). Another pathway affected by annexins is the NF-kB pathway, which appears to be 
important for A3-mediated metastasis in breast cancer (Du et al., 2018). Contrastingly, A1 
is associated with better prognosis in head and neck cancers despite being previously linked 
to breast cancer progression, as it regulates EGFR activity (Raulf et al., 2018).    
As shown in the previous chapter, A1-7 and A11 were all identified in the APEX2 screen, 
indicating a possible association with Ras. In particular, A6 and A11 were found to be linked 
with all Ras isoforms in both their active and inactive states (Fig. 4.9). Due to their affinity 
for phospholipids and role as a membrane scaffold, there is potential that annexins might be 
involved in Ras nanoclustering. To date, there has been minimal studies looking at the link 
between Ras and annexins. Two studies from the same research group highlighted a possible 
relationship between A6 and Ras, where it was hypothesised that A6 aids the recruitment of 
gap120 to the plasma membrane, resulting in the deactivation of Ras (Grewal et al., 2005; 
Vilá de Muga et al., 2009). With the exception of these studies, it appears that no further 
research exists between annexins and Ras. Therefore, in this chapter, the relationship 
between Ras and annexins will be investigated to establish whether annexins are involved 
in the organisation of Ras nanoclusters at the plasma membrane.  
5.2. AIMS 
5.2.1. To determine whether Ras and annexins interact.    
Annexins (A1-7, -11) were detected in the APEX2 data, indicating that these annexins are 
in close vicinity of Ras. However, this does not indicate that Ras and annexins interact. 
107 
 
Therefore, the first objective is to elucidate whether direct or indirect interactions, if any, 
occur between these two groups of proteins.   
5.2.2. To characterise the effect of annexins on Ras biology.    
The next objective was to characterise the relationship between annexins and Ras by 
determining if annexins affect Ras biology. In particular, it is of interest to explore whether 
annexins are capable of modulating Ras signalling and/or nanoclustering.  
5.3. ANNEXINS INTERACT WITH RAS 
5.3.1. Validation of annexins in Ras pulldown  
Various members of the annexin family were detected in the APEX2 dataset. Before 
elucidating whether these annexins are important for Ras biology, the detection of annexins 
was first optimised in order to validate whether annexins were present in the FLAG-Ras 
pulldown. As mentioned previously, A1-7 and A11 were detected in the dataset. Antibodies 
against A1, A2, A5, A6, A7 and A11 were tested in HeLa S3 cells transfected with APEX2 
tagged-KRAS WT (Fig. 5.2a). The results showed that each of these annexins were clearly 
detectable in the transfected cells.  
Next, validation of the mass spectrometry results by western blot was performed. Here, the 
APEX2 experiment was conducted using the same conditions as stated previously (Fig. 4.1). 
The pulldown of biotinylated proteins was blotted for two proteins that were detected in the 
APEX2 screen: A6 and septin-2 (SEPT2) (Fig. 5.2b). In the previous chapter, SEPT2 was 
detected in the KRAS and NRAS proximity proteomes. Whereas A6 was more enriched in 
KRAS and HRAS compared to NRAS. In this experiment, however, A6 was predominantly 
present in stimulated KRAS and to a lesser extent in serum starved KRAS and HRAS. 
SEPT2 displayed a similar biotinylation profile to A6, but these results were more reflective 
of the mass spectrometry data where SEPT2 was found to be mainly enriched in KRAS. 
Interestingly, the enrichment of both proteins appeared to coincide with the pattern of actin 
biotinylation. It was of interest to also note that expression of A6 was higher in all Ras-




Figure 5.2| Detection of annexins – a) Testing the presence of endogenous annexins in KRAS WT 
transfected HeLa S3 cells using their respective anti-A1, A2, A5, A6, A7 and A11 antibodies. An anti-
FLAG antibody was used to detect the FLAG-tagged APEX2-Ras and actin was used as a loading 
control. b) Validation of A6 and SEPT2 in the biotinylated population. The input (2.5%) and 
streptavidin pulldown are shown in the top and bottom blots, respectively. 
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In addition, the similar expression profiles between A6, SEPT2 and actin could suggest that 
the streptavidin pulldown process was not as clean as expected, since actin was not 
previously observed in other pulldown blots. Overall, the results have shown slight 
discrepancies to the mass spectrometry data seen in the previous chapter, however in general 
the results suggest that A6 is in close proximity to KRAS and HRAS. Therefore, in the next 
section, the interaction between A6 and Ras will be investigated.    
5.3.2. Identifying interaction between annexin 6 and the different Ras isoforms 
The next steps were to explore whether annexins and Ras interact. IP was used to test if a 
direct interaction occurred between exogenously expressed APEX2-tagged Ras and 
endogenous annexins. Here, additional annexins were tested alongside A6, since these 
annexins were also detected before. Specifically, A1, A2, A6 and A7 were measured in the 
FLAG IPs of APEX2-KRAS WT, -KG12V, -HRAS WT, -HG12V, -NRAS WT and -
NG12V transfected HeLa S3 cells (Fig. 5.3a).    
Previous mass spectrometry data showed that A1, A2 and A6 were present in all three Ras 
proximal proteomes, however only A6 was present in all conditions, i.e., serum-starved, 
stimulated and G12V. Whereas A7 predominantly appeared in KRAS. In Figure 5.3b, A1 
and A2 are absent in the pulldown lanes, suggesting that these annexins are not direct Ras 
interactors. Whereas A7 was present in the pulldown of HRAS and NRAS but absent from 
KRAS (Fig.5.3c), however it was later elucidated that these bands were not A7 and instead 
were caused by off-target labelling by the A2 antibody (not shown). Similar to the mass 
spectrometry data, A6 was detected in the pulldowns of all Ras isoforms (Fig.5.3b, c). 
However, there is a possibility that the observed bands in the pulldown lanes could be non-
specific since A6 is also present in the untransfected control. Troubleshooting using a 
different negative control such as GFP-FLAG as well as a lysate preclearing step with beads 
did not eliminate the observed problem. Therefore, further optimisation of the FLAG-
pulldown protocol is required. Nonetheless, these results do not exclude A6 as a direct 




Figure 5.3| Investigation of annexins as direct interactors of Ras – a) Schematic of the FLAG-Ras 
IP process. b) Representative blot of FLAG-Ras IP. Both input (2.5%) and pulldown samples were 
blotted for A1, A2, A6, A7, FLAG and actin (loading control). c) Quantification of annexins in the 




Figure 5.4| Absence of Ras in GFP-annexin pulldowns – a) Schematic of the enrichment of annexins 
from GFP-ANXA transfected HeLa S3 cell lysates using anti-GFP beads. b) Representative blot (from 
n=3) of measuring endogenous Ras in GFP-ANXA pulldowns (top) and validation of enriched GFP-
A2, -A6 and -A7 proteins (bottom). 
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To circumvent the possible non-specific enrichment associated with the FLAG IP method, 
an alternative IP experiment was designed to validate whether the previous results were 
representative of the Ras and annexin interaction. In these experiments, endogenous Ras 
was probed in the pulldowns of GFP-tagged annexins. Here, Hela S3 cells were transfected 
with GFP-FLAG, -A2, -A6 and -A7, then incubated with anti-GFP beads to elute the GFP 
proteins, which were later used to assess the presence of Ras (Fig.5.4a). 
As shown by the representative blots (Fig. 5.4b), all GFP proteins were successfully 
enriched. However, Ras was not detected in any of the pulldown lanes of A2, A6 or A7 (Fig. 
5.4b, top blot). An interesting observation is that all three of these annexins already appear 
to be abundant within HeLa S3 cells. Therefore, it would be of interest to know whether the 
endogenous Ras preferentially interacts with the endogenous annexins over the transiently 
transfected GFP-tagged annexins. The lack of Ras in the IP was consistently seen across all 
three experimental repeats (not shown), which could either indicate that Ras does not interact 
with A2, A6 or A7, or that IPs might not be a suitable technique for capturing the transient 
interaction that may occur between these two proteins.  
5.3.3. Visualisation of the Ras-annexin interaction  
Results from the previous experiments regarding the interaction between Ras and annexins 
remained fairly inconclusive. IPs have the disadvantage of only being able to capture strong 
or stable interactions, due to the harsh conditions of cell lysis and enrichment steps. 
Therefore, FRET was used to circumvent this problem and assess whether weak or transient 
interactions occur between annexins and Ras.  
The principal of FRET is based on the excitation of one fluorophore (donor) with light of 
one wavelength, followed by a non-radiative transfer of energy to another fluorophore 
(acceptor), which emits light of another wavelength. This phenomenon can only occur when 
the two molecules are within approximately 10nm (100Å); energy transfer is highly 
sensitive to the distance between the fluorophores (Sekar and Periasamy, 2003).  These 
fluorophores are chosen so that an overlap occurs between the spectrums of the donor 
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emission and the acceptor excitation in order for energy transfer to occur. In addition, there 
must be sufficient separation between the donor and acceptor emission spectrums so that 
fluorescence of each fluorophore can be measured (Sekar and Periasamy, 2003).   
 
Figure 5.5| Schematic of FRET  
For these experiments, eGFP-annexins: A2, A6 and A7 and a panel of mCherry-tagged Ras 
isoforms and G12V mutants were used (Fig.5.5). These were co-transfected into HeLa S3 
cells and visualised live 24 hours post-transfection. In addition to these samples, single 
transfections of A2, A6 or A7 were used as negative controls and to account for donor 
bleedthrough into the FRET channel. A positive control of co-expressed eGFP-HRAS WT 
and mCherry-HRAS WT was also used.  
To measure FRET, two types of analyses were performed: sensitised emission (SE) and 
acceptor photobleaching. For SE analysis, the co-transfected cells were visualised under 
three channels: eGFP, mCherry and FRET. If protein-protein interaction occurred, FRET 
was observed, whereby donor (eGFP) excitation led to acceptor excitation (mCherry) and 
subsequently, emission of the mCherry wavelength would be observed in the FRET channel. 
The increased emission of the acceptor (mCherry) results in a decrease of the donor (eGFP) 
emission, which forms the basis of the second type of FRET analysis: acceptor 
photobleaching. Where in this scenario, bleaching of the acceptor (mCherry) fluorophore 
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will increase the fluorescence of the donor fluorophore if the two molecules are in close 
proximity. 
Images taken of these co-transfected cells revealed that both types of fluorophores: eGFP-
annexin and mCherry-Ras were efficiently expressed (Fig.5.6). In general, annexins were 
predominantly expressed in the cytosol, whereas Ras expression varied depending on the 
partnering annexin. Interestingly the morphology differed between the different annexins. 
A6-transfected cells exhibited normal morphology, whereas both A2- and A7-transfected 
cells had a more rounded cell appearance. In addition, A2 cells appeared to have enlarged 
nuclei and Ras appeared to be mainly present in puncta, presumably endosomes. Whereas 
in A7-expressing cells, large vacuoles can be seen, which could be a result of A7 activity 
since A7 has been previously been implicated in the fusion of vesicles (Creutz, Pazoles and 
Pollard, 1978). Here, the distribution of Ras was similar to A2-expressing cells, where it 
was mainly found in endosomes. Unlike A2 and A7, Ras distribution was generally more 
cytosolic, or plasma membrane bound in A6-expressing cells. 
FRET efficiency (FRETε) for each pixel within an image was calculated by the subtraction 
of the cross-excitation (i.e., excitation of donor via excitation of acceptor) and bleedthrough 
(i.e., detection of donor in the acceptor channel) intensities from the FRET intensity and 
expressed as a percentage of the acceptor intensity. Observation of the FRETε images 
revealed varying levels of FRET amongst the different samples. The positive control 
displayed high levels of FRET along the plasma membrane as expected, whereas the 
negative control: A6, showed little FRET (Fig.5.6a), which was similar to the A2 and A7 
controls (not shown). Images showed that FRET was present in the majority of A6- (Fig.5.6a 
& b) and A7-expressing (Fig.5.6c) cells, however little to no FRET was observed in the A2-
transfected cells. For most A6 and A7 samples, FRET was present in the cytosol and plasma 
membrane, but absent from the nucleus. In A7, FRET also occurred in the observed puncta.  
To quantify FRET in a number of cells, acceptor photobleaching was used. Here, confocal 
images were taken before and after bleaching. Whole cell fluorescence was measured for 
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each cell and used to calculate the percentage difference in fluorescence after acceptor 
photobleaching. As shown by Figure 5.7, cells were efficiently photobleached, indicated by 
the significant decrease in acceptor fluorescence after frame 3, when acceptor 
photobleaching was initiated. For the HRAS WT-HRAS WT positive control, only a minute 
increase in donor fluorescence was seen (Fig.5.7a). However, it is likely that this small 
change in fluorescence reflects the observed FRET at the plasma membrane, which 
represents only a small proportion of the cell and therefore would only be portrayed as a 








Figure 5.6| Representative images of cells co-transfected with Ras and annexins - Confocal images 
of HeLa S3 cells co-transfected with a) eGFP-A6 and mCherry-Ras WT and b) G12V. A6 serves as a 
donor-only control and eGFP- and mCherry-HRAS WT was used as a positive control.  Other annexins: 
c) A2 and d) A7 with mutant G12V Ras are also shown. Each column represents the fluorescence 
channel, FRET and FRETE. FRETE (%) was calculated per pixel, correcting for bleedthrough and cross-
excitation. Scale bar, 20μm. 
As for the A6-transfected samples, KRAS WT and KG12V displayed a similar level increase 
in donor fluorescence as the HRAS WT-HRAS WT positive control. Whereas the donor 
fluorescence increased more notably in the A6 and HRAS WT/G12V samples, indicating 
that eGFP-A6 and mCherry-HRAS WT/G12V were likely to be in close proximity to each 
other or potentially interacting. Differently, A2 and A7 did not show an increase in donor 
fluorescence and instead showed degradation in fluorescence, therefore alterations to the 
bleaching process will be required to accommodate this problem. Overall, acceptor 
photobleaching along with SE analysis has revealed a possible interaction amongst A6 and 








Figure 5.7| Whole cell analysis of annexin and Ras FRET through acceptor photobleaching - 
HeLa S3 cells were co-transfected with either a) eGFP-HRAS WT and mCherry-HRAS WT, b) eGFP-
A6 and mCherry-Ras, c) eGFP-A2 and mCherry-mutant Ras or d) eGFP-A7 and mCherry-mutant Ras. 
Images were taken before and after bleaching (frame 3). Error bars indicate SD for 30 cells per A6 




5.4. RAS ACTIVITY REDUCED BY ANNEXINS 
5.4.1. Knockdown of A2 or A6 increases Ras activity 
As demonstrated previously, HeLa S3 cells endogenously express Ras, A2 and A6. 
Therefore, siRNAs could be used to reduce A2 or A6 expression to investigate their effect 
on Ras activity. The duration of siRNA treatment was optimised to achieve a sufficient 
reduction in its expression levels (Fig 5.8). Here, cells were treated with non-targeting 
(NT1), A2 or A6 siRNA for 48 or 72 hours. Measurements of A2 and A6 expression levels 
at 48 hours revealed a reduction of 46.5% and 84.9% respectively, compared to control. 
Whereas at 72 hours, levels decreased to 30.9% in A2 and 10.4% in A6. Subsequently, 72 
hours was chosen as it resulted in the lowest expression of A2 and A6. It is to be noted that 
two isoforms of A6 exist due to alternative splicing of the A6 gene. siRNA treatment targets 
both isoforms but for all other experiments, isoform 1 (A6-1) was used for exogenous 
expression of A6 (Smith et al., 1994) 
In these knockdown experiments (Fig.5.8b), cells were either non-stimulated or stimulated 
with FBS for 5 minutes following 5 hours of serum-starvation. Expression levels of activated 
Ras effectors: MEK, ERK and pAkt were measured along with Ras and A2 or A6.  The first 
observation is that both A2 and A6 expression was successfully reduced with 72 hours 
siRNA treatment. Secondly, very low levels of pMEK, pERK and pAkt were seen across 
the non-stimulated samples, of which were elevated in the stimulated samples. Interestingly, 
knockdown of either A2 or A6 in the stimulated samples resulted in a further increase of 
Ras effectors: pERK and pAkt. Modest increases of pERK levels were detected in both 
annexin knockdowns, although it was more noticeable in the A6 siRNA treated sample. The 
most dramatic change was seen in pAkt activity, where reduced expression of either A2 or 
A6 resulted in an increase of pAkt. Whereas pMEK levels remained relatively constant 
irrespective of A2 or A6 siRNA treatment. Overall, reduction of A2 or A6 expression led to 
increased activation of downstream Ras effector pathways (no statistical significance), 




Figure 5.8| Reduced A2 and A6 expression increased Ras effector activation – a) Optimisation of 
siRNA treatment. b)  Representative blots of Ras effector activity following A2 or A6 knockdown. 
Cells were subjected to NT1, A2 or A6 siRNA for 72hrs, then either untreated (-) or activated with FBS 
(+). Summary graphs (top panel – A2, bottom panel - A6, n=3) show the level of pMEK, pERK and 
pAkt expression (1AU) normalised to non-stimulated untransfected samples, error bars indicate SD.  
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5.5. EVALUATING THE EFFECT OF ANNEXIN 6 ON RAS 
NANOCLUSTERING  
5.5.1. A6 increases the random distribution of Ras. 
So far, it has been demonstrated that A6 and HRAS potentially interact and that A6 perturbs 
downstream Ras effector signalling. For these reasons, it was of interest to investigate 
whether A6 could play a role in Ras nanoclustering. One of the methods to investigate 
nanoclustering is via high resolution EM. Ras is a small protein that has a low electron-
density, therefore direct visualisation of Ras is not viable. However, conjugation of a larger 
more electron dense molecule such as a gold particle to Ras detecting antibodies can aid the 
visualisation of their spatial patterns on the plasma membrane (Prior et al., 2003). 
For these experiments, gold-tagged red fluorescent protein (RFP) antibodies were used to 
label mCherry-Ras proteins. HeLa S3 cells were co-transfected with mCherry-HRAS 
WT/G12V and GFP-A6. Single transfections of mCherry-HRAS WT or mCherry-HG12V 
were used as controls. These transfected cells were used to provide membrane samples for 
visualisation. Ras proteins on these plasma membrane samples were labelled with 3.5nm 
anti-RFP gold. Digital images of gold labelling were obtained, then spatial patterning of the 
gold particles (i.e., Ras) was evaluated using univariate Ripley’s K function. The non-linear 
transformation of the Ripley’s K function, L(r)-r reveals the spatial patterning of Ras 
between 0-240nm (r). Where, random distribution is depicted by an L(r)-r value of 0, whilst 
positive and negative values imply clustering and dispersion, respectively.  
The gold particle spatial patterning of Ras was analysed for each image per condition, the 
average of these L(r)-r values for each 1nm increment between 0-240nm is displayed in 
Figure 5.9a. Comparisons between Ras distribution with and without additional A6 
expression were made. Overall, the L(r)-r curves revealed that the Ras proteins were 
predominantly randomly distributed in all the tested conditions. It is well-established that 
Ras proteins form nanoclusters at the plasma membrane (Prior et al., 2003; Plowman et al., 
2005; Zhou and Hancock, 2015), therefore the observed random distribution is most likely 
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a reflection of poor labelling using the 3.5nm anti-RFP antibodies. From the curves and 
maximum L(r)-r (Lmax) values, it appears that in co-transfected conditions, i.e., samples with 
additional A6 expression, Ras proteins were more randomly distributed than their single-
transfection counterparts: HRAS WT and HG12V (Fig. 5.9a & b). This was more evident 
in HRAS WT than in HG12V, where a reduction in Lmax value from 0.543 to 0.346 can be 
seen when exogenous A6 was present. However, bootstrap analysis of the L(r)-r clustering 
did not show statistical significance.     
5.5.2. Higher ordered HG12V oligomers are reduced by A6 
Due to the low labelling intensities, significant changes of the overall Ras nanoclustering 
when co-expressed with A6 were not observed. However, for both HRAS WT and HG12V, 
the addition of A6 resulted in a consistent trend towards a more random/less clustered 
distribution (Fig. 5.9a & b). For further analysis, the population distribution of these Ras 
molecules was investigated using Ripley’s K function to count the number of gold particles 
for a defined distance of 15nm.  
As shown by Figure 5.9c & d, the majority of detected gold particles existed as monomers 
(>80%) for all conditions. This was expected since the previous results indicated a lack of 
clustering. The remaining gold particles decreased in frequency with increasing oligomer 
size for both HRAS WT and HG1V. For HRAS WT samples, differences in population 
distribution were minor with only a 2.3% decrease in monomers and slight incremental 
changes in dimers (+0.9%), trimers (+1.1%) and multimers (+0.26) in the presence of A6. 
Contrastingly, an increase in monomers (+5.6%) can be seen in HG12V and A6 co-
expressed samples compared to HG12V only. In accordance, a smaller percentage of higher 
ordered HG12V oligomers contributed to the total population when A6 was present. In 
particular, a significant decrease in trimers (p=0.009) was observed. Overall, the results 
suggest that A6 reduces HG12V clustering, possibly as a result of alterations to the 
population distribution but has no significant effect on the population distribution of HRAS 




Figure 5.9| A6 redistributes Ras populations – Digital images of gold-labelling in transfected-
samples: HRAS WT (n=21), HG12V (n=10), HRAS WT and A6 (n=14) and HG12V and A6 (n=11) 
were acquired. For each condition, (a) the average L(r)-r values between 0-240nm were plotted as 
well as their (b) maximum L(r)-r values (Lmax) +SEM. Population analysis of (c) HRAS WT and (d) 
HG12V +SEM is shown above. ** p < 0.01.  
5.6. DISCUSSION 
The detection of multiple annexins during the APEX2 screen and in the shortlisted proteins, 
as well as their link to the plasma membrane deemed them to be prospective regulators of 
Ras nanoclustering. The mass spectrometry data showed promising results of correctly 
biotinylated proteins, i.e., proteins proximal to Ras, such as Ras effectors: Raf and MEK, 
however reaffirmation of whether annexins was biotinylated by other means was required 
before conducting further investigations. Western blotting revealed the presence of A6 in 
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enriched biotinylated lysates generated from a repeat of the conditions used in the APEX2 
experiments. Although, there were slight discrepancies to the mass spectrometry data. 
Irrespectively, A6 was detected in KRAS (serum-starved and stimulated) and HRAS 
(serum-starved). Interestingly, A6 expression was similar to SEPT2 and actin. It has been 
previously reported using latrunculin that KG12V and tH nanoclusters but not HG12V have 
a dependence on actin (Plowman et al., 2005). From this, it could be speculated that there 
might be a possible link between A6, SEPT2, actin and Ras. Although further 
experimentation would be required to investigate whether this was an artefact of inefficient 
enrichment, since actin was not detected in the streptavidin pulldown experiments 
demonstrated previously using NRAS.   
With the validation that annexin is proximal to Ras, the interaction between annexins and 
Ras was explored. The co-IP experiments did not evidently show an interaction between 
annexins: A1, A2, A6 or A7 with Ras. This is supported by another study, in which A6 was 
not present in the Ras pulldown and vice versa, Ras was not detected in the A6 pulldown 
(de Vilá Muga et al., 2009). An interaction was only seen in this study when cells were 
stimulated with EGF (de Vilá Muga et al., 2009).  
Interestingly, FRET revealed interactions between A6 and the different Ras isoforms 
(HRAS>KRAS>NRAS), in particular A6 and HRAS WT/G12V (Fig. 5.7). It also 
highlighted a possible interaction between A7 and Ras, but the cell morphology was vastly 
different from normal cells, possibly due to the overexpression of A7. Lastly, A2 did not 
appear to interact with Ras. These novel findings are of interest since the relationship 
between A2/A7 and Ras have not been previously explored. Whereas, the relationship 
between A6 and Ras has been previously investigated (Grewal et al., 2005; de Vilá Muga et 
al., 2009). One study revealed FRET was more abundant in HG12V compared to HRAS 
WT, which differs from the results presented here as there were no evident discrepancies 
between the two forms of HRAS (de Vilá Muga et al., 2009). However, it is to be noted that 
FRET efficiency was calculated differently in their study, since the percentage represents 
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the normalisation of donor post- and pre-bleach intensities by the donor post-bleach value 
(de Vilá Muga et al., 2009). Nevertheless, both set of results showed that FRET occurred 
between A6 and HRAS. Although, the interaction was not detected in the co-IP experiments, 
this did not negate that no direct interaction occurred but instead raised the possibility that 
these interactions might be either weak and/or transient. In general, results presented in this 
chapter confirm that A6 is an interactor of Ras, which is consistent with other studies.     
To understand the consequence of the interaction between A6 and Ras, the effect of A6 on 
Ras activity was investigated. Reducing endogenous expression of either A2 or A6 resulted 
in the elevated activation of ERK and Akt (Fig. 5.8). Although, MEK activity did not 
increase and remained fairly similar to control. It is possible that MEK activity had already 
peaked around 4 minutes as shown in Chapter 3. Therefore, since cells were lysed at the 5-
minute timepoint, this could have been missed, so repeat experiments using additional 
timepoints should be investigated to see whether this is the case. In another study, transient 
expression of A6 in A6-absent BT20 cell lines appeared to reduce both Pan Ras and MEK 
activity compared to normal BT20 cells (de Vilá Muga et al., 2009). Interestingly, the 
observed effect occurred following 3 minutes of EGF stimulation, which further supports 
that it likely that peak MEK activity was missed in the knockdown experiments performed 
here (de Vilá Muga et al., 2009). The observed increase in ERK has also been formerly 
shown in EGF-stimulated HeLa cells that were treated prior with siRNA treatment against 
A6 (Grewal et al., 2005). Although the results presented here do not formally demonstrate 
that Ras activity is affected by A6, it has shown that A6 reduced the activity of downstream 
Ras effectors: Raf and PI3K, therefore highlighting their possible relevance to Ras biology. 
Altogether, the previous results indicated that A6 affected Ras downstream signalling and 
consequently could have an effect on Ras nanoclustering. This was investigated using EM 
immunogold labelling, however, results revealed a lack of Ras clustering even in control 
samples, i.e., single transfection of HRAS WT or HG12V. Typically, Lmax values in previous 
EM nanoclustering studies have ranged from 1.75 to 6 for GFP-tH, -HRAS and -HG12V 
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(Prior et al., 2003; Plowman et al., 2005; Belanis et al., 2008). Since HRAS WT and HG12V 
samples have consistently shown to exhibit nanoclustering, it raises the probability that 
issues arose here. The choice of cells does not appear to be the problem, as it has been 
previously shown that nanoclustering can be measured efficiently in HeLa cells and it would 
be expected that HeLa S3 cells would be similar (Eisenberg et al., 2011; Barceló et al., 
2013). From observation, the presence of membrane rip offs was often scarce and difficult 
to detect in samples. Additionally, there was also a lack of gold-labelling. These could all 
be contributing factors towards the lack of nanoclustering seen across the samples. 
Addressing these issues for future experiments could provide confidence as to whether the 
observed reduced clustering of HRAS WT and HG12V in the presence of A6 can be 
consistently seen.     
Analysing the population distribution of the gold-labelled Ras particles revealed that over 
80% of the observed population existed as monomers (Fig. 5.9c & d), which is considerably 
more than the previously reported percentage of 60% (Tian et al., 2010). A6 increased the 
percentage of monomeric Ras proteins in HG12V with a concomitant reduction in the 
number of multimers (Fig. 5.9d). It has previously been shown that Ras nanoclusters but not 
monomers can recruit Raf (Tian et al., 2007; Plowman et al., 2008). Therefore, the lack of 
nanoclusters and subsequent increase in monomers in the presence of A6 indicates A6 
promotes the disassembly of Ras nanoclusters. This could represent a form of novel negative 
Ras nanocluster regulators since only positive regulators to date have been discovered. As a 
result of decreased Ras clustering, it could be speculated that the number of signalling 
platforms would be reduced, thus affecting Ras activity. This is coherent with the results 
observed in the siRNA knockdown experiments where reduced A6 expression resulted in 
an increase in Ras effector activity. However, it would be important to repeat the nanocluster 
experiments with the conditions of the siRNA knockdown to directly confirm that the 
observed increase in Ras effector activity in the presence of low A6 expression was due to 
elevated clustering of HRAS proteins on the plasma membrane. 
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Although, these experiments would require further repeats with more reliable controls, the 
results nevertheless indicate that A6 promotes Ras inactivity in HG12V. This has been 
reported by other studies with the suggestion that A6 bridges the connection between Ras 
and gap120 via a calcium-dependent manner (Grewal et al., 2005). However, HG12V 
mutants are resistant to gap120 inactivation and therefore it is unlikely that this is the 
mechanism in which A6 inactivates Ras (Smith, Neel and Ikura, 2013).  
Collectively, the results suggest A6 reduces Ras nanoclustering in HRAS WT and HG12V, 
which has not been previously explored. In addition, results here suggest that A6-induced 
Ras effector inactivity in HG12V might occur due to the disassembly of signalling 












The primary aim of this project was to identify proteins involved in the regulation of Ras 
nanocluster organisation. Here, APEX2 was used to investigate the proximal proteomes of 
the three Ras isoforms: KRAS, HRAS and NRAS. This novel screen of the Ras 
microenvironment generated the first APEX2-Ras database, of which consists of over 2900 
Ras proximal proteins. Analysis of this database later revealed that a group of membrane-
associated proteins, annexins, could be of interest. Investigations into the relationship 
between annexins and Ras demonstrated that A6 interacts with HRAS and can negatively 
regulate HRAS nanoclustering.  
6.1. APEX2 AS A SCREENING TOOL  
In order to produce a shortlist of candidate proteins that might be involved in Ras 
nanoclustering, a wide unbiased screening methodology was adopted. Proximity labelling 
combined with mass spectrometry has become popular in use, with many studies showing 
success via the identification of novel interactors and regulators (Roux et al., 2012; H.-W. 
Rhee et al., 2013; Firat-Karalar et al., 2014; Hung et al., 2014; Van Itallie et al., 2014; 
Fredriksson et al., 2015; Mick et al., 2015; Dong et al., 2016; Lobingier et al., 2017; Paek 
et al., 2017). BioID and APEX are the forerunners of this type of methodology, with both 
offering different advantages. APEX generate substrates with a shorter half-life than BioID, 
thus more likely to capture dynamic transient proteome microenvironments (Roux et al., 
2012; Lam et al., 2015). Therefore, due to the short-lived nature of Ras nanoclusters, APEX 
seemed be the more suitable choice of enzyme for this project and so APEX2, the improved 
second-generation APEX was used.  
6.1.1. First APEX2 screen of the Ras proteome 
The preliminary experiments consisted of generating the tools for Ras proximity labelling 
in HeLa S3 cells, as well as adapting the original protocol based on the labelling of the 
mitochondrial intermembrane space for the study of the Ras proteome instead. Here, 6 
different APEX2-tagged Ras constructs: APEX2-KRAS WT, -KG12V, -HRAS WT, -
HG12V, -NRAS WT, -NG12V and 2 controls: APEX2-tH and -tK were designed and 
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generated. The full-length Ras constructs were able to localise correctly to the plasma 
membrane and additionally showed to activate downstream effectors such as Raf and PI3K. 
Various conditions such as the stimulation of Ras activity, biotinylation duration and bead 
quantity for the streptavidin pulldown were also optimised. This modified protocol with the 
newly made Ras constructs were used for the later large-scale mass spectrometry 
experiments.    
Here, the first APEX2-based proximity labelling of the Ras proteome was performed. 
Different Ras isoforms were tested in their unstimulated WT form, as well as in their active 
state (stimulated or in its mutant G12V form). As a result, a collective database of 2988 
proximal proteins was generated for the different conditions. The number of proteins 
detected with APEX2 was considerably higher than their respective conditions identified in 
other studies using BioID (Adhikari and Counter, 2018; Go et al., 2019; Kovalski et al., 
2019). The main reasons that could have attributed to these differences include the kinetics 
and biochemistry of the two labelling methods. Another possibility could be due to the 
analysis. LFQ was used here due to the number of conditions, whereas the BioID studies 
utilized SILAC-based mass spectrometry approaches. Although SILAC is better for accurate 
comparisons between conditions, the number of comparisons that could be made are limited 
to only three or less conditions.  
GO analysis revealed that the detected proteins belonged to various subcellular regions. 
Therefore, it appeared that the combination of the fast-labelling kinetics associated with 
APEX2 and the dynamic nature of Ras trafficking resulted in widespread labelling 
throughout the cell. As a result, shortlisting for potential candidates was problematic due to 
the large protein population. This highlighted the importance of reliable localisation markers 
for non-enclosed regions, as they aid the elimination of proteins that are not in the area of 
interest. Despite tK and tH being used, these were not as useful as expected, as they followed 
similar dynamics to the full-length Ras. Therefore, more stable well-known membrane 
proteins should be used instead as membrane markers. Nevertheless, in-depth analysis of 
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the dataset helped narrow down a group of membrane-related proteins proximal to Ras. 
Due to the time constraints of this project, transient expression of APEX2-Ras was used, 
which carries the disadvantage of varying protein expression. Therefore, only crude 
comparisons could be made between the Ras isoforms and in this case, merely an indication 
of whether a protein is present in the proximity of Ras within a particular sample, as opposed 
to absolute comparison of protein levels between the different conditions. However, for 
future experiments, stable expression of APEX2-Ras should be considered for a better 
assessment of the differences and similarities amongst the different isoforms and conditions.       
6.1.2. Newer proximity labelling techniques 
Since the invention of BioID and APEX, newer biotin-based enzymatic tags have been 
created such as TurboID, MiniTurbo and split-BioID/APEX (De Munter et al., 2017; Xue 
et al., 2017; Branon et al., 2018). The use of BioID has generally been favoured over APEX, 
possibly due to toxicity concerns of H2O2 treatment. Therefore, most recent advancements 
in proximity labelling methods were based on BioID (De Munter et al., 2017; Branon et al., 
2018). TurboID and MiniTurbo were both developed using the BirA* tag with the addition 
of further mutagenesis of the reactive biotin-5’-AMP binding motif. The MiniTurbo is 
essentially a smaller version of the TurboID with two less mutations. These tags have a 
better labelling efficiency and shorter labelling duration (~10min) compared to BioID 
(Branon et al., 2018).  
Whereas split-BioID/APEX consists of dividing the enzyme into N- and C-terminal 
fragments that can be fused to two different proteins (De Munter et al., 2017; Xue et al., 
2017). This type of tag forms the basis of conditional protein-fragment complementation, 
whereby activity of the enzyme is regained when the two proteins associate (De Munter et 
al., 2017; Xue et al., 2017). These newer labelling techniques should be considered for 
future experiments as they could provide potential advantages over APEX2. For example, 
split-APEX2 could be used to investigate proteins in the vicinity of active Ras with more 
accuracy, since the APEX2 fragments could be split between Ras and Raf, thus ensuring 
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that labelling only occurs when Ras is engaged to Raf. 
Overall, APEX2 has shown to be a valuable tool for investigating the Ras proteome. It has 
efficiently labelled well-known Ras-associated proteins, as well as highlighted possible 
novel Ras interactors and regulators. Through the process, it became apparent that it carries 
the main disadvantage of widespread labelling, which could be circumvented using a 
thorough selection of negative and positive localisation controls. Nonetheless, this large-
scale experiment has created a database that can be later used to support other studies of 
Ras.     
6.2. ANNEXIN 6 REDUCES HRAS NANOCLUSTERING 
 
Figure 6.1| Overview of Ras biology in relation to A6 – Schematic of the observed results in this 
study, A6 siRNA knockdown resulted in the reduction of Ras effector activity. Whereas 
overexpression of A6 led to decreased HRAS clustering on the plasma membrane.  
6.2.1. Key findings of the relationship between A6 and Ras 
The APEX2 methodology highlighted various annexins within the Ras proximal proteome, 
of which a select few were chosen for further analysis of their relationship with Ras. The 
main finding was that A6 interacted predominantly with the HRAS isoform in both its WT 
and G12V form. This interaction was most likely transient as it was not clearly detected in 
the IP experiments but evident using FRET. A6 also affected downstream Ras effector 
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pathways, whereby reduced A6 expression resulted in elevated Raf and PI3K activity (Fig. 
6.1).  
 
Figure 6.2| Schematic modelling of the effect of A6 on HRAS WT and HG12V distribution on 
the plasma membrane – Example spatial patterns of gold-labelled HRAS WT and HG12V proteins 
with/without A6 based on data generated.   
These findings have only ever been previously reported by another lab group, which 
suggested that the mechanism behind the observed A6 and active HRAS interaction was that 
A6 recruits gap120 in a calcium-dependent manner to the plasma membrane to inactivate 
Ras (Grewal et al., 2005; de Vilá Muga et al., 2009). More intriguingly, their results showed 
that A6 only interacted with HG12V, which seems to be contradictory of their proposed 
mechanism since its widely known that G12V mutants are insensitive to GAPs (Smith, Neel 
and Ikura, 2013). The lack of both follow-up studies as well as supporting evidence from 
other groups deemed it necessary to independently investigate this interaction in order to 
elucidate the underlying mechanism.  
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Ras nanoclustering was investigated due to the observed effects of A6 on downstream Ras 
effector signalling. Using EM immunogold labelling, the spatial patterning of HRAS on the 
plasma membrane was analysed. On the whole, gold-labelling was not as abundant as 
expected, but the results demonstrated a novel finding that A6 reduced the clustering of both 
HRAS WT and HG12V (Fig. 6.1 & 6.2). For HRAS WT, the population distribution was 
unaltered by A6, therefore it is likely that the observed overall reduced clustering effect was 
a result of Ras proteins being generally more dispersed in the presence of A6 (Fig 6.2). 
However, for HG12V, nanoclustering was likely decreased by the significant reduction of 
higher ordered oligomers (Fig 6.2). This phenomenon has not been observed previously and 
demonstrates a novel process in which Ras nanoclustering is negatively regulated.  
6.2.2. Clinical relevance of the A6-HRAS relationship 
Similar to Ras, A6 is also associated with cancer. Ras is often mutated, whereas A6 
expression vary dependent on the cancer type. It has been reported that A6 plays a potential 
tumour suppressor role in melanoma, breast and gastric cancers, but promotes tumorigenesis 
in other cancers such as cervical cancer and lymphoblastic leukaemia (Francia et al., 1996; 
Smith et al., 2002; Lomnytska et al., 2011; Sakwe et al., 2011; Koumangoye et al., 2013; 
X. Wang et al., 2013).  
In this project, A6 dampened Ras effector activity in the cervical epithelial cancer cell line: 
HeLa S3, which should consequently result in decreased cellular growth, although further 
experimentation using growth assays would be required to formally confirm this outcome. 
This differs from the currently reported role for A6 in cervical cancers, whereby A6 
expression improves prognosis, however, it is to be noted that cervical cancers are not 
primarily Ras driven (Mo, Coulson and Prior, 2018). However, it does highlight that the role 
of A6 is highly context-dependent and emphasises the importance of testing different cell 
lines.  
In colorectal cancer, a positive correlation between KRAS mutations and A1 overexpression 
has been observed (Su et al., 2010). Therefore, it is possible that this A6-HRAS relationship 
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could be of relevance to certain types of cancer, for example, melanoma, which has been 
linked to both low A6 expression and Ras mutations (Francia et al., 1996; Mo, Coulson and 
Prior, 2018).  
6.2.3. Interaction between A6 and Ras 
This study has revealed that A6 interacts with HRAS and that its expression can reduce the 
clustering of HRAS WT/G12V proteins. It could be speculated that the observed 
nanoclustering effect is concomitant of the A6 and HRAS interaction, however double 
immunogold labelling of both proteins would be required for validation. These main 
findings were established using A6-1, which are predominantly expressed in normal cells, 
whereas the A6 siRNA used for knockdown experiments targeted both isoforms. It has been 
reported that A6-2 is the more abundant isoform present in transformed cell lines, therefore 
A6-2 may also be important for Ras biology.  
Annexins can operate in either a calcium-dependent or independent manner. For A6, 
calcium binding sites are located in domains: 1, 2, 4, 5, 6 and 8 of the annexin core (Huber 
et al., 1990). However, it is unclear here whether A6 requires calcium to interact with Ras 
and is a factor to consider in future experiments. Past literature has shown that the A6-Ras 
interaction was increased when cells were treated with ionomycin, however under 
physiological conditions, it is unknown whether A6 is dependent on calcium in order to 
interact with Ras (de Vilá Muga et al., 2009).     
Future studies using structural analysis will be vital for understanding their interaction, as it 
would provide insight as to whether A6 directly blocks Ras from clustering with other Ras 
proteins, or indirectly via other means such as allosteric hindrance of possible dimerization 
sites or induction of conformational changes to Ras. 
6.2.4. Possible mechanisms behind A6-modulated Ras nanoclustering 
The fundamental process in which A6 reduces HRAS clustering is unknown, however some 
suggestions could be inferred from the current known or suggested roles of A6. Annexins 
are recognised for their ability to bind phospholipids as well as being instrumental for the 
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organisation of the plasma membrane and actin cytoskeleton. All of which are vital factors 
that are essential for the formation of Ras nanoclusters. Therefore, it is highly possible that 
these connections form the basis of this novel A6 regulatory role.    
 
Figure 6.3| Possible factors governing A6-modulated HRAS nanoclustering – A6 has different 
affinities for various lipid species and is commonly known for its role in mediating changes amongst 
the actin cytoskeleton and/or plasma membrane. These interlinked factors could contribute to its 
novel role as a negative regulator of HRAS nanoclustering. 
6.2.4.1. Lipid microenvironment 
A6 is the largest annexin with a unique double annexin core that allows it to connect up to 
two distinct membranes. Each domain within the core can bind up to three phospholipid 
polar head groups (Rescher and Gerke, 2004; Lizarbe et al., 2013). Since its been reported 
that only the first four annexin core domains are required for the modulation of Ras activity, 
the remaining domains should be available to bind other components, such as phospholipids, 
when bound to Ras (de Vilá Muga et al., 2009). It could be speculated that the ability of A6 
to bind to phospholipids in the plasma membrane in either a calcium-dependent or 
independent manner might be a prerequisite to bring A6 into close proximity to HRAS for 
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an interaction to occur (Golczak et al., 2004; Lizarbe et al., 2013).  
As discovered here, A6 interacts predominantly with HRAS WT and HG12V nanoclusters, 
which are exclusively localised in raft and non-raft domains containing specific 
phospholipids, respectively. This is consistent with studies showing that A6 can localise to 
both types of microdomains as well as caveolae and clathrin-coated pits (Kamal, Ying and 
Anderson, 1998; Alvarez-Guaita et al., 2015). It is thought that each annexin exhibits a 
preference for certain lipid species, but it is unknown which lipids are preferentially bound 
by A6 (Lizarbe et al., 2013). It is known that A6 can bind to PS, which is more prevalent in 
KRAS nanoclusters. Therefore, it would have been expected that interactions would be more 
noticeable between A6 and KRAS rather than HRAS (Pikuta et al., 1996; Cho, Park and 
Hancock, 2013). Although, the FRET data shows that KRAS could possibly interact with 
A6, it was not investigated whether A6 affects KRAS nanoclustering. Nevertheless, PS is 
also present in HRAS nanoclusters. It is possible that if phospholipids were an important 
component for governing exclusively the A6-HRAS interaction, then A6 could be more 
associated with lipid species that are specifically enriched in HRAS microdomains such as 
PI4P (Zhou and Hancock, 2015).  
6.2.4.2. Membrane remodelling and actin cytoskeleton reorganisation 
The process in which A6 modulates Ras nanoclustering could occur directly or indirectly. 
Direct hinderance of Ras could prevent its association with other Ras proteins or the plasma 
membrane. Alternatively, A6 could perturb nanoclustering indirectly via membrane 
remodelling and/or reorganisation of the actin cytoskeleton.  
A6 has often been proposed to be involved in membrane organisation due to its ability to 
bind to phospholipids in the plasma membrane and cytoskeletal proteins (Lizarbe et al., 
2013). However, direct evidence supporting this hypothesis has often been lacking, until 
more recently, a study confirmed A6 can alter the membrane structure (Alvarez-Guaita et 
al., 2015). Results demonstrated in live A431 cells that upregulation of A6 led to a decrease 
in membrane order. Depletion of cortical actin using latrunculin B increased the membrane 
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order of A6-expressing A431 cells compared to control, indicating the importance of the 
actin cytoskeleton for A6 remodelling of the plasma membrane (Alvarez-Guaita et al., 
2015).  
Latrunculin B has also been used to show that HRAS WT but not HG12V nanoclusters 
require intact actin for their formation (Plowman et al., 2005). This raises the possibility that 
the actin cytoskeleton might be an important factor for the observed A6-modulated reduction 
in HRAS WT clustering. The authors also suggest that A6 indirectly modulates membrane 
order via alterations to cholesterol homeostasis, which was not directly evident in their study 
but shown in their previous study where A6 depleted cholesterol levels in membrane 
fractions (Cubells et al., 2007; Alvarez-Guaita et al., 2015). However, the reliability of these 
conclusions is questionable since membrane fractionation experiments generate artefacts 
and the use of latrunculin B could cause global changes to the cell.  
In the same study, cluster analysis revealed that A6 expression increased the clustering of 
non-raft (Src15) markers greater than raft (Lck10) markers in A431 cells, whereas clustering 
of both markers were equally increased in mouse embryonic fibroblasts (MEF)-WT cells 
(Alvarez-Guaita et al., 2015). Although a direct comparison cannot be made, it is of interest 
that A6 exhibited almost an opposite effect in HeLa S3 cells, where clustering of both HRAS 
WT and HG12V were reduced, which respectively represented raft and non-raft domains. 
Therefore, highlighting that the role of A6 in terms of microdomain clustering is likely to 
be cell-type dependent.  
In general, the study performed here has contributed to the understanding of A6 in the 
context of Ras. The ability of A6 to interact with both HRAS WT and HG12V indicates that 
not only does A6 modulate both their respective raft and non-raft microdomains but also 
that A6 localises to these structures. Since A6 could reduce Ras nanoclustering in both 
HRAS WT and HG12V, it could be speculated that these unique microenvironments 
composed of different proteins and lipids provides a combinational signal that determines 
the mechanism in which A6 restructures these domains, possibly via the actin cytoskeleton, 
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in order to reduce HRAS clustering. The population distribution analysis showed that 
HG12V nanoclusters could be potentially reduced by the disassembly of higher ordered 
oligomers in the presence of A6, suggesting HG12V nanoclusters undergoes a different kind 
of remodelling compared to HRAS WT. In summary, it could be hypothesized that A6 
remodels microdomains in order to disrupt HRAS nanoclustering, which could form the 
basis of future investigations.   
6.3. FUTURE WORK 
Majority of this project was based on establishing the APEX2 method for the study of Ras 
and subsequently generating the proximity proteome database. The initial work was 
instrumental for the discovery of the A6-HRAS interaction and preliminary results have 
demonstrated a novel role for A6 in the context of Ras nanoclustering. However, further 
experiments are required such as: 
1. To repeat the comprehensive survey of the Ras proximity proteome with more 
accuracy, i.e., use of stably expressed APEX2-tagged Ras and reliable localisation 
markers. This will allow for more precise comparisons between isoforms and 
conditions, as well as aid the shortlisting process of membrane proteins. 
2. To fully characterise the role of A6 in Ras nanoclustering in all three Ras isoforms. 
Double immunogold labelling could be used to assess A6 in addition to Ras, since 
annexins have also shown to dimerize. This will provide insight of the spatial 
relationship between A6 and Ras on a nanoscale resolution. Due to the possibility 
of context-dependent effects, other cell lines should also be considered. 
3. To elucidate the A6-Ras interaction and the mechanism behind the regulation of 
HRAS nanoclustering by A6. Structural analysis could reveal how A6 and HRAS 
interact and provide insight on if other domains on A6 are available to bind lipids 
or other proteins. In terms of nanoclustering, it should be examined whether A6 
alters Ras clustering directly, or indirectly via the actin cytoskeleton and/or lipid 
microdomains on the plasma membrane. 
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6.4. CONCLUDING REMARKS 
To summarise, APEX2 was used to do a comprehensive survey of the proximity proteome 
microenvironment of all three Ras isoforms: KRAS, HRAS and NRAS in different 
conditions. This produced an extensive database that could be processed to understand the 
types of proteins present, as well as shortlist potential proteins that could regulate Ras 
nanoclustering. Following a series of different interaction studies and nanoclustering 
experiments, A6 was found to interact with HRAS (both WT and mutant) and reduce the 
clustering of these Ras proteins at the plasma membrane. Possibly as a consequence, 
downstream Ras effector pathways were also negatively affected by A6. Although A6 
cannot be used as a therapeutic target in Ras-driven cancers due to its universal role within 
the cell, it has been imperative to understand their interaction with Ras. Thus, APEX2 has 
been fundamental for advancing our knowledge of the Ras proteome and more importantly, 
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Appendix 1| Plasmid maps of APEX2-Ras constructs.  
 
FLAG-APEX2-KRAS WT 
Origin of vector: pEGFP-C3-KRASWT 





Origin of vector: pEGFP-C3-HRASWT 






Origin of vector: pEGFP-C3-NRASWT 






Origin of vector: pEGFP-C2-KG12V 
Origin of insert: TOPO- pFLAG-APEX2-C2 
 
 




Origin of vector: pEGFP-C1-HG12V  






Origin of vector: pEGFP-C3-NG12V 
Origin of insert: TOPO-pFLAG-APEX2-C3 
 




Origin of vector: pEGFP-C1-tK 







Origin of vector: pEGFP-C1-tH 
Origin of insert: TOPO-pFLAG-APEX2-C1 
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